<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated by DataTracks version 1.1.3 on 07-Mar-2014 [04:59:24] {PM} EST - www.datatracks.com -->
<!-- Based on XBRL 2.1 -->
<xbrli:xbrl xmlns:tgtx="http://www.tgtherapeuticsinc.com/20131231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr">
  <link:schemaRef xlink:type="simple" xlink:href="tgtx-20131231.xsd" />

<!--Context Section-->
  <xbrli:context id="P01_01_2011To12_31_2011">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>

      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To12_31_2012">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To12_31_2013">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P02_01_2012To02_24_2012">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-02-01</xbrli:startDate>

      <xbrli:endDate>2012-02-24</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn02_24_2012">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-02-24</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_01_2014">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2014-03-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2011To04_19_2011">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-04-01</xbrli:startDate>

      <xbrli:endDate>2011-04-19</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2012To04_30_2012">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-04-01</xbrli:startDate>

      <xbrli:endDate>2012-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn04_19_2011">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-04-19</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn04_30_2012">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn06_30_2013">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P07_01_2013To07_18_2013">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-07-01</xbrli:startDate>

      <xbrli:endDate>2013-07-18</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn07_18_2013">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-07-18</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P12_01_2011To12_30_2011">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-12-01</xbrli:startDate>

      <xbrli:endDate>2011-12-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P12_01_2011To12_31_2013">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-12-01</xbrli:startDate>

      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_29_2011">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-12-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_30_2011">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-12-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2011">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn11_30_2011">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

<!--Dimension Section-->
  <xbrli:context id="PAsOn12_31_2012_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2010To03_31_2010_ManhattanAndAristonPharmaceuticalsMergerMembertgtxTypeOfTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tgtx:TypeOfTransactionAxis">tgtx:ManhattanAndAristonPharmaceuticalsMergerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-03-01</xbrli:startDate>

      <xbrli:endDate>2010-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2010_ManhattanAndAristonPharmaceuticalsMergerMembertgtxTypeOfTransactionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tgtx:TypeOfTransactionAxis">tgtx:ManhattanAndAristonPharmaceuticalsMergerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2010-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2011_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2011_CommonStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To12_31_2012_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To12_31_2012_CommonStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To12_31_2013_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To12_31_2013_CommonStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_CommonStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_CommonStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To12_31_2012_RestrictedStockMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To12_31_2013_RestrictedStockMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To12_31_2012_EmployeeStockOptionMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To12_31_2013_EmployeeStockOptionMemberusgaapAwardTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_IncentivePlanMemberusgaapPlanNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tgtx:IncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To12_31_2013_RestrictedStockMemberusgaapPlanNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_EquityIncentivePlansMemberusgaapPlanNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tgtx:EquityIncentivePlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_CorporateMilestoneMembertgtxCorporateMilestoneAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tgtx:CorporateMilestoneAxis">tgtx:CorporateMilestoneMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_NonEmployeeRestrictedStockMembertgtxNonEmployeeStockOptionsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tgtx:NonEmployeeStockOptionsAxis">tgtx:NonEmployeeRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2011To12_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>

      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To12_31_2012_RestrictedStockMemberusgaapPlanNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_ConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">tgtx:ConvertibleNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_IconConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">tgtx:IconConvertibleNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_ConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">tgtx:ConvertibleNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_IconConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">tgtx:IconConvertibleNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_08_2010_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tgtx:IconClinicalResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2010-03-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2011_BeforeAmendmentMembertgtxAmendmentAxis_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tgtx:AmendmentAxis">tgtx:BeforeAmendmentMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tgtx:IconClinicalResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2011_AfterAmendmentMembertgtxAmendmentAxis_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tgtx:AmendmentAxis">tgtx:AfterAmendmentMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tgtx:IconClinicalResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tgtx:IconClinicalResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_AristonMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tgtx:AristonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To12_31_2013_AristonMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tgtx:AristonMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_08_2010_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2010-03-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2010To03_08_2010_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tgtx:IconClinicalResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-03-01</xbrli:startDate>

      <xbrli:endDate>2010-03-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2010To04_30_2010_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tgtx:IconClinicalResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-04-01</xbrli:startDate>

      <xbrli:endDate>2010-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn03_31_2011_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tgtx:IconClinicalResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To12_31_2013_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tgtx:IconClinicalResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tgtx:IconClinicalResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P08_01_2012To08_31_2012_OpusMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tgtx:OpusMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-08-01</xbrli:startDate>

      <xbrli:endDate>2012-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To12_31_2012_LfbGroupMembertgtxPlacementAgencyAgreementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tgtx:PlacementAgencyAgreementAxis">tgtx:LfbGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To12_31_2013_LfbGroupMembertgtxPlacementAgencyAgreementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tgtx:PlacementAgencyAgreementAxis">tgtx:LfbGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_LfbGroupMembertgtxPlacementAgencyAgreementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tgtx:PlacementAgencyAgreementAxis">tgtx:LfbGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_LfbGroupMembertgtxPlacementAgencyAgreementAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tgtx:PlacementAgencyAgreementAxis">tgtx:LfbGroupMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_PreferredStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_ContingentlyIssuableShareMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tgtx:ContingentlyIssuableShareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_TreasuryStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To12_31_2013_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To12_31_2013_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To12_31_2012_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2011To12_31_2011_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>

      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To12_31_2012_PreferredStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To12_31_2012_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_RestrictedCommonStockMembertgtxCompensationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="tgtx:CompensationAxis">tgtx:RestrictedCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To12_31_2012_RestrictedCommonStockMembertgtxCompensationAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tgtx:CompensationAxis">tgtx:RestrictedCommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2011To12_31_2011_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>

      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2011To12_31_2011_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>

      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To12_31_2012_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To12_31_2012_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To12_31_2013_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2011_PreferredStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2011_ContingentlyIssuableShareMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tgtx:ContingentlyIssuableShareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2011_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2011_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2011_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_PreferredStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_ContingentlyIssuableShareMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tgtx:ContingentlyIssuableShareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_TreasuryStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_UsFederalIncomeTaxMemberusgaapIncomeTaxAuthorityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">tgtx:UsFederalIncomeTaxMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To12_31_2013_UsFederalIncomeTaxMemberusgaapIncomeTaxAuthorityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">tgtx:UsFederalIncomeTaxMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_29_2011_TgBioMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tgtx:TgBioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-12-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P12_01_2011To12_29_2011_TgBioMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tgtx:TgBioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-12-01</xbrli:startDate>

      <xbrli:endDate>2011-12-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_29_2011_PreferredStockMemberusgaapStatementEquityComponentsAxis_TgBioMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tgtx:TgBioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-12-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn11_09_2012_LfbMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tgtx:LfbMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-11-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_PlacementAgentMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tgtx:PlacementAgentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_LfbMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tgtx:LfbMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn04_30_2012_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn04_30_2012_NationalHoldingsMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tgtx:NationalHoldingsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P12_01_2011To12_30_2011_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_TwoThousandTwelveIssuanceMembertgtxIssuancePeriodAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="tgtx:IssuancePeriodAxis">tgtx:TwoThousandTwelveIssuanceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-12-01</xbrli:startDate>

      <xbrli:endDate>2011-12-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P12_01_2011To12_30_2011_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis_TwoThousandElevenIssuanceMembertgtxIssuancePeriodAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="tgtx:IssuancePeriodAxis">tgtx:TwoThousandElevenIssuanceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-12-01</xbrli:startDate>

      <xbrli:endDate>2011-12-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P12_01_2011To12_30_2011_TwoThousandTwelveIssuanceMembertgtxIssuancePeriodAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tgtx:IssuancePeriodAxis">tgtx:TwoThousandTwelveIssuanceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-12-01</xbrli:startDate>

      <xbrli:endDate>2011-12-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn05_31_2012_IncentivePlanMemberusgaapPlanNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tgtx:IncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-05-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2011To12_31_2011_PreferredStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>

      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2011To12_31_2011_ContingentlyIssuableShareMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tgtx:ContingentlyIssuableShareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>

      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2011To12_31_2011_ThorntonRossLtdMembertgtxStatementScenariooAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tgtx:StatementScenariooAxis">tgtx:ThorntonRossLtdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>

      <xbrli:endDate>2011-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To12_31_2012_CollaborationAgreementMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tgtx:CollaborationAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To12_31_2013_LfbBiotechnologiesMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tgtx:LfbBiotechnologiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To12_31_2013_CollaborationAgreementMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tgtx:CollaborationAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P11_01_2012To11_09_2012_LfbBiotechnologiesMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tgtx:LfbBiotechnologiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-11-01</xbrli:startDate>

      <xbrli:endDate>2012-11-09</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn11_09_2012_LfbBiotechnologiesMemberdeiLegalEntityAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">tgtx:LfbBiotechnologiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-11-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To12_31_2012_TreasuryStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To12_31_2013_TreasuryStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2012_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2012-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>

        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To12_31_2012_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To12_31_2013_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_ExchangeTransactionMemberusgaapStatementScenarioAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">tgtx:ExchangeTransactionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P03_01_2010To03_08_2010_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2010-03-01</xbrli:startDate>

      <xbrli:endDate>2010-03-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2011_ExchangeForLicenseOptionMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tgtx:ExchangeForLicenseOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2011-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To12_31_2012_PreferredStockMemberusgaapStatementClassOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_USGovernmentAgenciesDebtSecuritiesMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To12_31_2013_USGovernmentAgenciesDebtSecuritiesMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To12_31_2013_EquityIncentivePlansMemberusgaapPlanNameAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tgtx:EquityIncentivePlansMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P11_01_2012To11_09_2012_LfbMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tgtx:LfbMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-11-01</xbrli:startDate>

      <xbrli:endDate>2012-11-09</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="PAsOn12_31_2013_TgBioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">tgtx:TgBioMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To12_31_2013_WarrantMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To12_31_2013_PlacementAgentMemberusgaapSubsidiarySaleOfStockAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tgtx:PlacementAgentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P04_01_2012To04_30_2012_CommonStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-04-01</xbrli:startDate>

      <xbrli:endDate>2012-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To12_31_2013_PreferredRestrictedStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tgtx:PreferredRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To12_31_2013_CommonRestrictedStockMemberusgaapStatementEquityComponentsAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tgtx:CommonRestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2012To12_31_2012_ResearchDevelopmentExpensesMembertgtxResearchDevelopmentExpensesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tgtx:ResearchDevelopmentExpensesAxis">tgtx:ResearchDevelopmentExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2012-01-01</xbrli:startDate>

      <xbrli:endDate>2012-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2013To12_31_2013_ResearchDevelopmentExpensesMembertgtxResearchDevelopmentExpensesAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="tgtx:ResearchDevelopmentExpensesAxis">tgtx:ResearchDevelopmentExpensesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2013-01-01</xbrli:startDate>

      <xbrli:endDate>2013-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:context id="P01_01_2014To01_23_2014_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001001316</xbrli:identifier>

      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tgtx:IconClinicalResearchMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>

    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>

      <xbrli:endDate>2014-01-23</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>

  <xbrli:unit id="shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>

  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>

  <xbrli:unit id="USD_per_Share">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>

      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>

  <xbrli:unit id="USD_Warrant">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>

      <xbrli:unitDenominator>
        <xbrli:measure>tgtx:Warrant</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>

  <xbrli:unit id="pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>

<!--Element Section-->
  <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2013To12_31_2013" id="Factid_1">              &lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;NOTE 4&lt;/font&gt;&lt;/strong&gt;  &lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times','serif'; FONT-SIZE: 10pt"&gt;&amp;#150; FAIR VALUE  MEASUREMENTS&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;We measure certain financial assets  and liabilities at fair value on a recurring basis in the financial  statements. The fair value hierarchy ranks the quality and  reliability of inputs, or assumptions, used in the determination of  fair value and requires financial assets and liabilities carried at  fair value to be classified and disclosed in one of the following  three categories:&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;table style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; TABLE-LAYOUT: fixed; FONT-SIZE: 10pt; dtth: tableHanging"   cellspacing="0" cellpadding="0" width="100%"&gt;  &lt;tr style="PADDING-BOTTOM: 0pt; VERTICAL-ALIGN: top; PADDING-TOP: 0in"&gt;  &lt;td style="WIDTH: 0.5in; WORD-WRAP: break-word; VERTICAL-ALIGN: top"&gt;&lt;/td&gt;  &lt;td style="WIDTH: 0.25in; WORD-WRAP: break-word; VERTICAL-ALIGN: top"&gt;  &lt;div&gt;&lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"&gt;&lt;font  style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;font style="FONT-FAMILY: SYMBOL"&gt;&amp;#8901;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="WORD-WRAP: break-word; VERTICAL-ALIGN: top"&gt;  &lt;div&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Level 1 &amp;#150; quoted prices in  active markets for identical assets and liabilities;&lt;/font&gt;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.75in"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;table style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; TABLE-LAYOUT: fixed; FONT-SIZE: 10pt; dtth: tableHanging"   cellspacing="0" cellpadding="0" width="100%"&gt;  &lt;tr style="PADDING-BOTTOM: 0pt; VERTICAL-ALIGN: top; PADDING-TOP: 0in"&gt;  &lt;td style="WIDTH: 0.5in; WORD-WRAP: break-word; VERTICAL-ALIGN: top"&gt;&lt;/td&gt;  &lt;td style="WIDTH: 0.25in; WORD-WRAP: break-word; VERTICAL-ALIGN: top"&gt;  &lt;div&gt;&lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"&gt;&lt;font  style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;font style="FONT-FAMILY: SYMBOL"&gt;&amp;#8901;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="WORD-WRAP: break-word; VERTICAL-ALIGN: top"&gt;  &lt;div&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Level 2 &amp;#150; inputs other than  Level 1 quoted prices that are directly or indirectly observable;  and&lt;/font&gt;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.75in"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;table style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; TABLE-LAYOUT: fixed; FONT-SIZE: 10pt; dtth: tableHanging"   cellspacing="0" cellpadding="0" width="100%"&gt;  &lt;tr style="PADDING-BOTTOM: 0pt; VERTICAL-ALIGN: top; PADDING-TOP: 0in"&gt;  &lt;td style="WIDTH: 0.5in; WORD-WRAP: break-word; VERTICAL-ALIGN: top"&gt;&lt;/td&gt;  &lt;td style="WIDTH: 0.25in; WORD-WRAP: break-word; VERTICAL-ALIGN: top"&gt;  &lt;div&gt;&lt;font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"&gt;&lt;font  style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;font style="FONT-FAMILY: SYMBOL"&gt;&amp;#8901;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="WORD-WRAP: break-word; VERTICAL-ALIGN: top"&gt;  &lt;div&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Level 3 &amp;#150; unobservable  inputs that are not corroborated by market data.&lt;/font&gt;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;As of December 31, 2013 and 2012, the  fair values of cash and cash equivalents, and notes and interest  payable, current portion approximate their carrying value.&lt;font  style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;  &lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;Upon the merger between  Manhattan and Ariston Pharmaceuticals, Inc. (&amp;#8220;Ariston&amp;#8221;)  in March 2010, Ariston issued $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;15,452,793&lt;/font&gt;  of five-year &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5&lt;/font&gt;%  notes payable (the &amp;#8220;5% Notes&amp;#8221;) in satisfaction of  several note payable issuances.&amp;#160;&amp;#160;The 5% Notes and accrued  and unpaid interest thereon are convertible at the option of the  holder into Common Stock at the conversion price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,125&lt;/font&gt;  per share.&amp;#160;&amp;#160;Ariston agreed to make quarterly payments on  the 5% Notes&amp;#160;equal to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  50&lt;/font&gt;% of the net product cash flow received from the  exploitation or commercialization of Ariston&amp;#8217;s product  candidates, AST-726 and AST-915.&amp;#160;&amp;#160;The Company has no  obligations under the 5% Notes aside from a) 50% of the net product  cash flows from Ariston&amp;#8217;s product candidates, if any, payable  to noteholders; and b) the conversion feature, discussed  above.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;In connection with the Exchange  Transaction in December 2011, the Company performed a valuation of  the assets and liabilities of Manhattan immediately prior to the  transaction. &lt;font style="COLOR: black"&gt;The cumulative liability  including accrued and unpaid interest of these notes was  approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;16,876,000&lt;/font&gt;  immediately prior to the Exchange Transaction, and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;18,614,000&lt;/font&gt;  and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;17,727,000&lt;/font&gt;  at December 31, 2013 and 2012, respectively.&lt;/font&gt; As these notes  payable are tied directly to net product cash flows derived from  the preexisting products of the Company, this note and accrued  interest was recorded at fair value of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3,287,700&lt;/font&gt;  as of the date of the Exchange Transaction. No payments have been  made on these notes as of December 31, 2013.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"   align="center"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;We elected the fair value option for  valuing the &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5&lt;/font&gt;%  Notes upon the completion of the reverse merger with TG Bio, as  discussed above. The Company elected the fair value option in order  to reflect in our financial statements the assumptions that market  participants use in evaluating these financial  instruments.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;For the year ended December 31, 2012,  the valuation method used to estimate the 5% Notes&amp;#8217; fair  value was a discounted cash flow model, where the expected cash  flows of AST-726 and AST-915 were discounted to the present using a  yield that incorporated compensation for the probability of success  in clinical development and marketing, among other factors. The  discount rate used in this discounted cash flow model approximated  &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  20&lt;/font&gt;% at December 31, 2012. As of December 31, 2013, as a  result of expiring intellectual property rights and other factors  as discussed below in Nonrecurring Fair Value Measurements, it was  determined that net product cash flows from AST-726 were unlikely.  As the Company has no other obligations under the 5% Notes aside  from the net product cash flows and the conversion feature, the  conversion feature was used to estimate the 5% Notes&amp;#8217; fair  value as of December 31, 2013. The assumptions, assessments and  projections of future revenues are subject to uncertainties, are  difficult to predict and require significant judgment. The use of  different assumptions, applying different judgment to inherently  subjective matters and changes in future market conditions could  result in significantly different estimates of fair value and the  differences could be material to our consolidated financial  statements.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;The Company&amp;#8217;s financial liabilities measured at fair  value on a recurring basis as of December 31, 2013 and 2012 were as  follows:&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="50%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="47%" colspan="11"&gt;  &lt;div&gt;Financial liabilities at fair value&lt;br/&gt;   as of December 31, 2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="50%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Level&amp;#160;1&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Level&amp;#160;2&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Level&amp;#160;3&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Total&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="50%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="50%"&gt;  &lt;div&gt;5% Notes&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;64,529&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;64,529&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="50%"&gt;  &lt;div&gt;Totals&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;64,529&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;64,529&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="48%" colspan="12"&gt;  &lt;div&gt;Financial&amp;#160;liabilities&amp;#160;at&amp;#160;fair&amp;#160;value&lt;br/&gt;   &amp;#160;as&amp;#160;of&amp;#160;December&amp;#160;31,&amp;#160;2012&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Level&amp;#160;1&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Level&amp;#160;2&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Level&amp;#160;3&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Total&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;5% Notes&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,479,098&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,479,098&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;Totals&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,479,098&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,479,098&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;The Level 3 amounts above represent  the fair value of the &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5&lt;/font&gt;%  Notes and related accrued interest.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;The following table summarizes the  changes in Level 3 instruments for the years ended December 31,  2012 and 2013:&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="62%"&gt;  &lt;div&gt;Balance at January 1, 2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;3,294,797&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="62%"&gt;  &lt;div&gt;Interest accrued on face value of 5% Notes&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;844,173&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="62%"&gt;  &lt;div&gt;Change in fair value of Level 3 liabilities&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(1,659,872)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="62%"&gt;  &lt;div&gt;Balance at December 31, 2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,479,098&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="62%"&gt;  &lt;div&gt;Interest accrued on face value of 5% Notes&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;886,382&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="62%"&gt;  &lt;div&gt;Change in fair value of Level 3 liabilities&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(3,300,951)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="62%"&gt;  &lt;div&gt;Balance at December 31, 2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;64,529&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;The change in the fair value of the  Level 3 liabilities is reported in other (income) expense in the  accompanying consolidated statements of operations.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times','serif'; FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Nonrecurring Fair Value  Measurements&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;The Company&amp;#8217;s assets measured at fair value on a  nonrecurring basis as of December 31, 2013 and 2012 were as  follows:&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times','serif'; FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="35%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="47%" colspan="8"&gt;  &lt;div&gt;Fair&amp;#160;value&amp;#160;measurements&lt;br/&gt;   &amp;#160;as&amp;#160;of&amp;#160;December&amp;#160;31,&amp;#160;2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="14%"&gt;  &lt;div&gt;Total&amp;#160;impairment&amp;#160;charge&amp;#160;  for&amp;#160;the&amp;#160;year&amp;#160;ended&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="35%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="15%" colspan="2"&gt;  &lt;div&gt;Level&amp;#160;1&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="15%" colspan="2"&gt;  &lt;div&gt;Level&amp;#160;2&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="15%" colspan="2"&gt;  &lt;div&gt;Level&amp;#160;3&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="14%"&gt;  &lt;div&gt;December&amp;#160;31,&amp;#160;2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="35%"&gt;  &lt;div&gt;Assets:&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="35%"&gt;  &lt;div&gt;In-process research and development&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;(2,797,600)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="35%"&gt;  &lt;div&gt;Total&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;(2,797,600)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times','serif'; FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="35%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="47%" colspan="8"&gt;  &lt;div&gt;Fair&amp;#160;value&amp;#160;measurements&lt;br/&gt;   as&amp;#160;of&amp;#160;December&amp;#160;31,&amp;#160;2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="14%"&gt;  &lt;div&gt;Total&amp;#160;impairment&amp;#160;charge  for&amp;#160;the&amp;#160;year&amp;#160;ended&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="35%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="15%" colspan="2"&gt;  &lt;div&gt;Level&amp;#160;1&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="15%" colspan="2"&gt;  &lt;div&gt;Level&amp;#160;2&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="15%" colspan="2"&gt;  &lt;div&gt;Level&amp;#160;3&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="14%"&gt;  &lt;div&gt;December&amp;#160;31,&amp;#160;2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="35%"&gt;  &lt;div&gt;Assets:&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="35%"&gt;  &lt;div&gt;In-process research and development&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;2,797,600&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;(1,104,700)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="35%"&gt;  &lt;div&gt;Total&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;2,797,600&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;(1,104,700)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt;  &lt;/div&gt;    &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;     &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times','serif'; FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;As of December 31, 2013, as a result  of expiring intellectual property rights, uncertain regulatory  pathways, and market changes affecting the commercial potential for  the Ariston in-process research and development asset (AST-726),  the Company determined that the asset's carrying value was no  longer recoverable. Accordingly, during the year ended December  31,&amp;#160;2013, we recorded a non-cash impairment charge of&amp;#160;  $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2,797,600&lt;/font&gt;,  which was recorded as impairment of in-process research and  development in our consolidated statements of operations. The fair  value of this asset was determined to be zero primarily as a result  of the expiring intellectual property rights surrounding the asset.  This fair value measurement technique is based on significant  inputs not observable in the market and thus represents a Level 3  measurement within the fair value hierarchy.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in"&gt;  &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;As of  December 31, 2012, as a result of market changes affecting the  commercial potential for the Ariston in-process research and  development assets (AST-726 and AST-915), the Company determined  that the asset's carrying value was no longer fully recoverable.  Accordingly, during the year ended December 31,&amp;#160;2012, we  recorded a non-cash impairment charge of&amp;#160; $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,104,700&lt;/font&gt;,  which was recorded as impairment of in-process research and  development in our consolidated statements of operations. The fair  value of this asset was determined using a discounted cash flow  model, where the expected cash flows of the Ariston assets are  discounted to the present using a yield that incorporates  compensation for the probability of success in clinical development  and marketing, among other factors. This fair value measurement  technique is based on significant inputs not observable in the  market and thus represents a Level 3 measurement within the fair  value hierarchy.&amp;#160;Also contributing to the impairment charge  recorded during the period ended December 31, 2012 was the  Company&amp;#8217;s decision during 2012 to discontinue future  development activities for AST-915, following the analysis from a  Phase I dose escalation trial, in which AST-915 failed to meet its  primary efficacy endpoint.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;  &lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>

  <us-gaap:DebtDisclosureTextBlock contextRef="P01_01_2013To12_31_2013" id="Factid_2">              &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;NOTE 6 &amp;#150; NOTES  PAYABLE&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;The following is a summary of notes payable:&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="27%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="35%" colspan="8"&gt;  &lt;div&gt;December&amp;#160;31,&amp;#160;2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="35%" colspan="8"&gt;  &lt;div&gt;December&amp;#160;31,&amp;#160;2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="27%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Current&lt;br/&gt;   portion,&amp;#160;net&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Non-current&amp;#160;&lt;br/&gt;   portion,&amp;#160;&lt;br/&gt;   net&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Total&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Current&lt;br/&gt;   portion,&amp;#160;net&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Non-current&amp;#160;&lt;br/&gt;   portion,&amp;#160;&lt;br/&gt;   net&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Total&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="27%"&gt;  &lt;div&gt;Convertible 5% Notes Payable&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;-&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;64,529&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;64,529&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;-&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,479,098&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,479,098&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="27%"&gt;  &lt;div&gt;ICON Convertible Note&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;677,778&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;-&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;677,778&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;677,778&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;-&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;677,778&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="27%"&gt;  &lt;div&gt;Totals&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;677,778&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;64,529&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;742,307&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;677,778&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,479,098&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;3,156,876&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt;  &lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;  We assumed the preceding notes payable as the result of the  Exchange Transaction between the Company and TG Therapeutics, Inc.  Accordingly, a valuation using the guidance in the accounting  literature for business combinations (ASC 805) was performed and  these notes have been presented at their fair value on the date of  the transaction.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Convertible 5% Notes  Payable&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;  On March 8, 2010, Manhattan entered into an Agreement and Plan of  Merger (the "Merger Agreement") by and among the Company, Ariston  and Ariston Merger Corp., a Delaware corporation and wholly-owned  subsidiary of the Company (the "Merger Sub").&amp;#160; Pursuant to the  terms and conditions set forth in the Merger Agreement, on March 8,  2010, the Merger Sub merged with and into Ariston (the "Merger"),  with Ariston being the surviving corporation of the Merger.&amp;#160;  As a result of the Merger, Ariston became a wholly-owned subsidiary  of Manhattan.&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;  The 5% Notes and accrued and unpaid interest thereon are  convertible at the option of the holder into Common Stock at the  conversion price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,125&lt;/font&gt;  per share.&amp;#160;&amp;#160;Ariston agreed to make quarterly payments on  the &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5&lt;/font&gt;%  Notes equal to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  50&lt;/font&gt;% of the net product cash flow received from the  exploitation or commercialization of Ariston&amp;#8217;s product  candidates, AST-726 and AST-915.&amp;#160;&amp;#160;&lt;font style="COLOR: black"&gt;The Company has no obligations under the &lt;font  style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  5&lt;/font&gt;% Notes aside from a) 50% of the net product cash flows  from Ariston&amp;#8217;s product candidates, if any, payable to  noteholders; and b) the conversion feature, discussed above.&lt;/font&gt;  Interest accrues monthly, is added to principal on an annual basis,  every March 8, and is payable at maturity, which is &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;March 8,  2015&lt;/font&gt;.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;In connection with the Exchange  Transaction in December 2011, the Company performed a valuation of  the assets and liabilities of Manhattan immediately prior to the  transaction. &lt;font style="COLOR: black"&gt;The cumulative liability  including accrued and unpaid interest of these notes was  approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;16,876,000&lt;/font&gt;  immediately prior to the Exchange Transaction, and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;18,614,000&lt;/font&gt;  and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;17,727,000&lt;/font&gt;  at December 31, 2013 and 2012, respectively.&lt;/font&gt; As these notes  payable are tied directly to net product cash flows derived from  the preexisting products of the Company, this note and accrued  interest was recorded at fair value of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3,287,700&lt;/font&gt;  as of the date of the Exchange Transaction. No payments have been  made on these notes as of December 31, 2013. See Note 4 for further  details.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;ICON Convertible Note Payable&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;  In connection with the merger with Ariston as discussed above,  Ariston satisfied an account payable of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,275,188&lt;/font&gt;  to ICON Clinical Research Limited (&amp;#8220;ICON&amp;#8221;) through the  payment of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;275,188&lt;/font&gt;  in cash and the issuance of a three-year &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5&lt;/font&gt;%  note payable (the &amp;#8220;ICON Note&amp;#8221;).&amp;#160;&amp;#160;The  principal was to be repaid in &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;36 monthly&lt;/font&gt;  installments of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;27,778&lt;/font&gt;  commencing in April 2010.&amp;#160;&amp;#160;Interest was payable monthly  in arrears. &amp;#160;&amp;#160;On March 1, 2011 Ariston entered into an  amended and restated convertible promissory note (the  &amp;#8220;Amended ICON Note&amp;#8221;) with ICON. The principal terms of  the Amended ICON Note are that monthly payments of principal and  interest will be waived for the thirteen month period ended  December 31, 2011 (the &amp;#8220;Waiver Period&amp;#8221;) in exchange for  a single payment of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;100,000&lt;/font&gt;  on March 31, 2011, an increase in the interest on the Amended ICON  Note from &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5&lt;/font&gt;%  to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;8&lt;/font&gt;%  per annum during the Waiver Period and a balloon payment on January  31, 2012. The Amended ICON Note is convertible at the option of the  holder into the Company&amp;#8217;s common stock at the conversion  price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;562.50&lt;/font&gt;  per share. During the year ended December 31, 2013, the Company  recorded $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;66,506&lt;/font&gt;  of interest expense on the Amended ICON Note. As of December 31,  2013 and 2012, the principal amount of the Amended ICON Note was  $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font  style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;677,778&lt;/font&gt;&lt;/font&gt;,  of which the entire balance has been classified as current and is  reflected as notes payable, current portion, net in the  accompanying consolidated balance sheets. Interest payable on the  Amended ICON Note was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;190,017&lt;/font&gt;  and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;123,511&lt;/font&gt;  as of December 31, 2013 and 2012, respectively, and is reflected as  interest payable in the accompanying consolidated balance sheets.  As of December 31, 2013, this note was in default as the Company  did not make the balloon payment due on January 31, 2012, or any  subsequent payments. In January 2014, the Company entered into a  settlement and release agreement with ICON related to this note,  whereby the Company paid&amp;#160; $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;772,369&lt;/font&gt;  in full settlement of the principal and interest due on this  note.&amp;#160;&lt;/font&gt;&lt;/div&gt;  &lt;/div&gt;  &lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtDisclosureTextBlock>

  <tgtx:LicenseAgreementDisclosureTextBlock contextRef="P01_01_2013To12_31_2013" id="Factid_3">              &lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;NOTE 8 &amp;#150; LICENSE  AGREEMENTS&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"   align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"   align="justify"&gt;&lt;strong&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt"&gt;  TG-1101&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"   align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"   align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;On  January 30, 2012, TG Bio&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt"&gt;  entered into an exclusive license agreement with LFB  Biotechnologies, GTC Biotherapeutics and LFB/GTC LLC, all  wholly-owned subsidiaries of LFB Group, relating to the development  of TG-1101 (the &amp;#8220;License Agreement&amp;#8221;)&lt;font style="COLOR: black"&gt;.&lt;/font&gt; Under the License Agreement, we acquired  the exclusive worldwide rights (exclusive of France/Belgium) for  the development and commercialization of TG-1101 (ublituximab). To  date, we have made no payments to LFB Group, who is eligible to  receive payments of up to an aggregate of approximately $&lt;font  style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;31.0&lt;/font&gt;  million upon our successful achievement of certain clinical  development, regulatory and sales milestones, in addition to  royalty payments on net sales of TG-1101. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;The  license will terminate on a country by country basis upon the  expiration of the last licensed patent right or 15 years after the  first commercial sale of a product in such country, unless the  agreement is earlier terminated.&lt;/font&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"   align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;&amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"   align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;In  connection with the License Agreement, our subsidiary TG Bio issued  &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  7,368,000&lt;/font&gt; shares of its common stock to LFB Group, and the  Company agreed to contribute $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;15&lt;/font&gt;  million, less applicable fees and expenses associated with the  financing, to TG Bio to fund the development of TG-1101 under the  License Agreement in exchange for &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  7,500,000&lt;/font&gt; shares of TG Bio common stock. The Company  recognized&amp;#160;$&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;16,578,000&lt;/font&gt;  of noncash research and development expense during the year ended  December 31, 2012 in connection with the issuance of these shares.  In addition, in connection with this share issuance, the Company  and TG Bio provided LFB Group the option to, in its sole  discretion, elect to convert its shares of TG Bio common stock into  &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  7,500,000&lt;/font&gt; shares of the Company&amp;#8217;s Common Stock.  Furthermore, should LFB Group choose to exercise the option for  Company Common Stock, the Board of Directors of the Company shall  appoint&amp;#160;an individual designated by LFB Group to serve as a  director of the Company until the next annual meeting of the  stockholders and until his or her successor has been duly elected.  Thereafter&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;  &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;the Board of Directors of the Company shall  nominate a designee named by LFB Group for election at each annual  meeting of the stockholders until such time as LFB Group owns less  than 10% of the outstanding Company Common  Stock.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;  &lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;On November 9, 2012,  LFB Group exercised their right to exchange their TG Bio common  stock for Company Common Stock. The Company and LFB Group entered  into a Securities Exchange Agreement pursuant to which, LFB Group  agreed to exchange its &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  7,500,000&lt;/font&gt; shares of the common stock of TG Bio, for &lt;font  style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  5,000,000&lt;/font&gt; shares of Company Common Stock, and a warrant to  purchase an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  2,500,000&lt;/font&gt; shares of Company Common Stock at a purchase price  of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.001&lt;/font&gt;  per share. In addition, upon the occurrence of certain financing  conditions, the Securities Exchange Agreement requires LFB Group to  purchase at least $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;750,000&lt;/font&gt;  in additional shares of Company Common Stock at a purchase price  per share equal to the then current Market Price (as defined  therein). In addition on November 9, 2012, in connection with the  Securities Exchange Agreement, the Board of Directors (the  &amp;#8220;Board&amp;#8221;) of the Company appointed Dr. Yann Echelard to  the Board as LFB Group&amp;#8217;s nominee. Effective November 9, 2012,  in connection with the aforementioned Securities Exchange  Agreement, TG Bio became a wholly owned subsidiary of the  Company.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"   align="justify"&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt"&gt;TG-1101 &amp;#150;  Ildong Sublicense&lt;/font&gt;&lt;/i&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;In November 2012, we entered into an  exclusive (within the territory) sublicense agreement with Ildong  relating to the development and commercialization of TG-1101 in  South Korea and Southeast Asia. Under the terms of the sublicense  agreement, Ildong has been granted a royalty bearing, exclusive  right, including the right to grant sublicenses, to develop and  commercialize TG-1101 in South Korea, Taiwan, Singapore, Indonesia,  Malaysia, Thailand, Philippines, Vietnam, and Myanmar.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;An upfront payment of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2,000,000&lt;/font&gt;,  which was received in December 2012, &lt;font style="COLOR: black"&gt;net  of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;330,000&lt;/font&gt;  of&amp;#160;income tax withheld&lt;/font&gt;, is being recognized as license  revenue on a straight-line basis over the life of the agreement,  which is through the expiration of the last licensed patent right  or 15 years after the first commercial sale of a product in such  country, unless the agreement is earlier terminated, and represents  the estimated period over which the Company will have certain  ongoing responsibilities under the sublicense agreement. The  Company recorded license revenue of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;152,000&lt;/font&gt;  and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;19,000&lt;/font&gt;  for the years ended December 31, 2013 and 2012, respectively, and,  at December 31, 2013 and 2012, has deferred revenue of  approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,829,000&lt;/font&gt;  and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,981,000&lt;/font&gt;,  respectively, associated with this $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2,000,000&lt;/font&gt;  payment (approximately $152,000 of which has been classified as a  current liability at December 31, 2013).&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;The Company may receive up to an  additional $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5.0&lt;/font&gt;  million in payments upon the achievement of pre-specified  milestones. In addition, upon commercialization, Ildong will make  royalty payments to the Company on net sales of TG-1101 in the  sublicense territory.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt"&gt;  TGR-1202&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;  &lt;font style="COLOR: black"&gt;On August 15, 2012, the Company and  Rhizen Pharmaceuticals S A (&amp;#8220;Rhizen&amp;#8221;) entered into an  exclusive global agreement to collaborate on the development and  commercialization of Rhizen&amp;#8217;s lead product candidate (the  &amp;#8220;Collaboration Agreement&amp;#8221;), a novel P13K delta  inhibitor, (&amp;#8220;TGR-1202&amp;#8221;) (previously referred to as  RP5264). The companies will jointly develop the product on a  worldwide basis, excluding India, initially focusing on indications  in the area of hematologic malignancies and autoimmune disease.  Beyond TGR-1202, Rhizen would contribute backup molecules providing  multiple opportunities for TG to develop differentiated therapies  against hematologic cancers and autoimmune  diseases.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt; &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;  &lt;font style="COLOR: black"&gt;The Company will make up-front licensing  payments and milestones based on early clinical development, and  will be responsible for the costs of clinical development of the  product through Phase II, after which the Company and Rhizen will  be jointly responsible for all development costs of the product.  The Company and Rhizen will each maintain an exclusive option,  exercisable at specific times during development, for the Company  to license the rights to TGR-1202, in which case Rhizen would be  eligible to receive upfront, development, and commercialization  milestone payments in addition to milestone payments and royalties  tied to net sales of the product, the aggregate of which could  exceed $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;182.5&lt;/font&gt;million.  Rhizen shall maintain rights to manufacture and supply the product  to the Company, and the Company will be responsible for all  clinical and regulatory development for TGR-1202  globally.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;In connection with the  Collaboration Agreement, the Company incurred upfront milestone  payments of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,000,000&lt;/font&gt;  during the year ended December 31, 2012. During the year ended  December 31, 2013, the Company recognized a $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2,000,000&lt;/font&gt;  milestone payment to Rhizen related to the&lt;/font&gt; &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;development of TGR-1202. All  milestone payments related to this agreement have been included in  other research and development expenses in the accompanying  consolidated financial statements.&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Pursuant to the terms of the Collaboration  Agreement, should either of the exclusive license options be  exercised, Rhizen would be eligible to receive up to an aggregate  of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;182.5&lt;/font&gt;  million upon the successful achievement of certain clinical  development, regulatory, and sales based milestones in addition to  royalties on net sales of TGR-1202.&lt;/font&gt;&lt;/div&gt;  &lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</tgtx:LicenseAgreementDisclosureTextBlock>

  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2013To12_31_2013" id="Factid_4">              &lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;NOTE 10 &amp;#150; RELATED PARTY  TRANSACTIONS&lt;/font&gt;&lt;/strong&gt;     &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-FAMILY: 'Times','serif'; FONT-SIZE: 10pt"&gt;On  December 30, 2011, OPN Capital Markets (&amp;#8220;OPNCM&amp;#8221;) and  its affiliated broker-dealer, National Securities Corporation  (&amp;#8220;NSC&amp;#8221; and collectively with OPNCM,  &amp;#8220;National&amp;#8221;), both affiliates of National Holdings  Corporation (&amp;#8220;National Holdings&amp;#8221;), entered into a  Placement Agency Agreement (the &amp;#8220;PAA&amp;#8221;) with the Company  in connection with the initial closing of the 2011 Equity  PIPE.&amp;#160;&amp;#160;Pursuant to the PAA, National acted as the  Company&amp;#8217;s placement agent for 2011 Equity PIPE.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-FAMILY: 'Times','serif'; FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-FAMILY: 'Times','serif'; FONT-SIZE: 10pt"&gt;Until  April 2012, Michael S. Weiss was a director and Non-Executive  Chairman of the Board of Directors of National  Holdings.&amp;#160;&amp;#160;He is also a stockholder of National Holdings  and, when combined with his ownership indirectly through Opus and  its affiliates, beneficially owns approximately &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5&lt;/font&gt;%  of National Holdings, the parent company of NSC.&amp;#160;Mr. Weiss  disclaims such beneficial ownership other than to the extent of his  pecuniary interest. In addition, at the time, Opus and NSC were  parties to a 50/50 joint venture that shared profits from OPNCM,  the investment banking division of NSC that was responsible for  managing the Offering. This joint venture was dissolved in April  2012.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-FAMILY: 'Times','serif'; FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-FAMILY: 'Times','serif'; FONT-SIZE: 10pt"&gt;As  placement agent, National received cash commissions equal to &lt;font  style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  10&lt;/font&gt;% of the gross proceeds of the 2011 Equity PIPE, five-year  warrants to purchase shares of Company Preferred Stock equal to  &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  10&lt;/font&gt;% of shares sold in the 2011 Equity PIPE, and a  non-accountable expense allowance equal to two percent of the gross  proceeds of the 2011 Equity PIPE for National&amp;#8217;s expenses (not  including up to $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;80,000&lt;/font&gt;  of National&amp;#8217;s legal expenses and any blue sky fees, both of  which the Company also reimbursed).&amp;#160;In connection with the  dissolution of the joint venture in January 2013, National waived  all rights to and surrendered to Opus the warrants discussed above.  In addition to acting as placement agent, National provided  advisory services in connection with the Exchange Transaction and  received an advisory fee of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;150,000&lt;/font&gt;  for such services.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font   style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;  &lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-FAMILY: 'Times','serif'"&gt;Under the terms of the  Company&amp;#8217;s License Agreement with LFB Group, the Company  utilizes LFB Group for certain development and manufacturing  services.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;  The Company incurred approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;6,267,000&lt;/font&gt;  and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,447,000&lt;/font&gt;  in such expenses during the years ended December 31, 2013 and 2012,  respectively, which have been included in other research and  development expenses in the accompanying consolidated statements of  operations. As of December 31, 2013 and 2012, respectively, the  Company has approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,745,000&lt;/font&gt;  and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;56,000&lt;/font&gt;  recorded in accounts payable related to the aforementioned  agreements with LFB Group. In conjunction with the development and  manufacturing services discussed above, certain agreements between  the Company and LFB Group require payments in advance of services  performed or goods delivered.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;  Accordingly, as of December 31, 2013 and 2012, respectively, the  Company recorded $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,629,340&lt;/font&gt;  and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;1,719,828&lt;/font&gt;  in prepaid research and development for such advance  payments.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-FAMILY: 'Times','serif'"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; BACKGROUND: transparent; TEXT-AUTOSPACE: ideograph-numeric"   align="justify"&gt;&lt;font style="FONT-FAMILY: 'Times','serif'"&gt;In  connection with the Collaboration Agreement with Rhizen in August  2012, the Company issued Opus &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  2,000,000&lt;/font&gt; shares of Company common stock subject to certain  vesting provisions based on the progress of the joint venture and  future success of the products governed by the Collaboration  Agreement. The issuance of the Company Common Stock was exempt from  registration under the Securities Act of 1933 pursuant to  Regulation D and Rule 506 promulgated thereunder. Accordingly, the  securities have not been registered under the Securities Act, and  until so registered, these securities may not be offered or sold in  the United States absent registration or availability of an  applicable exemption from registration. The Company recognized  approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;437,000&lt;/font&gt;  and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;134,000&lt;/font&gt;  of noncash compensation (research and development) expense during  the year ended December 31, 2013 and 2012, respectively, in  connection with the issuance of these shares.&lt;/font&gt;&lt;/div&gt;  &lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>

  <tgtx:BusinessDescriptionPolicyTextBlock contextRef="P01_01_2013To12_31_2013" id="Factid_5">              &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;DESCRIPTION OF  BUSINESS&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;We are a biopharmaceutical company  focused on the acquisition, development and commercialization of  innovative and medically important pharmaceutical products for the  treatment of cancer and other underserved therapeutic needs. We aim  to acquire rights to these technologies by licensing or otherwise  acquiring an ownership interest, funding their research and  development and eventually either out-licensing or bringing the  technologies to market. Currently, the Company is developing two  therapies targeting hematological malignancies.&lt;/font&gt; &lt;font style="FONT-FAMILY: 'Tahoma','sans-serif'; COLOR: #333333; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt"&gt;TG-1101 (ublituximab), is a  novel, &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  glycoengineered&lt;/font&gt;&amp;#160;monoclonal antibody that targets a  specific and unique epitope on the CD20 antigen found on mature  B-lymphocytes&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;. We are  also developing&lt;/font&gt; TGR-1202, an orally available PI3K delta  inhibitor. We also hold the development rights to AST-726, a  nasally delivered product for the treatment of Vitamin  B&lt;sub&gt;12&lt;/sub&gt; deficiency.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Exchange Transaction with TG  Therapeutics, Inc. and its majority  shareholders&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;On December 29, 2011, the Company  entered into and consummated an Exchange Transaction Agreement with  Opus Point Partners, LLC (&amp;#8220;Opus&amp;#8221;) and TG Biologics,  Inc. (formerly known as TG Therapeutics, Inc.) (&amp;#8220;TG  Bio&amp;#8221;) (the &amp;#8220;Agreement&amp;#8221;). Under the Agreement,  Opus exchanged (the &amp;#8220;Exchange Transaction&amp;#8221;) its shares  of common stock in TG Bio (&amp;#8220;TG Bio Common Stock&amp;#8221;) for  shares of Series A preferred stock in the Company (&amp;#8220;Company  Preferred Stock&amp;#8221;). In accordance with the terms of the  Agreement, &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  95&lt;/font&gt;% of the holders of common stock of TG Bio (one (1)  minority shareholder of TG Bio holding in aggregate &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  132,000&lt;/font&gt; shares of common stock of TG Bio did not  participate) surrendered their TG Bio common stock. The Agreement  caused the Company to issue to TG Bio&amp;#8217;s shareholders &lt;font  style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  281,250&lt;/font&gt; shares of Company Preferred Stock. &lt;font style="COLOR: black"&gt;Each share of Company Preferred Stock was  convertible into &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font  style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  8.89&lt;/font&gt;&lt;/font&gt; shares of the Common Stock provided that such  conversion rights were subject to sufficient available authorized  shares of Common Stock. In connection with the reverse stock split  effected by the Company on April 30, 2012 (as discussed below), all  shares of preferred stock issued in connection with the Agreement  were converted to Common Stock.&lt;/font&gt; The Company Preferred Stock  issued in connection with the Agreement provided the former TG Bio  shareholders with direct and/or indirect ownership of approximately  &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  95&lt;/font&gt;% of the Company&amp;#8217;s outstanding Company Common Stock  immediately following the consummation of the  transaction.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;Since the stockholders of TG Bio  received the majority of the voting shares of the Company, the  merger was accounted for as a reverse acquisition whereby TG Bio  was the accounting acquirer (legal acquiree) and the Company was  the accounting acquiree (legal acquirer) under the acquisition  method of accounting. TG Bio was incorporated in Delaware in  November 2010, but did not commence operations until April  2011.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;The filings with the Securities and  Exchange Commission (the &amp;#8220;SEC&amp;#8221;) include the historical  financial results of TG Bio and will hereafter collectively be  referred to as the Company.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;On April 30, 2012, the Company filed  a Certificate of Amendment to its Certificate of Incorporation to  change its name from Manhattan Pharmaceuticals, Inc.  (&amp;#8220;Manhattan&amp;#8221;) to TG Therapeutics, Inc. In conjunction  with this change, the subsidiary formerly named TG Therapeutics,  Inc. filed a Certificate of Amendment changing its name to TG  Biologics, Inc.&lt;/font&gt;&lt;/div&gt;  &lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</tgtx:BusinessDescriptionPolicyTextBlock>

  <us-gaap:LiquidityDisclosureTextBlock contextRef="P01_01_2013To12_31_2013" id="Factid_6">              &lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;LIQUIDITY AND CAPITAL  RESOURCES&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; BACKGROUND: transparent"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;We have incurred operating losses  since our inception, and expect to continue to incur operating  losses for the foreseeable future and may never become profitable.  As of December 31, 2013, we have an accumulated deficit of $&lt;font  style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;39,404,003&lt;/font&gt;.&lt;/font&gt;&lt;/div&gt;  &lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Our  primary source of cash has been proceeds from the sale of equity  securities, &lt;font style="COLOR: black"&gt;the upfront payment from our  Sublicense Agreement with Ildong Pharmaceutical Co. Ltd.  (&amp;#8220;Ildong&amp;#8221;), and warrant exercises&lt;/font&gt;. We have not  yet commercialized any of our drug candidates and cannot be sure if  we will ever be able to do so. Even if we commercialize one or more  of our drug candidates, we may not become profitable. Our ability  to achieve profitability depends on a number of factors, including  our ability to obtain regulatory approval for our drug candidates,  successfully complete any post-approval regulatory obligations and  successfully commercialize our drug candidates alone or in  partnership. We may continue to incur substantial operating losses  even if we begin to generate revenues from our drug  candidates.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; BACKGROUND: transparent"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;As of December 31, 2013, we had  $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;45,431,532&lt;/font&gt;  in cash, cash equivalents, investment securities, and interest  receivable. We currently anticipate that our cash and cash  equivalents to be sufficient to fund our anticipated operating cash  requirements for approximately&amp;#160;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;24&lt;/font&gt;  months from December 31, 2013. The actual amount of cash that we  will need to operate is subject to many factors, including, but not  limited to, the timing, design and conduct of clinical trials for  our drug candidates. We are dependent upon significant future  financing to provide the cash necessary to execute our current  operations, including the commercialization of any of our drug  candidates.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"   align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Our common stock is  quoted on &lt;font style="COLOR: black"&gt;the NASDAQ Capital  Market&lt;/font&gt; and trades under the symbol  &amp;#8220;TGTX.&amp;#8221;&lt;/font&gt;&lt;/div&gt;  &lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LiquidityDisclosureTextBlock>

  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2013To12_31_2013" id="Factid_7">              &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;CASH AND CASH  EQUIVALENTS&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;We treat liquid investments with  original maturities of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;less than three  months&lt;/font&gt; when purchased as cash and cash  equivalents.&lt;/font&gt;&lt;/div&gt;  &lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>

  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="P01_01_2013To12_31_2013" id="Factid_8">              &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;REVENUE  RECOGNITION&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;We recognize license revenue in  accordance with the revenue recognition guidance of the FASB  Accounting Standards Codification, or Codification. We analyze each  element of our licensing agreement to determine the appropriate  revenue recognition. The terms of the license agreement may include  payments to us of non-refundable up-front license fees, milestone  payments if specified objectives are achieved, and/or royalties on  product sales. We recognize revenue from upfront payments over the  period of significant involvement under the related agreements  unless the fee is in exchange for products delivered or services  rendered that represent the culmination of a separate earnings  process and no further performance obligation exists under the  contract. We recognize milestone payments as revenue upon the  achievement of specified milestones only if (1)&amp;#160;the milestone  payment is non-refundable, (2)&amp;#160;substantive effort is involved  in achieving the milestone, (3)&amp;#160;the amount of the milestone is  reasonable in relation to the effort expended or the risk  associated with achievement of the milestone, and (4)&amp;#160;the  milestone is at risk for both parties. If any of these conditions  are not met, we defer the milestone payment and recognize it as  revenue over the estimated period of performance under the  contract.&lt;/font&gt;&lt;/div&gt;  &lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>

  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P01_01_2013To12_31_2013" id="Factid_9">              &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;RESEARCH AND DEVELOPMENT  COSTS&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;Generally, research and development  costs are expensed as incurred. Nonrefundable advance payments for  goods or services that will be used or rendered for future research  and development activities are deferred and amortized over the  period that the goods are delivered or the related services are  performed, subject to an assessment of recoverability. We make  estimates of costs incurred in relation to external clinical  research organizations, or CROs, and clinical site costs. We  analyze the progress of clinical trials, including levels of  patient enrollment, invoices received and contracted costs when  evaluating the adequacy of the amount expensed and the related  prepaid asset and accrued liability. Significant judgments and  estimates must be made and used in determining the accrued balance  and expense in any accounting period. We review and accrue CRO  expenses and clinical trial study expenses based on work performed  and rely upon estimates of those costs applicable to the stage of  completion of a study. Accrued CRO costs are subject to revisions  as such trials progress to completion. Revisions are charged to  expense in the period in which the facts that give rise to the  revision become known. With respect to clinical site costs, the  financial terms of these agreements are subject to negotiation and  vary from contract to contract. Payments under these contracts may  be uneven, and depend on factors such as the achievement of certain  events, the successful recruitment of patients, the completion of  portions of the clinical trial or similar conditions. The objective  of our policy is to match the recording of expenses in our  financial statements to the actual services received and efforts  expended. As such, expense accruals related to clinical site costs  are recognized based on our estimate of the degree of completion of  the event or events specified in the specific clinical study or  trial contract.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;    &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font   style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>

  <us-gaap:InProcessResearchAndDevelopmentPolicy contextRef="P01_01_2013To12_31_2013" id="Factid_10">              &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font   style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;IN-PROCESS  RESEARCH AND DEVELOPMENT&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;  All acquired research and development projects are recorded at  their fair value as of the date acquisition. The fair values are  assessed as of the balance sheet date to ascertain if there has  been any impairment of the recorded value. If there is an  impairment, the asset is written down to its current fair value by  the recording of an expense. Impairment is tested on an annual  basis &lt;font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"&gt;or sooner, if  there is an indication of impairment,&lt;/font&gt; and consists of a  comparison of the fair value of the in-process research and  development with its carrying amount.&lt;/font&gt;&lt;/div&gt;  &lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>

  <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2013To12_31_2013" id="Factid_11">              &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;INCOME TAXES&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;Income taxes are accounted for under  the asset and liability method. Deferred tax assets and liabilities  are recognized for the future tax consequences attributable to  temporary differences between the financial statement carrying  amounts of existing assets and liabilities and their respective tax  bases, operating losses and tax credit carryforwards. Deferred tax  assets and liabilities are measured using enacted tax rates  expected to apply to taxable income in the years in which those  temporary differences are expected to be recovered or settled. The  effect on deferred tax assets and liabilities of a change in tax  rates is recognized in operations in the period that includes the  enactment date. If the likelihood of realizing the deferred tax  assets or liability is less than &amp;#8220;more likely than  not,&amp;#8221; a valuation allowance is then created.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;We, and our subsidiaries, file income  tax returns in the U.S. Federal jurisdiction and in various states.  We have tax net operating loss carryforwards that are subject to  examination for a number of years beyond the year in which they  were generated for tax purposes. Since a portion of these net  operating loss carryforwards may be utilized in the future, many of  these net operating loss carryforwards will remain subject to  examination.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;We recognize interest and penalties  related to uncertain income tax positions in income tax  expense.&lt;/font&gt;&lt;/div&gt;  &lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IncomeTaxPolicyTextBlock>

  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P01_01_2013To12_31_2013" id="Factid_12">              &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;STOCK - BASED  COMPENSATION&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;We recognize all share-based payments  to employees and to non-employee directors as compensation for  service&amp;#160;as compensation expense in the consolidated financial  statements based on the fair values of such payments. Stock-based  compensation expense recognized each period is based on the value  of the portion of share-based payment awards that is ultimately  expected to vest during the period. Forfeitures are estimated at  the time of grant and revised, if necessary, in subsequent periods  if actual forfeitures differ from those estimates.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;For share-based payments to  consultants and other third-parties, compensation expense is  determined at the &amp;#8220;measurement date.&amp;#8221; The expense is  recognized over the vesting period of the award. Until the  measurement date is reached, the total amount of compensation  expense remains uncertain. We record compensation expense based on  the fair value of the award at the reporting date. The awards to  consultants and other third-parties are then revalued, or the total  compensation is recalculated based on the then current fair value,  at each subsequent reporting date.&lt;/font&gt;&lt;/div&gt;  &lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>

  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P01_01_2013To12_31_2013" id="Factid_13">              &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;BASIC AND DILUTED NET (LOSS)  INCOME PER COMMON SHARE&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;Basic net income (loss) per common  share is calculated by dividing net income (loss) applicable to  common shares by the weighted-average number of common shares  outstanding for the period. Diluted net loss per common share is  the same as basic net income (loss) per common share, since  potentially dilutive securities from stock options, stock warrants  and convertible preferred stock would have an antidilutive effect  either because the Company incurred a net loss during the period  presented or because such potentially dilutive securities were out  of the money and the Company realized net income during the period  presented. The amounts of potentially dilutive securities excluded  from the calculation were &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  10,618,584&lt;/font&gt; and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  10,746,837&lt;/font&gt; at December 31, 2013 and 2012, respectively.  During the years ended December 31, 2013 and 2012 the Company  incurred a net loss, therefore, all of the dilutive securities are  excluded from the computation of diluted earnings per  share.&lt;/font&gt;&lt;/div&gt;  &lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>

  <tgtx:ImpairmentOfTangibleAndIntangibleAssetIncludingGoodwillPolicyTextBlock contextRef="P01_01_2013To12_31_2013" id="Factid_14">              &lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;LONG-LIVED ASSETS AND  GOODWILL&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;Long-lived assets are reviewed for an  impairment loss when circumstances indicate that the carrying value  of long-lived tangible and intangible assets with finite lives may  not be recoverable. Management&amp;#8217;s policy in determining  whether an impairment indicator exists, a triggering event,  comprises measurable operating performance criteria as well as  qualitative measures. If an analysis is necessitated by the  occurrence of a triggering event, we make certain assumptions in  determining the impairment amount. If the carrying amount of an  asset exceeds its estimated future cash flows, an impairment charge  is recognized.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;    &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font   style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in"&gt;  &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font  style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font  style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font   style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font   style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Goodwill  is reviewed for impairment annually, or when events arise that  could indicate that an impairment exists. We test for goodwill  impairment using a two-step process. The first step compares the  fair value of the reporting unit with the unit's carrying value,  including goodwill. When the carrying value of the reporting unit  is greater than fair value, the unit&amp;#8217;s goodwill may be  impaired, and the second step must be completed to measure the  amount of the goodwill impairment charge, if any. In the second  step, the implied fair value of the reporting unit&amp;#8217;s goodwill  is compared with the carrying amount of the unit&amp;#8217;s goodwill.  If the carrying amount is greater than the implied fair value, the  carrying value of the goodwill must be written down to its implied  fair value. We will continue to perform impairment tests annually,  at December 31, and whenever events or changes in circumstances  suggest that the carrying value of an asset may not be  recoverable.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font   style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font   style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;  &lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</tgtx:ImpairmentOfTangibleAndIntangibleAssetIncludingGoodwillPolicyTextBlock>

  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="P01_01_2013To12_31_2013" id="Factid_15">              &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;The Company&amp;#8217;s financial  liabilities measured at fair value on a recurring basis as of  December 31, 2013 and 2012 were as follows:&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="50%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="47%" colspan="11"&gt;  &lt;div&gt;Financial liabilities at fair value&lt;br/&gt;   as of December 31, 2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="50%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Level&amp;#160;1&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Level&amp;#160;2&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Level&amp;#160;3&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Total&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="50%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="50%"&gt;  &lt;div&gt;5% Notes&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;64,529&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;64,529&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="50%"&gt;  &lt;div&gt;Totals&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;64,529&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;64,529&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="48%" colspan="12"&gt;  &lt;div&gt;Financial&amp;#160;liabilities&amp;#160;at&amp;#160;fair&amp;#160;value&lt;br/&gt;   &amp;#160;as&amp;#160;of&amp;#160;December&amp;#160;31,&amp;#160;2012&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Level&amp;#160;1&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Level&amp;#160;2&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Level&amp;#160;3&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Total&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;5% Notes&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,479,098&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,479,098&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="51%"&gt;  &lt;div&gt;Totals&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,479,098&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,479,098&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;  &lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>

  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="P01_01_2013To12_31_2013" id="Factid_16">              &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;The following table summarizes the changes in Level 3  instruments for the years ended December 31, 2012 and  2013:&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="62%"&gt;  &lt;div&gt;Balance at January 1, 2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;3,294,797&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="62%"&gt;  &lt;div&gt;Interest accrued on face value of 5% Notes&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;844,173&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="62%"&gt;  &lt;div&gt;Change in fair value of Level 3 liabilities&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(1,659,872)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="62%"&gt;  &lt;div&gt;Balance at December 31, 2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,479,098&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="62%"&gt;  &lt;div&gt;Interest accrued on face value of 5% Notes&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;886,382&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="62%"&gt;  &lt;div&gt;Change in fair value of Level 3 liabilities&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(3,300,951)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="62%"&gt;  &lt;div&gt;Balance at December 31, 2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;64,529&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;  &lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>

  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2013To12_31_2013" id="Factid_17">              &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;The following table summarizes stock  option activity for the years ended December 31, 2013 and  2012:&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="37%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="14%"&gt;  &lt;div&gt;Number&lt;br/&gt;   of&amp;#160;shares&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="15%" colspan="2"&gt;  &lt;div&gt;Weighted-&lt;br/&gt;   average&lt;br/&gt;   exercise&amp;#160;price&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="14%"&gt;  &lt;div&gt;Weighted-&lt;br/&gt;   average&lt;br/&gt;   Contractual&lt;br/&gt;   Term&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="15%" colspan="2"&gt;  &lt;div&gt;Aggregate Intrinsic&amp;#160;&lt;br/&gt;   Value&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="37%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="14%"&gt;  &lt;div&gt;(in&amp;#160;years)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="37%"&gt;  &lt;div&gt;Outstanding at January 1, 2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;3,379&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;1,315.62&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 12px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="37%"&gt;  &lt;div&gt;Granted&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;46,000&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;4.40&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 12px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="37%"&gt;  &lt;div&gt;Exercised&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 12px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="37%"&gt;  &lt;div&gt;Forfeited&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;(2,475)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;720.45&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 12px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="37%"&gt;  &lt;div&gt;Expired&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="37%"&gt;  &lt;div&gt;Outstanding at December 31, 2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;46,904&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;61.08&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;9.44&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 12px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="37%"&gt;  &lt;div&gt;Granted&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 12px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="37%"&gt;  &lt;div&gt;Exercised&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 12px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="37%"&gt;  &lt;div&gt;Forfeited&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;(313)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;2,249.85&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 12px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="37%"&gt;  &lt;div&gt;Expired&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="37%"&gt;  &lt;div&gt;Outstanding at December 31, 2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;46,591&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;46.37&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;8.50&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="37%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="37%"&gt;  &lt;div&gt;Vested and expected to vest at December 31, 2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;9,591&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;208.30&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;8.16&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="37%"&gt;  &lt;div&gt;Exercisable at December 31, 2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;9,591&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;208.30&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;8.16&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;  &lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>

  <tgtx:ScheduleOfWarrantsActivityTableTextBlock contextRef="P01_01_2013To12_31_2013" id="Factid_18">              &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;The following table summarizes  warrant activity for the years ended December 31, 2013 and  2012:&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="44%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="10%"&gt;  &lt;div&gt;Warrants&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Weighted-&lt;br/&gt;   average&lt;br/&gt;   exercise&amp;#160;price&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Aggregate&lt;br/&gt;   Intrinsic&amp;#160;&lt;br/&gt;   Value&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="44%"&gt;  &lt;div&gt;Outstanding at January 1, 2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;1,625,911&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;5.27&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="44%"&gt;  &lt;div&gt;Issued&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;5,156,599&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;1.21&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="44%"&gt;  &lt;div&gt;Exercised&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="44%"&gt;  &lt;div&gt;Expired&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(1,503)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,739.75&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="44%"&gt;  &lt;div&gt;Outstanding at December 31, 2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;6,781,007&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;1.58&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;14,563,539&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="44%"&gt;  &lt;div&gt;Issued&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="44%"&gt;  &lt;div&gt;Exercised&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(1,018,068)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2.25&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="44%"&gt;  &lt;div&gt;Expired&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(43,992)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;16.26&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="44%"&gt;  &lt;div&gt;Outstanding at December 31, 2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;5,718,947&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;1.34&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;14,809,030&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt;  &lt;/div&gt;  &lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</tgtx:ScheduleOfWarrantsActivityTableTextBlock>

  <tgtx:ScheduleOfShareBasedCompensationExpenseTableTextBlock contextRef="P01_01_2013To12_31_2013" id="Factid_19">              &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;The following table summarizes  stock-based compensation expense information about stock options  and restricted stock for the years ended December 31, 2013 and  2012:&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="MARGIN: 0in; WIDTH: 85%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="60%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="60%"&gt;  &lt;div&gt;Stock-based compensation expense associated with restricted  stock&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;5,146,743&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;3,422,182&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="60%"&gt;  &lt;div&gt;Stock-based compensation expense associated with option  grants&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;56,405&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="60%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;5,203,148&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;3,422,182&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;  &lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</tgtx:ScheduleOfShareBasedCompensationExpenseTableTextBlock>

  <us-gaap:ScheduleOfDebtTableTextBlock contextRef="P01_01_2013To12_31_2013" id="Factid_20">              &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;The following is a summary of notes  payable:&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="27%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="35%" colspan="8"&gt;  &lt;div&gt;December&amp;#160;31,&amp;#160;2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="35%" colspan="8"&gt;  &lt;div&gt;December&amp;#160;31,&amp;#160;2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="27%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Current&lt;br/&gt;   portion,&amp;#160;net&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Non-current&amp;#160;&lt;br/&gt;   portion,&amp;#160;&lt;br/&gt;   net&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Total&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Current&lt;br/&gt;   portion,&amp;#160;net&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Non-current&amp;#160;&lt;br/&gt;   portion,&amp;#160;&lt;br/&gt;   net&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Total&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="27%"&gt;  &lt;div&gt;Convertible 5% Notes Payable&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;-&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;64,529&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;64,529&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;-&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,479,098&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,479,098&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="27%"&gt;  &lt;div&gt;ICON Convertible Note&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;677,778&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;-&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;677,778&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;677,778&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;-&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;677,778&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="27%"&gt;  &lt;div&gt;Totals&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;677,778&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;64,529&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;742,307&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;677,778&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,479,098&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;3,156,876&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;  &lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtTableTextBlock>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn12_31_2012" id="Factid_21" unitRef="USD" decimals="0">16455995</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn12_31_2013" id="Factid_22" unitRef="USD" decimals="0">40485466</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <tgtx:PrepaidResearchAndDevelopment contextRef="PAsOn12_31_2012" id="Factid_23" unitRef="USD" decimals="0">1990759</tgtx:PrepaidResearchAndDevelopment>

  <tgtx:PrepaidResearchAndDevelopment contextRef="PAsOn12_31_2013" id="Factid_24" unitRef="USD" decimals="0">1742824</tgtx:PrepaidResearchAndDevelopment>

  <us-gaap:OtherAssetsCurrent contextRef="PAsOn12_31_2012" id="Factid_25" unitRef="USD" decimals="0">29128</us-gaap:OtherAssetsCurrent>

  <us-gaap:OtherAssetsCurrent contextRef="PAsOn12_31_2013" id="Factid_26" unitRef="USD" decimals="0">47804</us-gaap:OtherAssetsCurrent>

  <us-gaap:AssetsCurrent contextRef="PAsOn12_31_2012" id="Factid_27" unitRef="USD" decimals="0">18475882</us-gaap:AssetsCurrent>

  <us-gaap:AssetsCurrent contextRef="PAsOn12_31_2013" id="Factid_28" unitRef="USD" decimals="0">42303263</us-gaap:AssetsCurrent>

  <us-gaap:PropertyPlantAndEquipmentNet contextRef="PAsOn12_31_2012" id="Factid_29" unitRef="USD" decimals="0">1164</us-gaap:PropertyPlantAndEquipmentNet>

  <us-gaap:PropertyPlantAndEquipmentNet contextRef="PAsOn12_31_2013" id="Factid_30" unitRef="USD" decimals="0">5718</us-gaap:PropertyPlantAndEquipmentNet>

  <tgtx:InProcessResearchAndDevelopment contextRef="PAsOn12_31_2012" id="Factid_31" unitRef="USD" decimals="0">2797600</tgtx:InProcessResearchAndDevelopment>

  <tgtx:InProcessResearchAndDevelopment contextRef="PAsOn12_31_2013" id="Factid_32" unitRef="USD" decimals="0">0</tgtx:InProcessResearchAndDevelopment>

  <us-gaap:Goodwill contextRef="PAsOn12_31_2012" id="Factid_33" unitRef="USD" decimals="0">799391</us-gaap:Goodwill>

  <us-gaap:Goodwill contextRef="PAsOn12_31_2013" id="Factid_34" unitRef="USD" decimals="0">799391</us-gaap:Goodwill>

  <us-gaap:OtherAssetsNoncurrent contextRef="PAsOn12_31_2012" id="Factid_35" unitRef="USD" decimals="0">0</us-gaap:OtherAssetsNoncurrent>

  <us-gaap:OtherAssetsNoncurrent contextRef="PAsOn12_31_2013" id="Factid_36" unitRef="USD" decimals="0">85121</us-gaap:OtherAssetsNoncurrent>

  <us-gaap:Assets contextRef="PAsOn12_31_2012" id="Factid_37" unitRef="USD" decimals="0">22074037</us-gaap:Assets>

  <us-gaap:Assets contextRef="PAsOn12_31_2013" id="Factid_38" unitRef="USD" decimals="0">48112390</us-gaap:Assets>

  <us-gaap:NotesPayableCurrent contextRef="PAsOn12_31_2012" id="Factid_39" unitRef="USD" decimals="0">677778</us-gaap:NotesPayableCurrent>

  <us-gaap:NotesPayableCurrent contextRef="PAsOn12_31_2013" id="Factid_40" unitRef="USD" decimals="0">677778</us-gaap:NotesPayableCurrent>

  <us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="PAsOn12_31_2012" id="Factid_41" unitRef="USD" decimals="0">1117397</us-gaap:OtherAccountsPayableAndAccruedLiabilities>

  <us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="PAsOn12_31_2013" id="Factid_42" unitRef="USD" decimals="0">4764502</us-gaap:OtherAccountsPayableAndAccruedLiabilities>

  <us-gaap:DeferredCompensationLiabilityCurrent contextRef="PAsOn12_31_2012" id="Factid_43" unitRef="USD" decimals="0">145000</us-gaap:DeferredCompensationLiabilityCurrent>

  <us-gaap:DeferredCompensationLiabilityCurrent contextRef="PAsOn12_31_2013" id="Factid_44" unitRef="USD" decimals="0">532500</us-gaap:DeferredCompensationLiabilityCurrent>

  <us-gaap:DeferredRevenueCurrent contextRef="PAsOn12_31_2012" id="Factid_45" unitRef="USD" decimals="0">152381</us-gaap:DeferredRevenueCurrent>

  <us-gaap:DeferredRevenueCurrent contextRef="PAsOn12_31_2013" id="Factid_46" unitRef="USD" decimals="0">152381</us-gaap:DeferredRevenueCurrent>

  <us-gaap:InterestPayableCurrent contextRef="PAsOn12_31_2012" id="Factid_47" unitRef="USD" decimals="0">123511</us-gaap:InterestPayableCurrent>

  <us-gaap:InterestPayableCurrent contextRef="PAsOn12_31_2013" id="Factid_48" unitRef="USD" decimals="0">190017</us-gaap:InterestPayableCurrent>

  <us-gaap:LiabilitiesCurrent contextRef="PAsOn12_31_2012" id="Factid_49" unitRef="USD" decimals="0">2216067</us-gaap:LiabilitiesCurrent>

  <us-gaap:LiabilitiesCurrent contextRef="PAsOn12_31_2013" id="Factid_50" unitRef="USD" decimals="0">6317178</us-gaap:LiabilitiesCurrent>

  <us-gaap:DeferredRevenueNoncurrent contextRef="PAsOn12_31_2012" id="Factid_51" unitRef="USD" decimals="0">1828571</us-gaap:DeferredRevenueNoncurrent>

  <us-gaap:DeferredRevenueNoncurrent contextRef="PAsOn12_31_2013" id="Factid_52" unitRef="USD" decimals="0">1676191</us-gaap:DeferredRevenueNoncurrent>

  <us-gaap:LongTermNotesPayable contextRef="PAsOn12_31_2012" id="Factid_53" unitRef="USD" decimals="0">2479098</us-gaap:LongTermNotesPayable>

  <us-gaap:LongTermNotesPayable contextRef="PAsOn12_31_2013" id="Factid_54" unitRef="USD" decimals="0">64529</us-gaap:LongTermNotesPayable>

  <us-gaap:Liabilities contextRef="PAsOn12_31_2012" id="Factid_55" unitRef="USD" decimals="0">6523736</us-gaap:Liabilities>

  <us-gaap:Liabilities contextRef="PAsOn12_31_2013" id="Factid_56" unitRef="USD" decimals="0">8057898</us-gaap:Liabilities>

  <us-gaap:CommitmentsAndContingencies contextRef="PAsOn12_31_2012" id="Factid_57" unitRef="USD" xsi:nil="true" />

  <us-gaap:CommitmentsAndContingencies contextRef="PAsOn12_31_2013" id="Factid_58" unitRef="USD" xsi:nil="true" />

  <us-gaap:PreferredStockValue contextRef="PAsOn12_31_2012" id="Factid_59" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>

  <us-gaap:PreferredStockValue contextRef="PAsOn12_31_2013" id="Factid_60" unitRef="USD" decimals="0">0</us-gaap:PreferredStockValue>

  <us-gaap:CommonStockValue contextRef="PAsOn12_31_2012" id="Factid_61" unitRef="USD" decimals="0">25821</us-gaap:CommonStockValue>

  <us-gaap:CommonStockValue contextRef="PAsOn12_31_2013" id="Factid_62" unitRef="USD" decimals="0">34336</us-gaap:CommonStockValue>

  <tgtx:ContingentlyIssuableShares contextRef="PAsOn12_31_2012" id="Factid_63" unitRef="USD" decimals="0">6</tgtx:ContingentlyIssuableShares>

  <tgtx:ContingentlyIssuableShares contextRef="PAsOn12_31_2013" id="Factid_64" unitRef="USD" decimals="0">6</tgtx:ContingentlyIssuableShares>

  <us-gaap:AdditionalPaidInCapital contextRef="PAsOn12_31_2012" id="Factid_65" unitRef="USD" decimals="0">34534805</us-gaap:AdditionalPaidInCapital>

  <us-gaap:AdditionalPaidInCapital contextRef="PAsOn12_31_2013" id="Factid_66" unitRef="USD" decimals="0">79658490</us-gaap:AdditionalPaidInCapital>

  <us-gaap:TreasuryStockValue contextRef="PAsOn12_31_2012" id="Factid_67" unitRef="USD" decimals="0">84538</us-gaap:TreasuryStockValue>

  <us-gaap:TreasuryStockValue contextRef="PAsOn12_31_2013" id="Factid_68" unitRef="USD" decimals="0">234337</us-gaap:TreasuryStockValue>

  <us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage contextRef="PAsOn12_31_2012" id="Factid_69" unitRef="USD" decimals="0">18925793</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>

  <us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage contextRef="PAsOn12_31_2013" id="Factid_70" unitRef="USD" decimals="0">39404003</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2012" id="Factid_71" unitRef="USD" decimals="0">15550301</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2013" id="Factid_72" unitRef="USD" decimals="0">40054492</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="PAsOn12_31_2012" id="Factid_73" unitRef="USD" decimals="0">22074037</us-gaap:LiabilitiesAndStockholdersEquity>

  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="PAsOn12_31_2013" id="Factid_74" unitRef="USD" decimals="0">48112390</us-gaap:LiabilitiesAndStockholdersEquity>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P01_01_2012To12_31_2012" id="Factid_75" unitRef="shares" decimals="INF">10746837</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="P01_01_2013To12_31_2013" id="Factid_76" unitRef="shares" decimals="INF">10618584</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>

  <tgtx:PeriodAnticipatedSufficientToFundOperatingCashFlow contextRef="P01_01_2013To12_31_2013" id="Factid_77">P24M</tgtx:PeriodAnticipatedSufficientToFundOperatingCashFlow>

  <us-gaap:LiabilitiesFairValueDisclosure contextRef="PAsOn12_31_2012" id="Factid_78" unitRef="USD" decimals="0">2479098</us-gaap:LiabilitiesFairValueDisclosure>

  <us-gaap:LiabilitiesFairValueDisclosure contextRef="PAsOn12_31_2012_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_79" unitRef="USD" decimals="0">0</us-gaap:LiabilitiesFairValueDisclosure>

  <us-gaap:LiabilitiesFairValueDisclosure contextRef="PAsOn12_31_2012_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_80" unitRef="USD" decimals="0">0</us-gaap:LiabilitiesFairValueDisclosure>

  <us-gaap:LiabilitiesFairValueDisclosure contextRef="PAsOn12_31_2012_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_81" unitRef="USD" decimals="0">2479098</us-gaap:LiabilitiesFairValueDisclosure>

  <us-gaap:LiabilitiesFairValueDisclosure contextRef="PAsOn12_31_2013" id="Factid_82" unitRef="USD" decimals="0">64529</us-gaap:LiabilitiesFairValueDisclosure>

  <us-gaap:LiabilitiesFairValueDisclosure contextRef="PAsOn12_31_2013_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_83" unitRef="USD" decimals="0">0</us-gaap:LiabilitiesFairValueDisclosure>

  <us-gaap:LiabilitiesFairValueDisclosure contextRef="PAsOn12_31_2013_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_84" unitRef="USD" decimals="0">0</us-gaap:LiabilitiesFairValueDisclosure>

  <us-gaap:LiabilitiesFairValueDisclosure contextRef="PAsOn12_31_2013_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_85" unitRef="USD" decimals="0">64529</us-gaap:LiabilitiesFairValueDisclosure>

  <us-gaap:NotesPayableFairValueDisclosure contextRef="PAsOn12_31_2012" id="Factid_86" unitRef="USD" decimals="0">2479098</us-gaap:NotesPayableFairValueDisclosure>

  <us-gaap:NotesPayableFairValueDisclosure contextRef="PAsOn12_31_2012_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_87" unitRef="USD" decimals="0">0</us-gaap:NotesPayableFairValueDisclosure>

  <us-gaap:NotesPayableFairValueDisclosure contextRef="PAsOn12_31_2012_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_88" unitRef="USD" decimals="0">0</us-gaap:NotesPayableFairValueDisclosure>

  <us-gaap:NotesPayableFairValueDisclosure contextRef="PAsOn12_31_2012_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_89" unitRef="USD" decimals="0">2479098</us-gaap:NotesPayableFairValueDisclosure>

  <us-gaap:NotesPayableFairValueDisclosure contextRef="PAsOn12_31_2013" id="Factid_90" unitRef="USD" decimals="0">64529</us-gaap:NotesPayableFairValueDisclosure>

  <us-gaap:NotesPayableFairValueDisclosure contextRef="PAsOn12_31_2013_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_91" unitRef="USD" decimals="0">0</us-gaap:NotesPayableFairValueDisclosure>

  <us-gaap:NotesPayableFairValueDisclosure contextRef="PAsOn12_31_2013_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_92" unitRef="USD" decimals="0">0</us-gaap:NotesPayableFairValueDisclosure>

  <us-gaap:NotesPayableFairValueDisclosure contextRef="PAsOn12_31_2013_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_93" unitRef="USD" decimals="0">64529</us-gaap:NotesPayableFairValueDisclosure>

  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="PAsOn12_31_2011" id="Factid_94" unitRef="USD" decimals="0">3294797</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>

  <tgtx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings contextRef="P01_01_2012To12_31_2012" id="Factid_95" unitRef="USD" decimals="0">844173</tgtx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings>

  <tgtx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings contextRef="P01_01_2013To12_31_2013" id="Factid_96" unitRef="USD" decimals="0">886382</tgtx:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings>

  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease contextRef="P01_01_2012To12_31_2012" id="Factid_97" unitRef="USD" decimals="0">-1659872</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>

  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease contextRef="P01_01_2013To12_31_2013" id="Factid_98" unitRef="USD" decimals="0">-3300951</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>

  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="PAsOn12_31_2012" id="Factid_99" unitRef="USD" decimals="0">2479098</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>

  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="PAsOn12_31_2013" id="Factid_100" unitRef="USD" decimals="0">64529</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>

  <us-gaap:NotesIssued1 contextRef="P03_01_2010To03_31_2010_ManhattanAndAristonPharmaceuticalsMergerMembertgtxTypeOfTransactionAxis" id="Factid_101" unitRef="USD" decimals="0">15452793</us-gaap:NotesIssued1>

  <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="PAsOn03_31_2010_ManhattanAndAristonPharmaceuticalsMergerMembertgtxTypeOfTransactionAxis" id="Factid_102" unitRef="pure" decimals="2">0.05</us-gaap:DebtInstrumentInterestRateEffectivePercentage>

  <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="PAsOn12_31_2012" id="Factid_103" unitRef="pure" decimals="2">0.05</us-gaap:DebtInstrumentInterestRateEffectivePercentage>

  <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="PAsOn12_31_2013" id="Factid_104" unitRef="pure" decimals="2">0.05</us-gaap:DebtInstrumentInterestRateEffectivePercentage>

  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="PAsOn03_31_2010_ManhattanAndAristonPharmaceuticalsMergerMembertgtxTypeOfTransactionAxis" id="Factid_105" unitRef="USD_per_Share" decimals="0">1125</us-gaap:DebtInstrumentConvertibleConversionPrice1>

  <tgtx:PercentageOfCashProceedsFromOperationToRepayConvertibleDebt contextRef="P03_01_2010To03_31_2010_ManhattanAndAristonPharmaceuticalsMergerMembertgtxTypeOfTransactionAxis" id="Factid_106" unitRef="pure" decimals="1">0.5</tgtx:PercentageOfCashProceedsFromOperationToRepayConvertibleDebt>

  <us-gaap:DebtInstrumentCarryingAmount contextRef="PAsOn12_31_2011" id="Factid_107" unitRef="USD" decimals="0">16876000</us-gaap:DebtInstrumentCarryingAmount>

  <us-gaap:DebtInstrumentCarryingAmount contextRef="PAsOn12_31_2012" id="Factid_108" unitRef="USD" decimals="0">17727000</us-gaap:DebtInstrumentCarryingAmount>

  <us-gaap:DebtInstrumentCarryingAmount contextRef="PAsOn12_31_2013" id="Factid_109" unitRef="USD" decimals="0">18614000</us-gaap:DebtInstrumentCarryingAmount>

  <us-gaap:DebtInstrumentFairValue contextRef="PAsOn12_31_2011" id="Factid_110" unitRef="USD" decimals="0">3287700</us-gaap:DebtInstrumentFairValue>

  <us-gaap:FairValueInputsDiscountRate contextRef="P01_01_2012To12_31_2012" id="Factid_111" unitRef="pure" decimals="1">0.2</us-gaap:FairValueInputsDiscountRate>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn12_31_2011" id="Factid_112" unitRef="shares" decimals="INF">3379</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="P01_01_2012To12_31_2012" id="Factid_113" unitRef="shares" decimals="INF">46000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="P01_01_2013To12_31_2013" id="Factid_114" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>

  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="P01_01_2012To12_31_2012" id="Factid_115" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>

  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="P01_01_2013To12_31_2013" id="Factid_116" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="P01_01_2012To12_31_2012" id="Factid_117" unitRef="shares" decimals="INF">2475</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="P01_01_2013To12_31_2013" id="Factid_118" unitRef="shares" decimals="INF">313</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="P01_01_2012To12_31_2012" id="Factid_119" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="P01_01_2013To12_31_2013" id="Factid_120" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn12_31_2012" id="Factid_121" unitRef="shares" decimals="INF">46904</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn12_31_2013" id="Factid_122" unitRef="shares" decimals="INF">46591</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="PAsOn12_31_2013" id="Factid_123" unitRef="shares" decimals="INF">9591</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="PAsOn12_31_2013" id="Factid_124" unitRef="shares" decimals="INF">9591</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn12_31_2011" id="Factid_125" unitRef="USD_per_Share" decimals="2">1315.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="P01_01_2012To12_31_2012" id="Factid_126" unitRef="USD_per_Share" decimals="2">4.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="P01_01_2013To12_31_2013" id="Factid_127" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="P01_01_2012To12_31_2012" id="Factid_128" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="P01_01_2013To12_31_2013" id="Factid_129" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="P01_01_2012To12_31_2012" id="Factid_130" unitRef="USD_per_Share" decimals="2">720.45</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="P01_01_2013To12_31_2013" id="Factid_131" unitRef="USD_per_Share" decimals="2">2249.85</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="P01_01_2012To12_31_2012" id="Factid_132" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="P01_01_2013To12_31_2013" id="Factid_133" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn12_31_2012" id="Factid_134" unitRef="USD_per_Share" decimals="2">61.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="PAsOn12_31_2013" id="Factid_135" unitRef="USD_per_Share" decimals="2">46.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="PAsOn12_31_2013" id="Factid_136" unitRef="USD_per_Share" decimals="2">208.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="PAsOn12_31_2013" id="Factid_137" unitRef="USD_per_Share" decimals="2">208.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>

  <tgtx:SharesBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm contextRef="P01_01_2012To12_31_2012" id="Factid_138">P9Y5M8D</tgtx:SharesBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2013To12_31_2013" id="Factid_139">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2013To12_31_2013" id="Factid_140">P8Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2013To12_31_2013" id="Factid_141">P8Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="PAsOn12_31_2011" id="Factid_142" unitRef="USD" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="PAsOn12_31_2013" id="Factid_143" unitRef="USD" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="PAsOn12_31_2013" id="Factid_144" unitRef="USD" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>

  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="PAsOn12_31_2013" id="Factid_145" unitRef="USD" decimals="0">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="PAsOn12_31_2011_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_146" unitRef="shares" decimals="INF">129375</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="PAsOn12_31_2011_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_147" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="P01_01_2012To12_31_2012_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_148" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="P01_01_2012To12_31_2012_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_149" unitRef="shares" decimals="INF">5901743</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="P01_01_2013To12_31_2013_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_150" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="P01_01_2013To12_31_2013_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_151" unitRef="shares" decimals="INF">944464</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="P01_01_2012To12_31_2012_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_152" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="P01_01_2012To12_31_2012_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_153" unitRef="shares" decimals="INF">437500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="P01_01_2013To12_31_2013_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_154" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="P01_01_2013To12_31_2013_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_155" unitRef="shares" decimals="INF">523750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="P01_01_2012To12_31_2012_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_156" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="P01_01_2012To12_31_2012_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_157" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="P01_01_2013To12_31_2013_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_158" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="P01_01_2013To12_31_2013_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_159" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="PAsOn12_31_2012_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_160" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="PAsOn12_31_2012_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_161" unitRef="shares" decimals="INF">6614243</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="PAsOn12_31_2013_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_162" unitRef="shares" decimals="INF">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="PAsOn12_31_2013_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_163" unitRef="shares" decimals="INF">7034957</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="PAsOn12_31_2011_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_164" unitRef="USD_per_Share" decimals="2">20.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="PAsOn12_31_2011_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_165" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="P01_01_2012To12_31_2012_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_166" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="P01_01_2012To12_31_2012_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_167" unitRef="USD_per_Share" decimals="2">4.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="P01_01_2013To12_31_2013_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_168" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="P01_01_2013To12_31_2013_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_169" unitRef="USD_per_Share" decimals="2">4.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="P01_01_2012To12_31_2012_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_170" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="P01_01_2012To12_31_2012_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_171" unitRef="USD_per_Share" decimals="2">2.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="P01_01_2013To12_31_2013_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_172" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="P01_01_2013To12_31_2013_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_173" unitRef="USD_per_Share" decimals="2">2.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="P01_01_2012To12_31_2012_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_174" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="P01_01_2012To12_31_2012_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_175" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="P01_01_2013To12_31_2013_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_176" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="P01_01_2013To12_31_2013_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_177" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="PAsOn12_31_2012_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_178" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="PAsOn12_31_2012_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_179" unitRef="USD_per_Share" decimals="2">4.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="PAsOn12_31_2013_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_180" unitRef="USD_per_Share" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="PAsOn12_31_2013_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_181" unitRef="USD_per_Share" decimals="2">4.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>

  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="PAsOn12_31_2011" id="Factid_182" unitRef="shares" decimals="INF">1625911</us-gaap:ClassOfWarrantOrRightOutstanding>

  <tgtx:WarrantOrRightIssued contextRef="P01_01_2012To12_31_2012" id="Factid_183" unitRef="shares" decimals="INF">5156599</tgtx:WarrantOrRightIssued>

  <tgtx:WarrantOrRightIssued contextRef="P01_01_2013To12_31_2013" id="Factid_184" unitRef="shares" decimals="INF">0</tgtx:WarrantOrRightIssued>

  <tgtx:WarrantOrRightExercised contextRef="P01_01_2012To12_31_2012" id="Factid_185" unitRef="shares" decimals="INF">0</tgtx:WarrantOrRightExercised>

  <tgtx:WarrantOrRightExercised contextRef="P01_01_2013To12_31_2013" id="Factid_186" unitRef="shares" decimals="INF">1018068</tgtx:WarrantOrRightExercised>

  <tgtx:WarrantOrRightExpired contextRef="P01_01_2012To12_31_2012" id="Factid_187" unitRef="shares" decimals="INF">1503</tgtx:WarrantOrRightExpired>

  <tgtx:WarrantOrRightExpired contextRef="P01_01_2013To12_31_2013" id="Factid_188" unitRef="shares" decimals="INF">43992</tgtx:WarrantOrRightExpired>

  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="PAsOn12_31_2012" id="Factid_189" unitRef="shares" decimals="INF">6781007</us-gaap:ClassOfWarrantOrRightOutstanding>

  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="PAsOn12_31_2013" id="Factid_190" unitRef="shares" decimals="INF">5718947</us-gaap:ClassOfWarrantOrRightOutstanding>

  <tgtx:WarrantOrRightOutstandingWeightedAverageExercisePrice contextRef="PAsOn12_31_2011" id="Factid_191" unitRef="USD_per_Share" decimals="2">5.27</tgtx:WarrantOrRightOutstandingWeightedAverageExercisePrice>

  <tgtx:WarrantOrRightIssuedWeightedAverageExercisePrice contextRef="P01_01_2012To12_31_2012" id="Factid_192" unitRef="USD_per_Share" decimals="2">1.21</tgtx:WarrantOrRightIssuedWeightedAverageExercisePrice>

  <tgtx:WarrantOrRightIssuedWeightedAverageExercisePrice contextRef="P01_01_2013To12_31_2013" id="Factid_193" unitRef="USD_per_Share" decimals="0">0</tgtx:WarrantOrRightIssuedWeightedAverageExercisePrice>

  <tgtx:WarrantOrRightExercisedWeightedAverageExercisePrice contextRef="P01_01_2012To12_31_2012" id="Factid_194" unitRef="USD_per_Share" decimals="0">0</tgtx:WarrantOrRightExercisedWeightedAverageExercisePrice>

  <tgtx:WarrantOrRightExercisedWeightedAverageExercisePrice contextRef="P01_01_2013To12_31_2013" id="Factid_195" unitRef="USD_per_Share" decimals="2">2.25</tgtx:WarrantOrRightExercisedWeightedAverageExercisePrice>

  <tgtx:WarrantOrRightExpiredWeightedAverageExercisePrice contextRef="P01_01_2012To12_31_2012" id="Factid_196" unitRef="USD_per_Share" decimals="2">2739.75</tgtx:WarrantOrRightExpiredWeightedAverageExercisePrice>

  <tgtx:WarrantOrRightExpiredWeightedAverageExercisePrice contextRef="P01_01_2013To12_31_2013" id="Factid_197" unitRef="USD_per_Share" decimals="2">16.26</tgtx:WarrantOrRightExpiredWeightedAverageExercisePrice>

  <tgtx:WarrantOrRightOutstandingWeightedAverageExercisePrice contextRef="PAsOn12_31_2012" id="Factid_198" unitRef="USD_per_Share" decimals="2">1.58</tgtx:WarrantOrRightOutstandingWeightedAverageExercisePrice>

  <tgtx:WarrantOrRightOutstandingWeightedAverageExercisePrice contextRef="PAsOn12_31_2013" id="Factid_199" unitRef="USD_per_Share" decimals="2">1.34</tgtx:WarrantOrRightOutstandingWeightedAverageExercisePrice>

  <tgtx:WarrantOrRightAggregateIntrinsicValue contextRef="PAsOn12_31_2011" id="Factid_200" unitRef="USD" decimals="0">0</tgtx:WarrantOrRightAggregateIntrinsicValue>

  <tgtx:WarrantOrRightAggregateIntrinsicValue contextRef="PAsOn12_31_2012" id="Factid_201" unitRef="USD" decimals="0">14563539</tgtx:WarrantOrRightAggregateIntrinsicValue>

  <tgtx:WarrantOrRightAggregateIntrinsicValue contextRef="PAsOn12_31_2013" id="Factid_202" unitRef="USD" decimals="0">14809030</tgtx:WarrantOrRightAggregateIntrinsicValue>

  <us-gaap:RestrictedStockExpense contextRef="P01_01_2012To12_31_2012_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_203" unitRef="USD" decimals="0">3422182</us-gaap:RestrictedStockExpense>

  <us-gaap:RestrictedStockExpense contextRef="P01_01_2013To12_31_2013_RestrictedStockMemberusgaapAwardTypeAxis" id="Factid_204" unitRef="USD" decimals="0">5146743</us-gaap:RestrictedStockExpense>

  <us-gaap:StockOptionPlanExpense contextRef="P01_01_2012To12_31_2012_EmployeeStockOptionMemberusgaapAwardTypeAxis" id="Factid_205" unitRef="USD" decimals="0">0</us-gaap:StockOptionPlanExpense>

  <us-gaap:StockOptionPlanExpense contextRef="P01_01_2013To12_31_2013_EmployeeStockOptionMemberusgaapAwardTypeAxis" id="Factid_206" unitRef="USD" decimals="0">56405</us-gaap:StockOptionPlanExpense>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2012To12_31_2012" id="Factid_207" unitRef="USD" decimals="0">3422182</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2013To12_31_2013" id="Factid_208" unitRef="USD" decimals="0">5203148</us-gaap:ShareBasedCompensation>

  <us-gaap:PreferredStockSharesAuthorized contextRef="PAsOn12_31_2013" id="Factid_209" unitRef="shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>

  <us-gaap:CommonStockSharesAuthorized contextRef="PAsOn12_31_2013" id="Factid_210" unitRef="shares" decimals="INF">500000000</us-gaap:CommonStockSharesAuthorized>

  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="PAsOn12_31_2013" id="Factid_211" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>

  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn12_31_2013" id="Factid_212" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="PAsOn12_31_2013_IncentivePlanMemberusgaapPlanNameAxis" id="Factid_213" unitRef="shares" decimals="INF">1107793</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>

  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2013To12_31_2013_RestrictedStockMemberusgaapPlanNameAxis" id="Factid_214">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>

  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="PAsOn12_31_2013" id="Factid_215" unitRef="USD" decimals="0">7977072</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>

  <tgtx:ShareBasedCompensationNonEmployeeStockOptionsOutstanding contextRef="PAsOn12_31_2013" id="Factid_216" unitRef="shares" decimals="INF">37000</tgtx:ShareBasedCompensationNonEmployeeStockOptionsOutstanding>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn12_31_2013_EquityIncentivePlansMemberusgaapPlanNameAxis" id="Factid_217" unitRef="shares" decimals="INF">591</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn12_31_2013_IncentivePlanMemberusgaapPlanNameAxis" id="Factid_218" unitRef="shares" decimals="INF">46000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn12_31_2013_CorporateMilestoneMembertgtxCorporateMilestoneAxis" id="Factid_219" unitRef="shares" decimals="INF">1800960</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="PAsOn12_31_2013_NonEmployeeRestrictedStockMembertgtxNonEmployeeStockOptionsAxis" id="Factid_220" unitRef="shares" decimals="INF">2556375</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>

  <tgtx:StockIssuedDuringPeriodSharesNewIssuesShelfRegistrationStatement contextRef="P01_01_2013To12_31_2013" id="Factid_221" unitRef="USD" decimals="-6">135000000</tgtx:StockIssuedDuringPeriodSharesNewIssuesShelfRegistrationStatement>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P01_01_2011To12_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_222" unitRef="shares" decimals="INF">4929523</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P02_01_2012To02_24_2012" id="Factid_223" unitRef="shares" decimals="INF">695428</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P07_01_2013To07_18_2013" id="Factid_224" unitRef="shares" decimals="INF">5700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:SharePrice contextRef="PAsOn07_18_2013" id="Factid_225" unitRef="USD_per_Share" decimals="2">6.15</us-gaap:SharePrice>

  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="P07_01_2013To07_18_2013" id="Factid_226" unitRef="USD" decimals="-6">35000000</us-gaap:ProceedsFromIssuanceOfCommonStock>

  <tgtx:StockIssuedDuringPeriodSharesNewIssuesOverallotments contextRef="P07_01_2013To07_18_2013" id="Factid_227" unitRef="shares" decimals="INF">855000</tgtx:StockIssuedDuringPeriodSharesNewIssuesOverallotments>

  <tgtx:NetProceedsFromSharesNewIssuesOverallotments contextRef="P07_01_2013To07_18_2013" id="Factid_228" unitRef="USD" decimals="1">37.6</tgtx:NetProceedsFromSharesNewIssuesOverallotments>

  <tgtx:UnderwritingDiscountsAndOfferingExpenses contextRef="P07_01_2013To07_18_2013" id="Factid_229" unitRef="USD" decimals="-5">2700000</tgtx:UnderwritingDiscountsAndOfferingExpenses>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2012To12_31_2012_RestrictedStockMemberusgaapPlanNameAxis" id="Factid_230" unitRef="USD" decimals="0">3422182</us-gaap:ShareBasedCompensation>

  <us-gaap:ShareBasedCompensation contextRef="P01_01_2013To12_31_2013_RestrictedStockMemberusgaapPlanNameAxis" id="Factid_231" unitRef="USD" decimals="0">5146743</us-gaap:ShareBasedCompensation>

  <us-gaap:NotesPayableCurrent contextRef="PAsOn12_31_2012_ConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis" id="Factid_232" unitRef="USD" decimals="0">0</us-gaap:NotesPayableCurrent>

  <us-gaap:NotesPayableCurrent contextRef="PAsOn12_31_2012_IconConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis" id="Factid_233" unitRef="USD" decimals="0">677778</us-gaap:NotesPayableCurrent>

  <us-gaap:NotesPayableCurrent contextRef="PAsOn12_31_2013_ConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis" id="Factid_234" unitRef="USD" decimals="0">0</us-gaap:NotesPayableCurrent>

  <us-gaap:NotesPayableCurrent contextRef="PAsOn12_31_2013_IconConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis" id="Factid_235" unitRef="USD" decimals="0">677778</us-gaap:NotesPayableCurrent>

  <us-gaap:LongTermNotesPayable contextRef="PAsOn12_31_2012_ConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis" id="Factid_236" unitRef="USD" decimals="0">2479098</us-gaap:LongTermNotesPayable>

  <us-gaap:LongTermNotesPayable contextRef="PAsOn12_31_2012_IconConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis" id="Factid_237" unitRef="USD" decimals="0">0</us-gaap:LongTermNotesPayable>

  <us-gaap:LongTermNotesPayable contextRef="PAsOn12_31_2013_ConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis" id="Factid_238" unitRef="USD" decimals="0">64529</us-gaap:LongTermNotesPayable>

  <us-gaap:LongTermNotesPayable contextRef="PAsOn12_31_2013_IconConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis" id="Factid_239" unitRef="USD" decimals="0">0</us-gaap:LongTermNotesPayable>

  <us-gaap:NotesPayable contextRef="PAsOn12_31_2012" id="Factid_240" unitRef="USD" decimals="0">3156876</us-gaap:NotesPayable>

  <us-gaap:NotesPayable contextRef="PAsOn12_31_2012_ConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis" id="Factid_241" unitRef="USD" decimals="0">2479098</us-gaap:NotesPayable>

  <us-gaap:NotesPayable contextRef="PAsOn12_31_2012_IconConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis" id="Factid_242" unitRef="USD" decimals="0">677778</us-gaap:NotesPayable>

  <us-gaap:NotesPayable contextRef="PAsOn12_31_2013" id="Factid_243" unitRef="USD" decimals="0">742307</us-gaap:NotesPayable>

  <us-gaap:NotesPayable contextRef="PAsOn12_31_2013_ConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis" id="Factid_244" unitRef="USD" decimals="0">64529</us-gaap:NotesPayable>

  <us-gaap:NotesPayable contextRef="PAsOn12_31_2013_IconConvertibleNotesMemberusgaapCashAndCashEquivalentsAxis" id="Factid_245" unitRef="USD" decimals="0">677778</us-gaap:NotesPayable>

  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="PAsOn12_31_2012" id="Factid_246" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>

  <us-gaap:PreferredStockSharesAuthorized contextRef="PAsOn12_31_2012" id="Factid_247" unitRef="shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>

  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="PAsOn12_31_2012" id="Factid_248" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>

  <us-gaap:CommonStockSharesAuthorized contextRef="PAsOn12_31_2012" id="Factid_249" unitRef="shares" decimals="INF">500000000</us-gaap:CommonStockSharesAuthorized>

  <us-gaap:CommonStockSharesIssued contextRef="PAsOn12_31_2012" id="Factid_250" unitRef="shares" decimals="INF">25820738</us-gaap:CommonStockSharesIssued>

  <us-gaap:CommonStockSharesIssued contextRef="PAsOn12_31_2013" id="Factid_251" unitRef="shares" decimals="INF">34336235</us-gaap:CommonStockSharesIssued>

  <us-gaap:CommonStockSharesOutstanding contextRef="PAsOn12_31_2012" id="Factid_252" unitRef="shares" decimals="INF">25807212</us-gaap:CommonStockSharesOutstanding>

  <us-gaap:CommonStockSharesOutstanding contextRef="PAsOn12_31_2013" id="Factid_253" unitRef="shares" decimals="INF">34294926</us-gaap:CommonStockSharesOutstanding>

  <us-gaap:TreasuryStockShares contextRef="PAsOn12_31_2012" id="Factid_254" unitRef="shares" decimals="INF">13526</us-gaap:TreasuryStockShares>

  <us-gaap:TreasuryStockShares contextRef="PAsOn12_31_2013" id="Factid_255" unitRef="shares" decimals="INF">41309</us-gaap:TreasuryStockShares>

  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="PAsOn03_08_2010_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis" id="Factid_256" unitRef="pure" decimals="2">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>

  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="PAsOn03_31_2011_BeforeAmendmentMembertgtxAmendmentAxis_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis" id="Factid_257" unitRef="pure" decimals="2">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>

  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="PAsOn03_31_2011_AfterAmendmentMembertgtxAmendmentAxis_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis" id="Factid_258" unitRef="pure" decimals="2">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>

  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="PAsOn12_31_2013_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis" id="Factid_259" unitRef="pure" decimals="2">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>

  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="PAsOn12_31_2013_AristonMemberusgaapBusinessAcquisitionAxis" id="Factid_260" unitRef="pure" decimals="2">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>

  <tgtx:PercentageOfCashProceedsFromOperationToRepayInterestOnConvertibleDebt contextRef="P01_01_2013To12_31_2013_AristonMemberusgaapBusinessAcquisitionAxis" id="Factid_261" unitRef="pure" decimals="1">0.5</tgtx:PercentageOfCashProceedsFromOperationToRepayInterestOnConvertibleDebt>

  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="PAsOn03_08_2010_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis" id="Factid_262" unitRef="USD_per_Share" decimals="0">1125</us-gaap:DebtInstrumentConvertibleConversionPrice1>

  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="PAsOn03_31_2011_AfterAmendmentMembertgtxAmendmentAxis_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis" id="Factid_263" unitRef="USD_per_Share" decimals="2">562.50</us-gaap:DebtInstrumentConvertibleConversionPrice1>

  <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="PAsOn03_08_2010_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis" id="Factid_264" unitRef="USD" decimals="0">1275188</us-gaap:AccountsPayableCurrentAndNoncurrent>

  <us-gaap:RepaymentsOfShortTermDebt contextRef="P03_01_2010To03_08_2010_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis" id="Factid_265" unitRef="USD" decimals="0">275188</us-gaap:RepaymentsOfShortTermDebt>

  <us-gaap:DebtInstrumentPeriodicPaymentPrincipal contextRef="P04_01_2010To04_30_2010_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis" id="Factid_266" unitRef="USD" decimals="0">27778</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>

  <tgtx:OneTimeSettlementAmountForWaiverOfInterestAndPrincipalPayments contextRef="PAsOn03_31_2011_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis" id="Factid_267" unitRef="USD" decimals="0">100000</tgtx:OneTimeSettlementAmountForWaiverOfInterestAndPrincipalPayments>

  <us-gaap:InterestAndDebtExpense contextRef="P01_01_2013To12_31_2013_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis" id="Factid_268" unitRef="USD" decimals="0">66506</us-gaap:InterestAndDebtExpense>

  <us-gaap:NotesPayableCurrent contextRef="PAsOn12_31_2012_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis" id="Factid_269" unitRef="USD" decimals="0">677778</us-gaap:NotesPayableCurrent>

  <us-gaap:NotesPayableCurrent contextRef="PAsOn12_31_2013_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis" id="Factid_270" unitRef="USD" decimals="0">677778</us-gaap:NotesPayableCurrent>

  <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="PAsOn12_31_2012_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis" id="Factid_271" unitRef="USD" decimals="0">123511</us-gaap:InterestPayableCurrentAndNoncurrent>

  <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="PAsOn12_31_2013_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis" id="Factid_272" unitRef="USD" decimals="0">190017</us-gaap:InterestPayableCurrentAndNoncurrent>

  <us-gaap:DeferredRevenue contextRef="PAsOn12_31_2012" id="Factid_273" unitRef="USD" decimals="0">1981000</us-gaap:DeferredRevenue>

  <us-gaap:DeferredRevenue contextRef="PAsOn12_31_2013" id="Factid_274" unitRef="USD" decimals="0">1829000</us-gaap:DeferredRevenue>

  <tgtx:AdditionalAmountReceivableOnAchievementOfPreSpecifiedMilestones contextRef="P01_01_2013To12_31_2013" id="Factid_275" unitRef="USD" decimals="-5">5000000</tgtx:AdditionalAmountReceivableOnAchievementOfPreSpecifiedMilestones>

  <us-gaap:IncomeTaxExpenseBenefit contextRef="P01_01_2012To12_31_2012" id="Factid_276" unitRef="USD" decimals="0">330000</us-gaap:IncomeTaxExpenseBenefit>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P08_01_2012To08_31_2012_OpusMemberdeiLegalEntityAxis" id="Factid_277" unitRef="shares" decimals="INF">2000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:OtherResearchAndDevelopmentExpense contextRef="P01_01_2012To12_31_2012_LfbGroupMembertgtxPlacementAgencyAgreementAxis" id="Factid_278" unitRef="USD" decimals="0">1447000</us-gaap:OtherResearchAndDevelopmentExpense>

  <us-gaap:OtherResearchAndDevelopmentExpense contextRef="P01_01_2013To12_31_2013_LfbGroupMembertgtxPlacementAgencyAgreementAxis" id="Factid_279" unitRef="USD" decimals="0">6267000</us-gaap:OtherResearchAndDevelopmentExpense>

  <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="PAsOn12_31_2012_LfbGroupMembertgtxPlacementAgencyAgreementAxis" id="Factid_280" unitRef="USD" decimals="0">56000</us-gaap:AccountsPayableCurrentAndNoncurrent>

  <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="PAsOn12_31_2013_LfbGroupMembertgtxPlacementAgencyAgreementAxis" id="Factid_281" unitRef="USD" decimals="0">1745000</us-gaap:AccountsPayableCurrentAndNoncurrent>

  <us-gaap:LicensesRevenue contextRef="P01_01_2012To12_31_2012" id="Factid_282" unitRef="USD" decimals="0">19048</us-gaap:LicensesRevenue>

  <us-gaap:LicensesRevenue contextRef="P01_01_2013To12_31_2013" id="Factid_283" unitRef="USD" decimals="0">152381</us-gaap:LicensesRevenue>

  <us-gaap:LicensesRevenue contextRef="P12_01_2011To12_31_2013" id="Factid_284" unitRef="USD" decimals="0">171429</us-gaap:LicensesRevenue>

  <tgtx:NonCashStockExpense contextRef="P01_01_2012To12_31_2012" id="Factid_285" unitRef="USD" decimals="0">16578000</tgtx:NonCashStockExpense>

  <tgtx:NonCashStockExpense contextRef="P01_01_2013To12_31_2013" id="Factid_286" unitRef="USD" decimals="0">0</tgtx:NonCashStockExpense>

  <tgtx:NonCashStockExpense contextRef="P12_01_2011To12_31_2013" id="Factid_287" unitRef="USD" decimals="0">16875000</tgtx:NonCashStockExpense>

  <tgtx:NonCashCompensationResearchAndDevelopmentExpenses contextRef="P01_01_2012To12_31_2012" id="Factid_288" unitRef="USD" decimals="0">455809</tgtx:NonCashCompensationResearchAndDevelopmentExpenses>

  <tgtx:NonCashCompensationResearchAndDevelopmentExpenses contextRef="P01_01_2013To12_31_2013" id="Factid_289" unitRef="USD" decimals="0">1041519</tgtx:NonCashCompensationResearchAndDevelopmentExpenses>

  <tgtx:NonCashCompensationResearchAndDevelopmentExpenses contextRef="P12_01_2011To12_31_2013" id="Factid_290" unitRef="USD" decimals="0">1497328</tgtx:NonCashCompensationResearchAndDevelopmentExpenses>

  <us-gaap:OtherResearchAndDevelopmentExpense contextRef="P01_01_2012To12_31_2012" id="Factid_291" unitRef="USD" decimals="0">3994182</us-gaap:OtherResearchAndDevelopmentExpense>

  <us-gaap:OtherResearchAndDevelopmentExpense contextRef="P01_01_2013To12_31_2013" id="Factid_292" unitRef="USD" decimals="0">12621161</us-gaap:OtherResearchAndDevelopmentExpense>

  <us-gaap:OtherResearchAndDevelopmentExpense contextRef="P12_01_2011To12_31_2013" id="Factid_293" unitRef="USD" decimals="0">16645626</us-gaap:OtherResearchAndDevelopmentExpense>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P01_01_2012To12_31_2012" id="Factid_294" unitRef="USD" decimals="0">21027991</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P01_01_2013To12_31_2013" id="Factid_295" unitRef="USD" decimals="0">13662680</us-gaap:ResearchAndDevelopmentExpense>

  <us-gaap:ResearchAndDevelopmentExpense contextRef="P12_01_2011To12_31_2013" id="Factid_296" unitRef="USD" decimals="0">35017954</us-gaap:ResearchAndDevelopmentExpense>

  <tgtx:NonCashCompensationGeneralAndAdministrativeExpenses contextRef="P01_01_2012To12_31_2012" id="Factid_297" unitRef="USD" decimals="0">2966373</tgtx:NonCashCompensationGeneralAndAdministrativeExpenses>

  <tgtx:NonCashCompensationGeneralAndAdministrativeExpenses contextRef="P01_01_2013To12_31_2013" id="Factid_298" unitRef="USD" decimals="0">4161629</tgtx:NonCashCompensationGeneralAndAdministrativeExpenses>

  <tgtx:NonCashCompensationGeneralAndAdministrativeExpenses contextRef="P12_01_2011To12_31_2013" id="Factid_299" unitRef="USD" decimals="0">7214496</tgtx:NonCashCompensationGeneralAndAdministrativeExpenses>

  <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="P01_01_2012To12_31_2012" id="Factid_300" unitRef="USD" decimals="0">1815083</us-gaap:OtherGeneralAndAdministrativeExpense>

  <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="P01_01_2013To12_31_2013" id="Factid_301" unitRef="USD" decimals="0">2496461</us-gaap:OtherGeneralAndAdministrativeExpense>

  <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="P12_01_2011To12_31_2013" id="Factid_302" unitRef="USD" decimals="0">4779741</us-gaap:OtherGeneralAndAdministrativeExpense>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P01_01_2012To12_31_2012" id="Factid_303" unitRef="USD" decimals="0">4781456</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P01_01_2013To12_31_2013" id="Factid_304" unitRef="USD" decimals="0">6658090</us-gaap:GeneralAndAdministrativeExpense>

  <us-gaap:GeneralAndAdministrativeExpense contextRef="P12_01_2011To12_31_2013" id="Factid_305" unitRef="USD" decimals="0">11994237</us-gaap:GeneralAndAdministrativeExpense>

  <tgtx:ImpairmentOfInProcessResearchAndDevelopment contextRef="P01_01_2012To12_31_2012" id="Factid_306" unitRef="USD" decimals="0">1104700</tgtx:ImpairmentOfInProcessResearchAndDevelopment>

  <tgtx:ImpairmentOfInProcessResearchAndDevelopment contextRef="P01_01_2013To12_31_2013" id="Factid_307" unitRef="USD" decimals="0">2797600</tgtx:ImpairmentOfInProcessResearchAndDevelopment>

  <tgtx:ImpairmentOfInProcessResearchAndDevelopment contextRef="P12_01_2011To12_31_2013" id="Factid_308" unitRef="USD" decimals="0">3902300</tgtx:ImpairmentOfInProcessResearchAndDevelopment>

  <us-gaap:OperatingExpenses contextRef="P01_01_2012To12_31_2012" id="Factid_309" unitRef="USD" decimals="0">26914147</us-gaap:OperatingExpenses>

  <us-gaap:OperatingExpenses contextRef="P01_01_2013To12_31_2013" id="Factid_310" unitRef="USD" decimals="0">23118370</us-gaap:OperatingExpenses>

  <us-gaap:OperatingExpenses contextRef="P12_01_2011To12_31_2013" id="Factid_311" unitRef="USD" decimals="0">50914491</us-gaap:OperatingExpenses>

  <us-gaap:OperatingIncomeLoss contextRef="P01_01_2012To12_31_2012" id="Factid_312" unitRef="USD" decimals="0">-26895099</us-gaap:OperatingIncomeLoss>

  <us-gaap:OperatingIncomeLoss contextRef="P01_01_2013To12_31_2013" id="Factid_313" unitRef="USD" decimals="0">-22965989</us-gaap:OperatingIncomeLoss>

  <us-gaap:OperatingIncomeLoss contextRef="P12_01_2011To12_31_2013" id="Factid_314" unitRef="USD" decimals="0">-50743062</us-gaap:OperatingIncomeLoss>

  <us-gaap:InvestmentIncomeNet contextRef="P01_01_2012To12_31_2012" id="Factid_315" unitRef="USD" decimals="0">15787</us-gaap:InvestmentIncomeNet>

  <us-gaap:InvestmentIncomeNet contextRef="P01_01_2013To12_31_2013" id="Factid_316" unitRef="USD" decimals="0">30822</us-gaap:InvestmentIncomeNet>

  <us-gaap:InvestmentIncomeNet contextRef="P12_01_2011To12_31_2013" id="Factid_317" unitRef="USD" decimals="0">46609</us-gaap:InvestmentIncomeNet>

  <us-gaap:OtherIncome contextRef="P01_01_2012To12_31_2012" id="Factid_318" unitRef="USD" decimals="0">272232</us-gaap:OtherIncome>

  <us-gaap:OtherIncome contextRef="P01_01_2013To12_31_2013" id="Factid_319" unitRef="USD" decimals="0">108894</us-gaap:OtherIncome>

  <us-gaap:OtherIncome contextRef="P12_01_2011To12_31_2013" id="Factid_320" unitRef="USD" decimals="0">381126</us-gaap:OtherIncome>

  <us-gaap:InterestExpense contextRef="P01_01_2012To12_31_2012" id="Factid_321" unitRef="USD" decimals="0">905744</us-gaap:InterestExpense>

  <us-gaap:InterestExpense contextRef="P01_01_2013To12_31_2013" id="Factid_322" unitRef="USD" decimals="0">952888</us-gaap:InterestExpense>

  <us-gaap:InterestExpense contextRef="P12_01_2011To12_31_2013" id="Factid_323" unitRef="USD" decimals="0">1865729</us-gaap:InterestExpense>

  <tgtx:ChangeInFairValueOfNonCurrentNotePayable contextRef="P01_01_2012To12_31_2012" id="Factid_324" unitRef="USD" decimals="0">1659872</tgtx:ChangeInFairValueOfNonCurrentNotePayable>

  <tgtx:ChangeInFairValueOfNonCurrentNotePayable contextRef="P01_01_2013To12_31_2013" id="Factid_325" unitRef="USD" decimals="0">3300951</tgtx:ChangeInFairValueOfNonCurrentNotePayable>

  <tgtx:ChangeInFairValueOfNonCurrentNotePayable contextRef="P12_01_2011To12_31_2013" id="Factid_326" unitRef="USD" decimals="0">4960823</tgtx:ChangeInFairValueOfNonCurrentNotePayable>

  <us-gaap:NonoperatingIncomeExpense contextRef="P01_01_2012To12_31_2012" id="Factid_327" unitRef="USD" decimals="0">1042147</us-gaap:NonoperatingIncomeExpense>

  <us-gaap:NonoperatingIncomeExpense contextRef="P01_01_2013To12_31_2013" id="Factid_328" unitRef="USD" decimals="0">2487779</us-gaap:NonoperatingIncomeExpense>

  <us-gaap:NonoperatingIncomeExpense contextRef="P12_01_2011To12_31_2013" id="Factid_329" unitRef="USD" decimals="0">3522829</us-gaap:NonoperatingIncomeExpense>

  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="P01_01_2012To12_31_2012" id="Factid_330" unitRef="USD" decimals="0">-25852952</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>

  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="P01_01_2013To12_31_2013" id="Factid_331" unitRef="USD" decimals="0">-20478210</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>

  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="P12_01_2011To12_31_2013" id="Factid_332" unitRef="USD" decimals="0">-47220233</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>

  <us-gaap:IncomeTaxExpenseBenefit contextRef="P01_01_2013To12_31_2013" id="Factid_333" unitRef="USD" decimals="0">0</us-gaap:IncomeTaxExpenseBenefit>

  <us-gaap:IncomeTaxExpenseBenefit contextRef="P12_01_2011To12_31_2013" id="Factid_334" unitRef="USD" decimals="0">330000</us-gaap:IncomeTaxExpenseBenefit>

  <us-gaap:ProfitLoss contextRef="P01_01_2012To12_31_2012" id="Factid_335" unitRef="USD" decimals="0">-26182952</us-gaap:ProfitLoss>

  <us-gaap:ProfitLoss contextRef="P01_01_2013To12_31_2013" id="Factid_336" unitRef="USD" decimals="0">-20478210</us-gaap:ProfitLoss>

  <us-gaap:ProfitLoss contextRef="P12_01_2011To12_31_2013" id="Factid_337" unitRef="USD" decimals="0">-47550233</us-gaap:ProfitLoss>

  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="P01_01_2012To12_31_2012" id="Factid_338" unitRef="USD" decimals="0">-8110233</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>

  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="P01_01_2013To12_31_2013" id="Factid_339" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>

  <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="P12_01_2011To12_31_2013" id="Factid_340" unitRef="USD" decimals="0">-8146230</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2012To12_31_2012" id="Factid_341" unitRef="USD" decimals="0">-18072719</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P01_01_2013To12_31_2013" id="Factid_342" unitRef="USD" decimals="0">-20478210</us-gaap:NetIncomeLoss>

  <us-gaap:NetIncomeLoss contextRef="P12_01_2011To12_31_2013" id="Factid_343" unitRef="USD" decimals="0">-39404003</us-gaap:NetIncomeLoss>

  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="P01_01_2012To12_31_2012" id="Factid_344" unitRef="USD_per_Share" decimals="2">-1.38</us-gaap:EarningsPerShareBasicAndDiluted>

  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="P01_01_2013To12_31_2013" id="Factid_345" unitRef="USD_per_Share" decimals="2">-0.81</us-gaap:EarningsPerShareBasicAndDiluted>

  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P01_01_2012To12_31_2012" id="Factid_346" unitRef="shares" decimals="INF">13113758</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="P01_01_2013To12_31_2013" id="Factid_347" unitRef="shares" decimals="INF">25413964</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2012_PreferredStockMemberusgaapStatementEquityComponentsAxis" id="Factid_348" unitRef="USD" decimals="0">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_349" unitRef="USD" decimals="0">25821</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2012_ContingentlyIssuableShareMemberusgaapStatementEquityComponentsAxis" id="Factid_350" unitRef="USD" decimals="0">6</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2012_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_351" unitRef="USD" decimals="0">34534805</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2012_TreasuryStockMemberusgaapStatementEquityComponentsAxis" id="Factid_352" unitRef="USD" decimals="0">-84538</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2012_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_353" unitRef="USD" decimals="0">-18925793</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2012_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" id="Factid_354" unitRef="USD" decimals="0">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2012_PreferredStockMemberusgaapStatementEquityComponentsAxis" id="Factid_355" unitRef="shares" decimals="INF">0</us-gaap:SharesOutstanding>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_356" unitRef="shares" decimals="INF">25820738</us-gaap:SharesOutstanding>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2012_TreasuryStockMemberusgaapStatementEquityComponentsAxis" id="Factid_357" unitRef="shares" decimals="INF">13526</us-gaap:SharesOutstanding>

  <tgtx:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2013To12_31_2013" id="Factid_358" unitRef="USD" decimals="0">2280773</tgtx:StockIssuedDuringPeriodValueExerciseOfWarrants>

  <tgtx:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2013To12_31_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_359" unitRef="USD" decimals="0">1013</tgtx:StockIssuedDuringPeriodValueExerciseOfWarrants>

  <tgtx:StockIssuedDuringPeriodValueExerciseOfWarrants contextRef="P01_01_2013To12_31_2013_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_360" unitRef="USD" decimals="0">2279760</tgtx:StockIssuedDuringPeriodValueExerciseOfWarrants>

  <tgtx:StockIssuedDuringPeriodSharesExerciseOfWarrants contextRef="P01_01_2013To12_31_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_361" unitRef="shares" decimals="INF">1013009</tgtx:StockIssuedDuringPeriodSharesExerciseOfWarrants>

  <tgtx:StockIssuedDuringPeriodValueExerciseOfWarrantsCashLess contextRef="P01_01_2013To12_31_2013" id="Factid_362" unitRef="USD" decimals="0">-1</tgtx:StockIssuedDuringPeriodValueExerciseOfWarrantsCashLess>

  <tgtx:StockIssuedDuringPeriodValueExerciseOfWarrantsCashLess contextRef="P01_01_2013To12_31_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_363" unitRef="USD" decimals="0">3</tgtx:StockIssuedDuringPeriodValueExerciseOfWarrantsCashLess>

  <tgtx:StockIssuedDuringPeriodValueExerciseOfWarrantsCashLess contextRef="P01_01_2013To12_31_2013_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_364" unitRef="USD" decimals="0">-4</tgtx:StockIssuedDuringPeriodValueExerciseOfWarrantsCashLess>

  <tgtx:StockIssuedDuringPeriodSharesExerciseOfWarrantsCashLess contextRef="P01_01_2013To12_31_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_365" unitRef="shares" decimals="INF">3024</tgtx:StockIssuedDuringPeriodSharesExerciseOfWarrantsCashLess>

  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="P01_01_2011To12_31_2011" id="Factid_366" unitRef="USD" decimals="0">1150</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>

  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="P01_01_2011To12_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_367" unitRef="USD" decimals="0">1150</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>

  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="P01_01_2012To12_31_2012" id="Factid_368" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>

  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="P01_01_2012To12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_369" unitRef="USD" decimals="0">5902</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>

  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="P01_01_2012To12_31_2012_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_370" unitRef="USD" decimals="0">-5902</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>

  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="P01_01_2013To12_31_2013" id="Factid_371" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>

  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="P01_01_2013To12_31_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_372" unitRef="USD" decimals="0">944</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>

  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="P01_01_2013To12_31_2013_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_373" unitRef="USD" decimals="0">-944</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>

  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="P01_01_2011To12_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_374" unitRef="shares" decimals="INF">1150000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>

  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="P01_01_2012To12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_375" unitRef="shares" decimals="INF">5901743</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>

  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="P01_01_2013To12_31_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_376" unitRef="shares" decimals="INF">944464</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2011To12_31_2011" id="Factid_377" unitRef="USD" decimals="0">9655816</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2011To12_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_378" unitRef="USD" decimals="0">4930</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2011To12_31_2011_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_379" unitRef="USD" decimals="0">9650886</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2012To12_31_2012" id="Factid_380" unitRef="USD" decimals="0">12181406</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2012To12_31_2012_PreferredStockMemberusgaapStatementEquityComponentsAxis" id="Factid_381" unitRef="USD" decimals="0">696</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2012To12_31_2012_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_382" unitRef="USD" decimals="0">12180710</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2013To12_31_2013" id="Factid_383" unitRef="USD" decimals="0">37648280</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2013To12_31_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_384" unitRef="USD" decimals="0">6555</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="P01_01_2013To12_31_2013_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_385" unitRef="USD" decimals="0">37641725</us-gaap:StockIssuedDuringPeriodValueNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P01_01_2012To12_31_2012_PreferredStockMemberusgaapStatementEquityComponentsAxis" id="Factid_386" unitRef="shares" decimals="INF">695428</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="P01_01_2013To12_31_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_387" unitRef="shares" decimals="INF">6555000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="P01_01_2011To12_31_2011" id="Factid_388" unitRef="USD" decimals="0">86494</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="P01_01_2011To12_31_2011_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_389" unitRef="USD" decimals="0">86494</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="P01_01_2012To12_31_2012_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_RestrictedCommonStockMembertgtxCompensationAxis" id="Factid_390" unitRef="USD" decimals="0">3233674</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="P01_01_2012To12_31_2012_RestrictedCommonStockMembertgtxCompensationAxis" id="Factid_391" unitRef="USD" decimals="0">3233674</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="P01_01_2012To12_31_2012" id="Factid_392" unitRef="USD" decimals="0">188509</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="P01_01_2012To12_31_2012_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_393" unitRef="USD" decimals="0">188509</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="P01_01_2013To12_31_2013" id="Factid_394" unitRef="USD" decimals="0">5203148</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="P01_01_2013To12_31_2013_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_395" unitRef="USD" decimals="0">5203148</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>

  <us-gaap:ProfitLoss contextRef="P01_01_2011To12_31_2011" id="Factid_396" unitRef="USD" decimals="0">-889071</us-gaap:ProfitLoss>

  <us-gaap:ProfitLoss contextRef="P01_01_2011To12_31_2011_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_397" unitRef="USD" decimals="0">-853074</us-gaap:ProfitLoss>

  <us-gaap:ProfitLoss contextRef="P01_01_2011To12_31_2011_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" id="Factid_398" unitRef="USD" decimals="0">-35997</us-gaap:ProfitLoss>

  <us-gaap:ProfitLoss contextRef="P01_01_2012To12_31_2012_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_399" unitRef="USD" decimals="0">-18072719</us-gaap:ProfitLoss>

  <us-gaap:ProfitLoss contextRef="P01_01_2012To12_31_2012_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" id="Factid_400" unitRef="USD" decimals="0">-8110233</us-gaap:ProfitLoss>

  <us-gaap:ProfitLoss contextRef="P01_01_2013To12_31_2013_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_401" unitRef="USD" decimals="0">-20478210</us-gaap:ProfitLoss>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2011" id="Factid_402" unitRef="USD" decimals="0">9636202</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2011_PreferredStockMemberusgaapStatementEquityComponentsAxis" id="Factid_403" unitRef="USD" decimals="0">413</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_404" unitRef="USD" decimals="0">5061</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2011_ContingentlyIssuableShareMemberusgaapStatementEquityComponentsAxis" id="Factid_405" unitRef="USD" decimals="0">6</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2011_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_406" unitRef="USD" decimals="0">10472115</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2011_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_407" unitRef="USD" decimals="0">-853074</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2011_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" id="Factid_408" unitRef="USD" decimals="0">11681</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2013_PreferredStockMemberusgaapStatementEquityComponentsAxis" id="Factid_409" unitRef="USD" decimals="0">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_410" unitRef="USD" decimals="0">34336</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2013_ContingentlyIssuableShareMemberusgaapStatementEquityComponentsAxis" id="Factid_411" unitRef="USD" decimals="0">6</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2013_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_412" unitRef="USD" decimals="0">79658490</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2013_TreasuryStockMemberusgaapStatementEquityComponentsAxis" id="Factid_413" unitRef="USD" decimals="0">-234337</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2013_AccumulatedDeficitDuringDevelopmentStageMemberusgaapStatementEquityComponentsAxis" id="Factid_414" unitRef="USD" decimals="0">-39404003</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="PAsOn12_31_2013_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" id="Factid_415" unitRef="USD" decimals="0">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2011_PreferredStockMemberusgaapStatementEquityComponentsAxis" id="Factid_416" unitRef="shares" decimals="INF">413388</us-gaap:SharesOutstanding>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_417" unitRef="shares" decimals="INF">5061399</us-gaap:SharesOutstanding>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2013_PreferredStockMemberusgaapStatementEquityComponentsAxis" id="Factid_418" unitRef="shares" decimals="INF">0</us-gaap:SharesOutstanding>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2013_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_419" unitRef="shares" decimals="INF">34336235</us-gaap:SharesOutstanding>

  <us-gaap:SharesOutstanding contextRef="PAsOn12_31_2013_TreasuryStockMemberusgaapStatementEquityComponentsAxis" id="Factid_420" unitRef="shares" decimals="INF">41309</us-gaap:SharesOutstanding>

  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="P01_01_2013To12_31_2013" id="Factid_421" unitRef="USD" decimals="0">2664970</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>

  <us-gaap:ShareBasedCompensation contextRef="P12_01_2011To12_31_2013" id="Factid_422" unitRef="USD" decimals="0">8711824</us-gaap:ShareBasedCompensation>

  <tgtx:SharesIssuedInConnectionWithInLicensingAgreement contextRef="P01_01_2012To12_31_2012" id="Factid_423" unitRef="USD" decimals="0">16578000</tgtx:SharesIssuedInConnectionWithInLicensingAgreement>

  <tgtx:SharesIssuedInConnectionWithInLicensingAgreement contextRef="P01_01_2013To12_31_2013" id="Factid_424" unitRef="USD" decimals="0">0</tgtx:SharesIssuedInConnectionWithInLicensingAgreement>

  <tgtx:SharesIssuedInConnectionWithInLicensingAgreement contextRef="P12_01_2011To12_31_2013" id="Factid_425" unitRef="USD" decimals="0">16875000</tgtx:SharesIssuedInConnectionWithInLicensingAgreement>

  <us-gaap:Depreciation contextRef="P01_01_2012To12_31_2012" id="Factid_426" unitRef="USD" decimals="0">235</us-gaap:Depreciation>

  <us-gaap:Depreciation contextRef="P01_01_2013To12_31_2013" id="Factid_427" unitRef="USD" decimals="0">1127</us-gaap:Depreciation>

  <us-gaap:Depreciation contextRef="P12_01_2011To12_31_2013" id="Factid_428" unitRef="USD" decimals="0">1362</us-gaap:Depreciation>

  <tgtx:ChangeInFairValueOfNotesPayable contextRef="P01_01_2012To12_31_2012" id="Factid_429" unitRef="USD" decimals="0">815699</tgtx:ChangeInFairValueOfNotesPayable>

  <tgtx:ChangeInFairValueOfNotesPayable contextRef="P01_01_2013To12_31_2013" id="Factid_430" unitRef="USD" decimals="0">2414569</tgtx:ChangeInFairValueOfNotesPayable>

  <tgtx:ChangeInFairValueOfNotesPayable contextRef="P12_01_2011To12_31_2013" id="Factid_431" unitRef="USD" decimals="0">3230268</tgtx:ChangeInFairValueOfNotesPayable>

  <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="P01_01_2012To12_31_2012" id="Factid_432" unitRef="USD" decimals="0">1932710</us-gaap:IncreaseDecreaseInOtherCurrentAssets>

  <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="P01_01_2013To12_31_2013" id="Factid_433" unitRef="USD" decimals="0">-229258</us-gaap:IncreaseDecreaseInOtherCurrentAssets>

  <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="P12_01_2011To12_31_2013" id="Factid_434" unitRef="USD" decimals="0">1699859</us-gaap:IncreaseDecreaseInOtherCurrentAssets>

  <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="P01_01_2012To12_31_2012" id="Factid_435" unitRef="USD" decimals="0">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>

  <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="P01_01_2013To12_31_2013" id="Factid_436" unitRef="USD" decimals="0">85121</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>

  <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="P12_01_2011To12_31_2013" id="Factid_437" unitRef="USD" decimals="0">85121</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>

  <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="P01_01_2012To12_31_2012" id="Factid_438" unitRef="USD" decimals="0">595757</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>

  <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="P01_01_2013To12_31_2013" id="Factid_439" unitRef="USD" decimals="0">4034605</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>

  <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="P12_01_2011To12_31_2013" id="Factid_440" unitRef="USD" decimals="0">5038672</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>

  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="P01_01_2012To12_31_2012" id="Factid_441" unitRef="USD" decimals="0">61571</us-gaap:IncreaseDecreaseInInterestPayableNet>

  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="P01_01_2013To12_31_2013" id="Factid_442" unitRef="USD" decimals="0">66506</us-gaap:IncreaseDecreaseInInterestPayableNet>

  <us-gaap:IncreaseDecreaseInInterestPayableNet contextRef="P12_01_2011To12_31_2013" id="Factid_443" unitRef="USD" decimals="0">135174</us-gaap:IncreaseDecreaseInInterestPayableNet>

  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="P01_01_2012To12_31_2012" id="Factid_444" unitRef="USD" decimals="0">1980952</us-gaap:IncreaseDecreaseInDeferredRevenue>

  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="P01_01_2013To12_31_2013" id="Factid_445" unitRef="USD" decimals="0">-152381</us-gaap:IncreaseDecreaseInDeferredRevenue>

  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="P12_01_2011To12_31_2013" id="Factid_446" unitRef="USD" decimals="0">1828571</us-gaap:IncreaseDecreaseInDeferredRevenue>

  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="P01_01_2012To12_31_2012" id="Factid_447" unitRef="USD" decimals="0">-5187964</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="P01_01_2013To12_31_2013" id="Factid_448" unitRef="USD" decimals="0">-10824231</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="P12_01_2011To12_31_2013" id="Factid_449" unitRef="USD" decimals="0">-16098772</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>

  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="P01_01_2012To12_31_2012" id="Factid_450" unitRef="USD" decimals="0">1399</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>

  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="P01_01_2013To12_31_2013" id="Factid_451" unitRef="USD" decimals="0">5681</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>

  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="P12_01_2011To12_31_2013" id="Factid_452" unitRef="USD" decimals="0">7080</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>

  <us-gaap:CashAcquiredFromAcquisition contextRef="P01_01_2012To12_31_2012" id="Factid_453" unitRef="USD" decimals="0">0</us-gaap:CashAcquiredFromAcquisition>

  <us-gaap:CashAcquiredFromAcquisition contextRef="P01_01_2013To12_31_2013" id="Factid_454" unitRef="USD" decimals="0">0</us-gaap:CashAcquiredFromAcquisition>

  <us-gaap:CashAcquiredFromAcquisition contextRef="P12_01_2011To12_31_2013" id="Factid_455" unitRef="USD" decimals="0">10386</us-gaap:CashAcquiredFromAcquisition>

  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="P01_01_2012To12_31_2012" id="Factid_456" unitRef="USD" decimals="0">-1399</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="P01_01_2013To12_31_2013" id="Factid_457" unitRef="USD" decimals="0">-4925552</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="P12_01_2011To12_31_2013" id="Factid_458" unitRef="USD" decimals="0">-4916565</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>

  <us-gaap:ProceedsFromWarrantExercises contextRef="P01_01_2012To12_31_2012" id="Factid_459" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromWarrantExercises>

  <us-gaap:ProceedsFromWarrantExercises contextRef="P01_01_2013To12_31_2013" id="Factid_460" unitRef="USD" decimals="0">2280773</us-gaap:ProceedsFromWarrantExercises>

  <us-gaap:ProceedsFromWarrantExercises contextRef="P12_01_2011To12_31_2013" id="Factid_461" unitRef="USD" decimals="0">2280773</us-gaap:ProceedsFromWarrantExercises>

  <us-gaap:RepaymentsOfShortTermDebt contextRef="P01_01_2012To12_31_2012" id="Factid_462" unitRef="USD" decimals="0">200001</us-gaap:RepaymentsOfShortTermDebt>

  <us-gaap:RepaymentsOfShortTermDebt contextRef="P01_01_2013To12_31_2013" id="Factid_463" unitRef="USD" decimals="0">0</us-gaap:RepaymentsOfShortTermDebt>

  <us-gaap:RepaymentsOfShortTermDebt contextRef="P12_01_2011To12_31_2013" id="Factid_464" unitRef="USD" decimals="0">200001</us-gaap:RepaymentsOfShortTermDebt>

  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="P01_01_2012To12_31_2012" id="Factid_465" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromIssuanceOfCommonStock>

  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="P01_01_2013To12_31_2013" id="Factid_466" unitRef="USD" decimals="0">37648280</us-gaap:ProceedsFromIssuanceOfCommonStock>

  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="P12_01_2011To12_31_2013" id="Factid_467" unitRef="USD" decimals="0">47472962</us-gaap:ProceedsFromIssuanceOfCommonStock>

  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="P01_01_2012To12_31_2012" id="Factid_468" unitRef="USD" decimals="0">12257309</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>

  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="P01_01_2013To12_31_2013" id="Factid_469" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>

  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="P12_01_2011To12_31_2013" id="Factid_470" unitRef="USD" decimals="0">12257309</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>

  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="P01_01_2012To12_31_2012" id="Factid_471" unitRef="USD" decimals="0">75903</us-gaap:PaymentsOfStockIssuanceCosts>

  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="P01_01_2013To12_31_2013" id="Factid_472" unitRef="USD" decimals="0">0</us-gaap:PaymentsOfStockIssuanceCosts>

  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="P12_01_2011To12_31_2013" id="Factid_473" unitRef="USD" decimals="0">75903</us-gaap:PaymentsOfStockIssuanceCosts>

  <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="P01_01_2012To12_31_2012" id="Factid_474" unitRef="USD" decimals="0">84538</us-gaap:PaymentsForRepurchaseOfCommonStock>

  <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="P01_01_2013To12_31_2013" id="Factid_475" unitRef="USD" decimals="0">149799</us-gaap:PaymentsForRepurchaseOfCommonStock>

  <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="P12_01_2011To12_31_2013" id="Factid_476" unitRef="USD" decimals="0">234337</us-gaap:PaymentsForRepurchaseOfCommonStock>

  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="P01_01_2012To12_31_2012" id="Factid_477" unitRef="USD" decimals="0">11896867</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="P01_01_2013To12_31_2013" id="Factid_478" unitRef="USD" decimals="0">39779254</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>

  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="P12_01_2011To12_31_2013" id="Factid_479" unitRef="USD" decimals="0">61500803</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>

  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="P01_01_2012To12_31_2012" id="Factid_480" unitRef="USD" decimals="0">6707504</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>

  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="P01_01_2013To12_31_2013" id="Factid_481" unitRef="USD" decimals="0">24029471</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>

  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="P12_01_2011To12_31_2013" id="Factid_482" unitRef="USD" decimals="0">40485466</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn12_31_2011" id="Factid_483" unitRef="USD" decimals="0">9748491</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="PAsOn11_30_2011" id="Factid_484" unitRef="USD" decimals="0">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>

  <tgtx:ConversionOfNotesPayableToPreferredStock contextRef="P01_01_2012To12_31_2012" id="Factid_485" unitRef="USD" decimals="0">0</tgtx:ConversionOfNotesPayableToPreferredStock>

  <tgtx:ConversionOfNotesPayableToPreferredStock contextRef="P01_01_2013To12_31_2013" id="Factid_486" unitRef="USD" decimals="0">0</tgtx:ConversionOfNotesPayableToPreferredStock>

  <tgtx:ConversionOfNotesPayableToPreferredStock contextRef="P12_01_2011To12_31_2013" id="Factid_487" unitRef="USD" decimals="0">55271</tgtx:ConversionOfNotesPayableToPreferredStock>

  <tgtx:AccruedFinancingCosts contextRef="P01_01_2012To12_31_2012" id="Factid_488" unitRef="USD" decimals="0">0</tgtx:AccruedFinancingCosts>

  <tgtx:AccruedFinancingCosts contextRef="P01_01_2013To12_31_2013" id="Factid_489" unitRef="USD" decimals="0">0</tgtx:AccruedFinancingCosts>

  <tgtx:AccruedFinancingCosts contextRef="P12_01_2011To12_31_2013" id="Factid_490" unitRef="USD" decimals="0">61138</tgtx:AccruedFinancingCosts>

  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="P01_01_2013To12_31_2013" id="Factid_491">              &lt;div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;NOTE 1 - ORGANIZATION AND SUMMARY  OF SIGNIFICANT ACCOUNTING POLICIES&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;DESCRIPTION OF BUSINESS&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;We are a biopharmaceutical company  focused on the acquisition, development and commercialization of  innovative and medically important pharmaceutical products for the  treatment of cancer and other underserved therapeutic needs. We aim  to acquire rights to these technologies by licensing or otherwise  acquiring an ownership interest, funding their research and  development and eventually either out-licensing or bringing the  technologies to market. Currently, the Company is developing two  therapies targeting hematological malignancies.&lt;/font&gt; &lt;font style="FONT-FAMILY: 'Tahoma','sans-serif'; COLOR: #333333; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;&lt;font style="FONT-SIZE: 10pt"&gt;TG-1101 (ublituximab), is a  novel, &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  glycoengineered&lt;/font&gt;&amp;#160;monoclonal antibody that targets a  specific and unique epitope on the CD20 antigen found on mature  B-lymphocytes&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;. We are  also developing&lt;/font&gt; TGR-1202, an orally available PI3K delta  inhibitor. We also hold the development rights to AST-726, a  nasally delivered product for the treatment of Vitamin  B&lt;sub&gt;12&lt;/sub&gt; deficiency.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Exchange Transaction with TG  Therapeutics, Inc. and its majority  shareholders&lt;/font&gt;&lt;/i&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;On December 29, 2011, the Company  entered into and consummated an Exchange Transaction Agreement with  Opus Point Partners, LLC (&amp;#8220;Opus&amp;#8221;) and TG Biologics,  Inc. (formerly known as TG Therapeutics, Inc.) (&amp;#8220;TG  Bio&amp;#8221;) (the &amp;#8220;Agreement&amp;#8221;). Under the Agreement,  Opus exchanged (the &amp;#8220;Exchange Transaction&amp;#8221;) its shares  of common stock in TG Bio (&amp;#8220;TG Bio Common Stock&amp;#8221;) for  shares of Series A preferred stock in the Company (&amp;#8220;Company  Preferred Stock&amp;#8221;). In accordance with the terms of the  Agreement, &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  95&lt;/font&gt;% of the holders of common stock of TG Bio (one (1)  minority shareholder of TG Bio holding in aggregate &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  132,000&lt;/font&gt; shares of common stock of TG Bio did not  participate) surrendered their TG Bio common stock. The Agreement  caused the Company to issue to TG Bio&amp;#8217;s shareholders &lt;font  style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  281,250&lt;/font&gt; shares of Company Preferred Stock. &lt;font style="COLOR: black"&gt;Each share of Company Preferred Stock was  convertible into &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;font  style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  8.89&lt;/font&gt;&lt;/font&gt; shares of the Common Stock provided that such  conversion rights were subject to sufficient available authorized  shares of Common Stock. In connection with the reverse stock split  effected by the Company on April 30, 2012 (as discussed below), all  shares of preferred stock issued in connection with the Agreement  were converted to Common Stock.&lt;/font&gt; The Company Preferred Stock  issued in connection with the Agreement provided the former TG Bio  shareholders with direct and/or indirect ownership of approximately  &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  95&lt;/font&gt;% of the Company&amp;#8217;s outstanding Company Common Stock  immediately following the consummation of the  transaction.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;Since the stockholders of TG Bio  received the majority of the voting shares of the Company, the  merger was accounted for as a reverse acquisition whereby TG Bio  was the accounting acquirer (legal acquiree) and the Company was  the accounting acquiree (legal acquirer) under the acquisition  method of accounting. TG Bio was incorporated in Delaware in  November 2010, but did not commence operations until April  2011.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;The filings with the Securities and  Exchange Commission (the &amp;#8220;SEC&amp;#8221;) include the historical  financial results of TG Bio and will hereafter collectively be  referred to as the Company.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;On April 30, 2012, the Company filed  a Certificate of Amendment to its Certificate of Incorporation to  change its name from Manhattan Pharmaceuticals, Inc.  (&amp;#8220;Manhattan&amp;#8221;) to TG Therapeutics, Inc. In conjunction  with this change, the subsidiary formerly named TG Therapeutics,  Inc. filed a Certificate of Amendment changing its name to TG  Biologics, Inc.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;LIQUIDITY AND CAPITAL RESOURCES&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; BACKGROUND: transparent"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;We have incurred operating losses  since our inception, and expect to continue to incur operating  losses for the foreseeable future and may never become profitable.  As of December 31, 2013, we have an accumulated deficit of $&lt;font  style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;39,404,003&lt;/font&gt;.&lt;font   style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;  &lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;Our primary source of cash has been  proceeds from the sale of equity securities, &lt;font style="COLOR: black"&gt;the upfront payment from our Sublicense Agreement  with Ildong Pharmaceutical Co. Ltd. (&amp;#8220;Ildong&amp;#8221;), and  warrant exercises&lt;/font&gt;. We have not yet commercialized any of our  drug candidates and cannot be sure if we will ever be able to do  so. Even if we commercialize one or more of our drug candidates, we  may not become profitable. Our ability to achieve profitability  depends on a number of factors, including our ability to obtain  regulatory approval for our drug candidates, successfully complete  any post-approval regulatory obligations and successfully  commercialize our drug candidates alone or in partnership. We may  continue to incur substantial operating losses even if we begin to  generate revenues from our drug candidates.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; BACKGROUND: transparent"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;As of December 31, 2013, we had  $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;45,431,532&lt;/font&gt;  in cash, cash equivalents, investment securities, and interest  receivable. We currently anticipate that our cash and cash  equivalents to be sufficient to fund our anticipated operating cash  requirements for approximately&amp;#160;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;24&lt;/font&gt;  months from December 31, 2013. The actual amount of cash that we  will need to operate is subject to many factors, including, but not  limited to, the timing, design and conduct of clinical trials for  our drug candidates. We are dependent upon significant future  financing to provide the cash necessary to execute our current  operations, including the commercialization of any of our drug  candidates.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"   align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Our common stock is  quoted on &lt;font style="COLOR: black"&gt;the NASDAQ Capital  Market&lt;/font&gt; and trades under the symbol  &amp;#8220;TGTX.&amp;#8221;&lt;/font&gt;&lt;/div&gt;    &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;     &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;REVERSE STOCK SPLIT&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;On April 30, 2012, the  Company effected a reverse split of its Common Stock at a &lt;font  style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;ratio of 56.25 for 1&lt;/font&gt;, pursuant to a previously  obtained stockholder authorization. All share amounts and per share  prices in this Annual Report on Form 10-K have been retroactively  adjusted to reflect the effect of our reverse stock split, on a  fifty-six and one quarter (56.25) for one (1) basis, unless  otherwise indicated.&amp;#160;&amp;#160;The exercise price for all stock  options and warrants and the conversion price for convertible  securities in the accompanying consolidated financial statements  have been adjusted to reflect the reverse stock split by  multiplying the original exercise or conversion price by fifty-six  and one quarter (56.25).&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"   align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;RECENTLY ISSUED ACCOUNTING STANDARDS&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; BACKGROUND: transparent"&gt;  &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; BACKGROUND: transparent"&gt;  &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: TimesNewRomanPSMT; FONT-SIZE: 10pt"&gt;In July 2013, the  Financial Accounting Standards Board, or FASB, issued a new  accounting standard which will require the presentation of certain  unrecognized tax benefits as reductions to deferred tax assets  rather than as liabilities in the consolidated balance sheets when  a net operating loss carryforward, a similar tax loss, or a tax  credit carryforward exists. The new standard requires adoption on a  prospective basis in the first quarter of 2015; however, early  adoption is permitted. The Company does not anticipate that this  adoption will have a significant impact on its financial position,  results of operations, or cash flows.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; BACKGROUND: transparent"&gt;  &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; BACKGROUND: transparent"&gt;  &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;Other pronouncements  issued by the FASB or other authoritative accounting standards  group with future effective dates are either not applicable or not  significant to the consolidated financial statements of the  Company.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"   align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;BASIS OF PRESENTATION&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;  The Company has generated limited revenue from its operations and,  accordingly, the financial statements have been prepared in  accordance with the provisions of accounting and reporting for  Development Stage Enterprises.&lt;/font&gt;&lt;/div&gt;    &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;     &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;USE OF ESTIMATES&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;The preparation of financial  statements in conformity with U.S. generally accepted accounting  principles (&amp;#8220;GAAP&amp;#8221;) requires management to make  estimates and judgments that affect the reported amounts of assets  and liabilities and the disclosure of contingent assets and  liabilities at the date of the financial statements and the  reported amounts of revenues and expenses during the applicable  reporting period. Actual results could differ from those estimates.  Such differences could be material to the financial  statements.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;CASH AND CASH EQUIVALENTS&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;We treat liquid investments with  original maturities of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;less than three  months&lt;/font&gt; when purchased as cash and cash equivalents.&lt;font  style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font   style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;INVESTMENT  SECURITIES&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;Investment securities at December 31,  2013 consist of long-term government securities. We classify our  long-term debt securities as held-to-maturity. Held-to-maturity  securities are those securities in which we have the ability and  intent to hold the security until maturity. Held-to-maturity  securities are recorded at amortized cost, adjusted for the  amortization or accretion of premiums or discounts. Premiums and  discounts are amortized or accreted over the life of the related  held-to-maturity security as an adjustment to yield using the  effective interest method.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;A decline in the market value of any  investment security below cost, that is deemed to be other than  temporary, results in a reduction in the carrying amount to fair  value. The impairment is charged to operations and a new cost basis  for the security is established. Other-than-temporary impairment  charges are included in interest and other income, net. Unrealized  gains, if determined to be temporary, are included in accumulated  other comprehensive income in stockholders&amp;#8217; equity. Dividend  and interest income are recognized when earned.&lt;/font&gt;&lt;/div&gt;    &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;     &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;REVENUE RECOGNITION&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;We recognize license revenue in  accordance with the revenue recognition guidance of the FASB  Accounting Standards Codification, or Codification. We analyze each  element of our licensing agreement to determine the appropriate  revenue recognition. The terms of the license agreement may include  payments to us of non-refundable up-front license fees, milestone  payments if specified objectives are achieved, and/or royalties on  product sales. We recognize revenue from upfront payments over the  period of significant involvement under the related agreements  unless the fee is in exchange for products delivered or services  rendered that represent the culmination of a separate earnings  process and no further performance obligation exists under the  contract. We recognize milestone payments as revenue upon the  achievement of specified milestones only if (1)&amp;#160;the milestone  payment is non-refundable, (2)&amp;#160;substantive effort is involved  in achieving the milestone, (3)&amp;#160;the amount of the milestone is  reasonable in relation to the effort expended or the risk  associated with achievement of the milestone, and (4)&amp;#160;the  milestone is at risk for both parties. If any of these conditions  are not met, we defer the milestone payment and recognize it as  revenue over the estimated period of performance under the  contract.&lt;/font&gt;&lt;/div&gt;    &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;     &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;RESEARCH AND DEVELOPMENT COSTS&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;Generally, research and development  costs are expensed as incurred. Nonrefundable advance payments for  goods or services that will be used or rendered for future research  and development activities are deferred and amortized over the  period that the goods are delivered or the related services are  performed, subject to an assessment of recoverability. We make  estimates of costs incurred in relation to external clinical  research organizations, or CROs, and clinical site costs. We  analyze the progress of clinical trials, including levels of  patient enrollment, invoices received and contracted costs when  evaluating the adequacy of the amount expensed and the related  prepaid asset and accrued liability. Significant judgments and  estimates must be made and used in determining the accrued balance  and expense in any accounting period. We review and accrue CRO  expenses and clinical trial study expenses based on work performed  and rely upon estimates of those costs applicable to the stage of  completion of a study. Accrued CRO costs are subject to revisions  as such trials progress to completion. Revisions are charged to  expense in the period in which the facts that give rise to the  revision become known. With respect to clinical site costs, the  financial terms of these agreements are subject to negotiation and  vary from contract to contract. Payments under these contracts may  be uneven, and depend on factors such as the achievement of certain  events, the successful recruitment of patients, the completion of  portions of the clinical trial or similar conditions. The objective  of our policy is to match the recording of expenses in our  financial statements to the actual services received and efforts  expended. As such, expense accruals related to clinical site costs  are recognized based on our estimate of the degree of completion of  the event or events specified in the specific clinical study or  trial contract.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;IN-PROCESS RESEARCH AND  DEVELOPMENT&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;  All acquired research and development projects are recorded at  their fair value as of the date acquisition. The fair values are  assessed as of the balance sheet date to ascertain if there has  been any impairment of the recorded value. If there is an  impairment, the asset is written down to its current fair value by  the recording of an expense. Impairment is tested on an annual  basis &lt;font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"&gt;or sooner, if  there is an indication of impairment,&lt;/font&gt; and consists of a  comparison of the fair value of the in-process research and  development with its carrying amount.&lt;/font&gt;&lt;/div&gt;    &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;     &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-FAMILY: 'Times','serif'; FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;INCOME TAXES&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;Income taxes are accounted for under  the asset and liability method. Deferred tax assets and liabilities  are recognized for the future tax consequences attributable to  temporary differences between the financial statement carrying  amounts of existing assets and liabilities and their respective tax  bases, operating losses and tax credit carryforwards. Deferred tax  assets and liabilities are measured using enacted tax rates  expected to apply to taxable income in the years in which those  temporary differences are expected to be recovered or settled. The  effect on deferred tax assets and liabilities of a change in tax  rates is recognized in operations in the period that includes the  enactment date. If the likelihood of realizing the deferred tax  assets or liability is less than &amp;#8220;more likely than  not,&amp;#8221; a valuation allowance is then created.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;We, and our subsidiaries, file income  tax returns in the U.S. Federal jurisdiction and in various states.  We have tax net operating loss carryforwards that are subject to  examination for a number of years beyond the year in which they  were generated for tax purposes. Since a portion of these net  operating loss carryforwards may be utilized in the future, many of  these net operating loss carryforwards will remain subject to  examination.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;We recognize interest and penalties  related to uncertain income tax positions in income tax  expense.&lt;/font&gt;&lt;/div&gt;    &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;     &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;STOCK - BASED COMPENSATION&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;We recognize all share-based payments  to employees and to non-employee directors as compensation for  service&amp;#160;as compensation expense in the consolidated financial  statements based on the fair values of such payments. Stock-based  compensation expense recognized each period is based on the value  of the portion of share-based payment awards that is ultimately  expected to vest during the period. Forfeitures are estimated at  the time of grant and revised, if necessary, in subsequent periods  if actual forfeitures differ from those estimates.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;For share-based payments to  consultants and other third-parties, compensation expense is  determined at the &amp;#8220;measurement date.&amp;#8221; The expense is  recognized over the vesting period of the award. Until the  measurement date is reached, the total amount of compensation  expense remains uncertain. We record compensation expense based on  the fair value of the award at the reporting date. The awards to  consultants and other third-parties are then revalued, or the total  compensation is recalculated based on the then current fair value,  at each subsequent reporting date.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;BASIC AND DILUTED NET (LOSS) INCOME PER COMMON  SHARE&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;Basic net income (loss) per common  share is calculated by dividing net income (loss) applicable to  common shares by the weighted-average number of common shares  outstanding for the period. Diluted net loss per common share is  the same as basic net income (loss) per common share, since  potentially dilutive securities from stock options, stock warrants  and convertible preferred stock would have an antidilutive effect  either because the Company incurred a net loss during the period  presented or because such potentially dilutive securities were out  of the money and the Company realized net income during the period  presented. The amounts of potentially dilutive securities excluded  from the calculation were &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  10,618,584&lt;/font&gt; and &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  10,746,837&lt;/font&gt; at December 31, 2013 and 2012, respectively.  During the years ended December 31, 2013 and 2012 the Company  incurred a net loss, therefore, all of the dilutive securities are  excluded from the computation of diluted earnings per share.&lt;font  style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;LONG-LIVED ASSETS AND GOODWILL&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;Long-lived assets are reviewed for an  impairment loss when circumstances indicate that the carrying value  of long-lived tangible and intangible assets with finite lives may  not be recoverable. Management&amp;#8217;s policy in determining  whether an impairment indicator exists, a triggering event,  comprises measurable operating performance criteria as well as  qualitative measures. If an analysis is necessitated by the  occurrence of a triggering event, we make certain assumptions in  determining the impairment amount. If the carrying amount of an  asset exceeds its estimated future cash flows, an impairment charge  is recognized.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;Goodwill  is reviewed for impairment annually, or when events arise that  could indicate that an impairment exists. We test for goodwill  impairment using a two-step process. The first step compares the  fair value of the reporting unit with the unit's carrying value,  including goodwill. When the carrying value of the reporting unit  is greater than fair value, the unit&amp;#8217;s goodwill may be  impaired, and the second step must be completed to measure the  amount of the goodwill impairment charge, if any. In the second  step, the implied fair value of the reporting unit&amp;#8217;s goodwill  is compared with the carrying amount of the unit&amp;#8217;s goodwill.  If the carrying amount is greater than the implied fair value, the  carrying value of the goodwill must be written down to its implied  fair value. We will continue to perform impairment tests annually,  at December 31, and whenever events or changes in circumstances  suggest that the carrying value of an asset may not be  recoverable.&lt;/div&gt;  &lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>

  <us-gaap:PreferredStockSharesIssued contextRef="PAsOn12_31_2012" id="Factid_492" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>

  <us-gaap:PreferredStockSharesIssued contextRef="PAsOn12_31_2013" id="Factid_493" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>

  <us-gaap:PreferredStockSharesOutstanding contextRef="PAsOn12_31_2012" id="Factid_494" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>

  <us-gaap:PreferredStockSharesOutstanding contextRef="PAsOn12_31_2013" id="Factid_495" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>

  <us-gaap:CashAndCashEquivalentsDisclosureTextBlock contextRef="P01_01_2013To12_31_2013" id="Factid_496">              &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;NOTE 2 &amp;#150; CASH AND CASH  EQUIVALE&lt;/font&gt;NTS&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;/div&gt;    &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;     &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="50%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;December&amp;#160;31,&amp;#160;2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;December&amp;#160;31,&amp;#160;2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="50%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="50%"&gt;  &lt;div&gt;Money market funds&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;554,069&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;500,007&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="50%"&gt;  &lt;div&gt;Checking and bank deposits&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;39,931,397&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;15,955,988&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="50%"&gt;  &lt;div&gt;Total&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;40,485,466&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;16,455,995&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;  &lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>

  <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="P01_01_2013To12_31_2013" id="Factid_497">              &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="MARGIN: 0in; WIDTH: 75%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="50%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;December&amp;#160;31,&amp;#160;2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;December&amp;#160;31,&amp;#160;2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="50%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="50%"&gt;  &lt;div&gt;Money market funds&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;554,069&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;500,007&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="50%"&gt;  &lt;div&gt;Checking and bank deposits&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;39,931,397&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;15,955,988&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="50%"&gt;  &lt;div&gt;Total&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;40,485,466&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;16,455,995&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;  &lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>

  <us-gaap:Cash contextRef="PAsOn12_31_2012" id="Factid_498" unitRef="USD" decimals="0">15955988</us-gaap:Cash>

  <us-gaap:Cash contextRef="PAsOn12_31_2013" id="Factid_499" unitRef="USD" decimals="0">39931397</us-gaap:Cash>

  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2013To12_31_2013" id="Factid_500">              &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;NOTE 7 &amp;#150; INCOME  TAXES&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;We account for income taxes under the  asset and liability method. Deferred tax assets and liabilities are  determined based on differences between the financial reporting and  tax basis of assets and liabilities and are measured using the  enacted tax rates and laws that will be in effect when the  differences are expected to reverse. A valuation allowance is  established when necessary to reduce deferred tax assets to the  amount expected to be realized. In determining the need for a  valuation allowance, management reviews both positive and negative  evidence, including current and historical results of operations,  future income projections and the overall prospects of our  business. Based upon management's assessment of all available  evidence, we believe that it is more-likely-than-not that the  deferred tax assets will not be realizable, and therefore, a  valuation allowance has been established. The valuation allowance  for deferred tax assets was approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;46,283,000&lt;/font&gt;  and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;36,271,000&lt;/font&gt;  as of December 31, 2013 and 2012, respectively.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;As of December 31, 2013, we have U.S.  net operating loss carryforwards (&amp;#8220;NOLs&amp;#8221;) of  approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;84,182,000&lt;/font&gt;.  For income tax purposes, these NOLs will expire in various amounts  through &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  2033&lt;/font&gt;. The Tax Reform Act of 1986 contains provisions which  limit the ability to utilize net operating loss carryforwards in  the case of certain events including significant changes in  ownership interests. The Exchange Transaction with TG Bio may have  resulted in a &amp;#8220;change in ownership&amp;#8221; as defined by IRC  Section 382 of the Internal Revenue Code of 1986, as amended.  Accordingly, a substantial portion of the Company&amp;#8217;s NOLs  above may be subject to annual limitations in reducing any future  year&amp;#8217;s taxable income.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="TEXT-DECORATION: none"&gt;  &amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;The  tax effects of temporary differences that give rise to significant  portions of the deferred tax assets and deferred tax liabilities at  December 31, 2013 and 2012 are presented below.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Deferred tax assets (liabilities):&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Net operating loss carryforwards&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;32,399,879&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;32,190,080&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Research and development credit&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,266,167&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;1,882,238&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Noncash compensation&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;10,971,912&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;3,051,920&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Acquired in-process research and development&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(1,202,556)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Foreign tax credit&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;330,000&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Other&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;644,899&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;19,241&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Deferred tax asset, excluding valuation allowance&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;46,282,857&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;36,270,923&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Less valuation allowance&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(46,282,857)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(36,270,923)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Net deferred tax assets&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt;  &lt;/div&gt;    &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;     &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;There was no current or deferred income tax expense for the  year ended December&amp;#160;31, 2013. The Company recorded $&lt;font  style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;330,000&lt;/font&gt;  in income tax expense for the year ended December 31, 2012, as a  result of South Korean taxes withheld associated with the Ildong  sublicense agreement (see Note 8).&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;  &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;Income tax expense differed from amounts computed by  applying the US Federal income tax rate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  34&lt;/font&gt;% to pretax loss as follows:&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="23%" colspan="5"&gt;  &lt;div&gt;For&amp;#160;the&amp;#160;year&amp;#160;ended&amp;#160;December&amp;#160;31,&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Loss before income taxes, as reported in the consolidated  statements&lt;br/&gt;   &amp;#160;&amp;#160;&amp;#160;of operations&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(20,478,210)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(25,852,952)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Computed &amp;#8220;expected&amp;#8221; tax benefit&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(6,962,592)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(8,790,003)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Increase (decrease) in income taxes resulting from:&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Expected benefit from state and local taxes&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(917,810)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(1,758,001)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Research and development credits&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(250,000)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(75,000)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Other&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;43,026&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;230,643&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Permanent difference related to contingent note payable&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(1,924,558)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Foreign tax withholding&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;330,000&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Change in the balance of the valuation allowance for deferred  tax&lt;br/&gt;   &amp;#160;&amp;#160;&amp;#160;assets&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;10,011,934&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;10,392,361&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;330,000&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt;  &lt;/div&gt;    &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;     &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;We file income tax returns in the U.S  Federal and various state and local jurisdictions. With certain  exceptions, the Company is no longer subject to U.S. Federal and  state income tax examinations by tax authorities for years prior to  2010. However, NOLs and tax credits generated from those prior  years could still be adjusted upon audit.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;The Company recognizes interest and  penalties to uncertain tax position in income tax expense in the  statement of operations. There was no accrual for interest and  penalties related to uncertain tax positions for 2013.&amp;#160;We do  not believe that there will be a material change in our  unrecognized tax positions over the next twelve months.&amp;#160;All of  the unrecognized tax benefits, if recognized, would be offset by  the valuation allowance.&lt;/font&gt;&lt;/div&gt;  &lt;/div&gt;  &lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:IncomeTaxDisclosureTextBlock>

  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P01_01_2013To12_31_2013" id="Factid_501">              &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;The tax effects of temporary  differences that give rise to significant portions of the deferred  tax assets and deferred tax liabilities at December 31, 2013 and  2012 are presented below.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Deferred tax assets (liabilities):&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Net operating loss carryforwards&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;32,399,879&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;32,190,080&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Research and development credit&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,266,167&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;1,882,238&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Noncash compensation&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;10,971,912&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;3,051,920&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Acquired in-process research and development&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(1,202,556)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Foreign tax credit&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;330,000&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Other&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;644,899&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;19,241&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Deferred tax asset, excluding valuation allowance&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;46,282,857&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;36,270,923&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Less valuation allowance&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(46,282,857)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(36,270,923)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Net deferred tax assets&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt;  &lt;/div&gt;  &lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>

  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P01_01_2013To12_31_2013" id="Factid_502">              &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;Income tax expense differed from  amounts computed by applying the US Federal income tax rate of  &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  34&lt;/font&gt;% to pretax loss as follows:&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="23%" colspan="5"&gt;  &lt;div&gt;For&amp;#160;the&amp;#160;year&amp;#160;ended&amp;#160;December&amp;#160;31,&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Loss before income taxes, as reported in the consolidated  statements&lt;br/&gt;   &amp;#160;&amp;#160;&amp;#160;of operations&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(20,478,210)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(25,852,952)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Computed &amp;#8220;expected&amp;#8221; tax benefit&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(6,962,592)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(8,790,003)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Increase (decrease) in income taxes resulting from:&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Expected benefit from state and local taxes&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(917,810)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(1,758,001)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Research and development credits&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(250,000)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(75,000)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Other&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;43,026&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;230,643&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Permanent difference related to contingent note payable&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(1,924,558)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Foreign tax withholding&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;330,000&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;Change in the balance of the valuation allowance for deferred  tax&lt;br/&gt;   &amp;#160;&amp;#160;&amp;#160;assets&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;10,011,934&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;10,392,361&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="75%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;330,000&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt;  &lt;/div&gt;  &lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>

  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="PAsOn12_31_2012" id="Factid_503" unitRef="USD" decimals="0">32190080</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>

  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="PAsOn12_31_2013" id="Factid_504" unitRef="USD" decimals="0">32399879</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>

  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="PAsOn12_31_2012" id="Factid_505" unitRef="USD" decimals="0">1882238</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>

  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="PAsOn12_31_2013" id="Factid_506" unitRef="USD" decimals="0">2266167</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>

  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="PAsOn12_31_2012" id="Factid_507" unitRef="USD" decimals="0">3051920</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>

  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="PAsOn12_31_2013" id="Factid_508" unitRef="USD" decimals="0">10971912</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>

  <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="PAsOn12_31_2012" id="Factid_509" unitRef="USD" decimals="0">-1202556</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>

  <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="PAsOn12_31_2013" id="Factid_510" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>

  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign contextRef="PAsOn12_31_2012" id="Factid_511" unitRef="USD" decimals="0">330000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign>

  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign contextRef="PAsOn12_31_2013" id="Factid_512" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign>

  <us-gaap:DeferredTaxAssetsOther contextRef="PAsOn12_31_2012" id="Factid_513" unitRef="USD" decimals="0">19241</us-gaap:DeferredTaxAssetsOther>

  <us-gaap:DeferredTaxAssetsOther contextRef="PAsOn12_31_2013" id="Factid_514" unitRef="USD" decimals="0">644899</us-gaap:DeferredTaxAssetsOther>

  <us-gaap:DeferredTaxAssetsGross contextRef="PAsOn12_31_2012" id="Factid_515" unitRef="USD" decimals="0">36270923</us-gaap:DeferredTaxAssetsGross>

  <us-gaap:DeferredTaxAssetsGross contextRef="PAsOn12_31_2013" id="Factid_516" unitRef="USD" decimals="0">46282857</us-gaap:DeferredTaxAssetsGross>

  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="PAsOn12_31_2012" id="Factid_517" unitRef="USD" decimals="0">36270923</us-gaap:DeferredTaxAssetsValuationAllowance>

  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="PAsOn12_31_2013" id="Factid_518" unitRef="USD" decimals="0">46282857</us-gaap:DeferredTaxAssetsValuationAllowance>

  <us-gaap:DeferredTaxAssetsNet contextRef="PAsOn12_31_2012" id="Factid_519" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxAssetsNet>

  <us-gaap:DeferredTaxAssetsNet contextRef="PAsOn12_31_2013" id="Factid_520" unitRef="USD" decimals="0">0</us-gaap:DeferredTaxAssetsNet>

  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="P01_01_2012To12_31_2012" id="Factid_521" unitRef="USD" decimals="0">-1758001</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>

  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="P01_01_2013To12_31_2013" id="Factid_522" unitRef="USD" decimals="0">-917810</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>

  <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="P01_01_2012To12_31_2012" id="Factid_523" unitRef="USD" decimals="0">75000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>

  <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="P01_01_2013To12_31_2013" id="Factid_524" unitRef="USD" decimals="0">250000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>

  <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="P01_01_2012To12_31_2012" id="Factid_525" unitRef="USD" decimals="0">230643</us-gaap:IncomeTaxReconciliationOtherAdjustments>

  <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="P01_01_2013To12_31_2013" id="Factid_526" unitRef="USD" decimals="0">43026</us-gaap:IncomeTaxReconciliationOtherAdjustments>

  <tgtx:EffectiveIncomeTaxReconciliationForeignWithHoldingTax contextRef="P01_01_2012To12_31_2012" id="Factid_527" unitRef="USD" decimals="0">330000</tgtx:EffectiveIncomeTaxReconciliationForeignWithHoldingTax>

  <tgtx:EffectiveIncomeTaxReconciliationForeignWithHoldingTax contextRef="P01_01_2013To12_31_2013" id="Factid_528" unitRef="USD" decimals="0">0</tgtx:EffectiveIncomeTaxReconciliationForeignWithHoldingTax>

  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="P01_01_2012To12_31_2012" id="Factid_529" unitRef="USD" decimals="0">10392361</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>

  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="P01_01_2013To12_31_2013" id="Factid_530" unitRef="USD" decimals="0">10011934</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>

  <us-gaap:OperatingLossCarryforwards contextRef="PAsOn12_31_2013_UsFederalIncomeTaxMemberusgaapIncomeTaxAuthorityAxis" id="Factid_531" unitRef="USD" decimals="0">84182000</us-gaap:OperatingLossCarryforwards>

  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="P01_01_2013To12_31_2013_UsFederalIncomeTaxMemberusgaapIncomeTaxAuthorityAxis" id="Factid_532" unitRef="pure" decimals="2">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>

  <us-gaap:EquityMethodInvestmentsDisclosureTextBlock contextRef="P01_01_2013To12_31_2013" id="Factid_533">              &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;NOTE 9 &amp;#150; JOINT  VENTURE&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;On April 19, 2011, H Pharmaceuticals  K/S (the &amp;#8220;Hedrin JV&amp;#8221;), of which the Company was a &lt;font  style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  15&lt;/font&gt;% limited partner at the time, filed a demand for  arbitration against Thornton &amp;amp; Ross, LTD.  (&amp;#8220;T&amp;amp;R&amp;#8221;) with respect to alleged breaches by T&amp;amp;R  of an Exclusive License Agreement (the &amp;#8220;Hedrin  License&amp;#8221;) dated June 28, 2007, which was originally entered  into between the Company and T&amp;amp;R, and which the Company  assigned in 2008 to the Hedrin JV, with T&amp;amp;R&amp;#8217;s consent.  The Hedrin JV is seeking damages from T&amp;amp;R in the amount of  approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;7,000,000&lt;/font&gt;.  The Company was not a party to the initial arbitration  demand.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;On May 20, 2011, T&amp;amp;R filed an  answer to the arbitration demand in which T&amp;amp;R asserted  counterclaims against the Hedrin JV for alleged breaches by the  Hedrin JV of the Hedrin License and for declaratory relief that the  Hedrin License was properly terminated by T&amp;amp;R. In addition,  T&amp;amp;R impleaded an individual (who is not associated with the  Company), Nordic Biotech Venture Fund II K/S (an investment fund)  and the Company, demanding arbitration against them based on  alleged breaches of the Hedrin License and other related claims. In  December 2011, the Company was removed by the arbitrator as a party  to the arbitration. T&amp;amp;R is seeking damages of approximately  $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;20,000,000&lt;/font&gt;.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;The Hedrin JV and T&amp;amp;R held a  mediation session in order to avoid the arbitration process. The  mediation process did not produce a result. During 2011, Nordic  made an additional capital contribution to the Hedrin JV in order  to fund the arbitration. As a result of that capital contribution,  as of December 31, 2011, the Company owned a &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  13&lt;/font&gt;% interest in the Hedrin JV, and no further information  has been available since that date. The arbitration process is  ongoing.&lt;/font&gt;&lt;/div&gt;  &lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>

  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="PAsOn04_19_2011" id="Factid_534" unitRef="pure" decimals="2">0.15</us-gaap:EquityMethodInvestmentOwnershipPercentage>

  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="PAsOn12_31_2011" id="Factid_535" unitRef="pure" decimals="2">0.13</us-gaap:EquityMethodInvestmentOwnershipPercentage>

  <dei:DocumentType contextRef="P01_01_2013To12_31_2013" id="Factid_536">10-K</dei:DocumentType>

  <dei:AmendmentFlag contextRef="P01_01_2013To12_31_2013" id="Factid_537">false</dei:AmendmentFlag>

  <dei:DocumentPeriodEndDate contextRef="P01_01_2013To12_31_2013" id="Factid_538">2013-12-31</dei:DocumentPeriodEndDate>

  <dei:DocumentFiscalYearFocus contextRef="P01_01_2013To12_31_2013" id="Factid_539">2013</dei:DocumentFiscalYearFocus>

  <dei:DocumentFiscalPeriodFocus contextRef="P01_01_2013To12_31_2013" id="Factid_540">FY</dei:DocumentFiscalPeriodFocus>

  <dei:TradingSymbol contextRef="P01_01_2013To12_31_2013" id="Factid_541">TGTX</dei:TradingSymbol>

  <dei:EntityCommonStockSharesOutstanding contextRef="PAsOn03_01_2014" id="Factid_542" unitRef="shares" decimals="INF">34373925</dei:EntityCommonStockSharesOutstanding>

  <dei:EntityRegistrantName contextRef="P01_01_2013To12_31_2013" id="Factid_543">TG THERAPEUTICS, INC.</dei:EntityRegistrantName>

  <dei:EntityCentralIndexKey contextRef="P01_01_2013To12_31_2013" id="Factid_544">0001001316</dei:EntityCentralIndexKey>

  <dei:CurrentFiscalYearEndDate contextRef="P01_01_2013To12_31_2013" id="Factid_545">--12-31</dei:CurrentFiscalYearEndDate>

  <dei:EntityWellKnownSeasonedIssuer contextRef="P01_01_2013To12_31_2013" id="Factid_546">No</dei:EntityWellKnownSeasonedIssuer>

  <dei:EntityVoluntaryFilers contextRef="P01_01_2013To12_31_2013" id="Factid_547">No</dei:EntityVoluntaryFilers>

  <dei:EntityCurrentReportingStatus contextRef="P01_01_2013To12_31_2013" id="Factid_548">Yes</dei:EntityCurrentReportingStatus>

  <dei:EntityFilerCategory contextRef="P01_01_2013To12_31_2013" id="Factid_549">Smaller Reporting Company</dei:EntityFilerCategory>

  <dei:EntityPublicFloat contextRef="PAsOn06_30_2013" id="Factid_550" unitRef="USD" decimals="0">74983321</dei:EntityPublicFloat>

  <tgtx:BusinessAcquisitionSharesRepurchasedPercentage contextRef="PAsOn12_29_2011" id="Factid_551" unitRef="pure" decimals="2">0.95</tgtx:BusinessAcquisitionSharesRepurchasedPercentage>

  <tgtx:BusinessAcquisitionSharesNotSurrendered contextRef="PAsOn12_29_2011_TgBioMemberusgaapBusinessAcquisitionAxis" id="Factid_552" unitRef="shares" decimals="INF">132000</tgtx:BusinessAcquisitionSharesNotSurrendered>

  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="P12_01_2011To12_29_2011_TgBioMemberusgaapBusinessAcquisitionAxis" id="Factid_553" unitRef="shares" decimals="INF">281250</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>

  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="PAsOn12_29_2011_PreferredStockMemberusgaapStatementEquityComponentsAxis_TgBioMemberusgaapBusinessAcquisitionAxis" id="Factid_554" unitRef="shares" decimals="INF">8.89</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>

  <tgtx:PercentageOfStockissuedAfterExchangeTransaction contextRef="PAsOn12_29_2011_TgBioMemberusgaapBusinessAcquisitionAxis" id="Factid_555" unitRef="pure" decimals="2">0.95</tgtx:PercentageOfStockissuedAfterExchangeTransaction>

  <tgtx:FairValuePerShareIssued contextRef="PAsOn12_30_2011" id="Factid_556" unitRef="USD_per_Share" decimals="2">2.25</tgtx:FairValuePerShareIssued>

  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="P02_01_2012To02_24_2012" id="Factid_557" unitRef="USD" decimals="0">13908560</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>

  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="P12_01_2011To12_30_2011" id="Factid_558" unitRef="USD" decimals="0">11091425</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>

  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="PAsOn04_30_2012" id="Factid_559" unitRef="shares" decimals="INF">1545396</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>

  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="PAsOn11_09_2012_LfbMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_560" unitRef="shares" decimals="INF">2500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>

  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="PAsOn12_30_2011" id="Factid_561" unitRef="shares" decimals="INF">1232381</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>

  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="PAsOn12_31_2013" id="Factid_562" unitRef="shares" decimals="INF">2777962</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>

  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="PAsOn12_31_2013_PlacementAgentMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_563" unitRef="shares" decimals="INF">1111111</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>

  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="PAsOn12_31_2013_LfbMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_564" unitRef="shares" decimals="INF">2500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="PAsOn04_30_2012" id="Factid_565" unitRef="USD_Warrant" decimals="2">2.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="PAsOn11_09_2012_LfbMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_566" unitRef="USD_Warrant" decimals="3">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="PAsOn12_30_2011" id="Factid_567" unitRef="USD_Warrant" decimals="2">2.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="PAsOn12_31_2013" id="Factid_568" unitRef="USD_Warrant" decimals="2">2.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="PAsOn12_31_2013_PlacementAgentMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_569" unitRef="USD_Warrant" decimals="2">2.48</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="PAsOn12_31_2013_LfbMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_570" unitRef="USD_Warrant" decimals="3">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>

  <tgtx:ClassOfWarrantOrRightsExercisablePeriod contextRef="P04_01_2012To04_30_2012" id="Factid_571">P5Y</tgtx:ClassOfWarrantOrRightsExercisablePeriod>

  <tgtx:ClassOfWarrantOrRightsExercisablePeriod contextRef="P12_01_2011To12_30_2011" id="Factid_572">P5Y</tgtx:ClassOfWarrantOrRightsExercisablePeriod>

  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="PAsOn04_30_2012_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_573" unitRef="shares" decimals="INF">8.89</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>

  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="PAsOn12_31_2013" id="Factid_574" unitRef="shares" decimals="INF">8.89</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>

  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="PAsOn04_30_2012_NationalHoldingsMemberdeiLegalEntityAxis" id="Factid_575" unitRef="pure" decimals="2">0.05</us-gaap:EquityMethodInvestmentOwnershipPercentage>

  <tgtx:AgentCashCommissionPercentageOnProceedsFromSharesIssuance contextRef="P12_01_2011To12_30_2011_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_TwoThousandTwelveIssuanceMembertgtxIssuancePeriodAxis" id="Factid_576" unitRef="pure" decimals="1">0.1</tgtx:AgentCashCommissionPercentageOnProceedsFromSharesIssuance>

  <tgtx:AgentWarrantPercentageOnIssuanceOfShares contextRef="P12_01_2011To12_30_2011_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis_TwoThousandElevenIssuanceMembertgtxIssuancePeriodAxis" id="Factid_577" unitRef="pure" decimals="1">0.1</tgtx:AgentWarrantPercentageOnIssuanceOfShares>

  <us-gaap:PreferredStockLiquidationPreference contextRef="PAsOn02_24_2012" id="Factid_578" unitRef="USD_per_Share" decimals="2">20.00</us-gaap:PreferredStockLiquidationPreference>

  <tgtx:Warrantterm contextRef="P12_01_2011To12_30_2011_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis_TwoThousandElevenIssuanceMembertgtxIssuancePeriodAxis" id="Factid_579">P5Y</tgtx:Warrantterm>

  <tgtx:AgentNonAccountableExpensePercentageOnGrossProceedsFromShareIssuance contextRef="P12_01_2011To12_30_2011_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis_TwoThousandElevenIssuanceMembertgtxIssuancePeriodAxis" id="Factid_580" unitRef="pure" decimals="2">0.02</tgtx:AgentNonAccountableExpensePercentageOnGrossProceedsFromShareIssuance>

  <us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="PAsOn12_31_2013" id="Factid_581" unitRef="USD" decimals="0">45431532</us-gaap:CashCashEquivalentsAndShortTermInvestments>

  <tgtx:LegalExpensesReimbursedToAgent contextRef="P12_01_2011To12_30_2011_TwoThousandTwelveIssuanceMembertgtxIssuancePeriodAxis" id="Factid_582" unitRef="USD" decimals="0">80000</tgtx:LegalExpensesReimbursedToAgent>

  <tgtx:AdvisoryFeesExpensesPrivatePlacement contextRef="P12_01_2011To12_30_2011_TwoThousandTwelveIssuanceMembertgtxIssuancePeriodAxis" id="Factid_583" unitRef="USD" decimals="0">150000</tgtx:AdvisoryFeesExpensesPrivatePlacement>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="PAsOn05_31_2012_IncentivePlanMemberusgaapPlanNameAxis" id="Factid_584" unitRef="shares" decimals="INF">6000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="PAsOn12_31_2013_EquityIncentivePlansMemberusgaapPlanNameAxis" id="Factid_585" unitRef="shares" decimals="INF">5333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>

  <us-gaap:InterestReceivableCurrent contextRef="PAsOn12_31_2012" id="Factid_586" unitRef="USD" decimals="0">0</us-gaap:InterestReceivableCurrent>

  <us-gaap:InterestReceivableCurrent contextRef="PAsOn12_31_2013" id="Factid_587" unitRef="USD" decimals="0">27169</us-gaap:InterestReceivableCurrent>

  <us-gaap:LongTermInvestments contextRef="PAsOn12_31_2012" id="Factid_588" unitRef="USD" decimals="0">0</us-gaap:LongTermInvestments>

  <us-gaap:LongTermInvestments contextRef="PAsOn12_31_2013" id="Factid_589" unitRef="USD" decimals="0">4918897</us-gaap:LongTermInvestments>

  <tgtx:ReverseStockSplitPolicyTextBlock contextRef="P01_01_2013To12_31_2013" id="Factid_590">              &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;REVERSE STOCK  SPLIT&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;On April 30, 2012, the  Company effected a reverse split of its Common Stock at a &lt;font  style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;ratio of 56.25 for 1&lt;/font&gt;, pursuant to a previously  obtained stockholder authorization. All share amounts and per share  prices in this Annual Report on Form 10-K have been retroactively  adjusted to reflect the effect of our reverse stock split, on a  fifty-six and one quarter (56.25) for one (1) basis, unless  otherwise indicated.&amp;#160;&amp;#160;The exercise price for all stock  options and warrants and the conversion price for convertible  securities in the accompanying consolidated financial statements  have been adjusted to reflect the reverse stock split by  multiplying the original exercise or conversion price by fifty-six  and one quarter (56.25).&lt;/font&gt;&lt;/div&gt;  &lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</tgtx:ReverseStockSplitPolicyTextBlock>

  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2013To12_31_2013" id="Factid_591">              &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;RECENTLY ISSUED ACCOUNTING  STANDARDS&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; BACKGROUND: transparent"&gt;  &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; BACKGROUND: transparent"&gt;  &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: TimesNewRomanPSMT; FONT-SIZE: 10pt"&gt;In July 2013, the  Financial Accounting Standards Board, or FASB, issued a new  accounting standard which will require the presentation of certain  unrecognized tax benefits as reductions to deferred tax assets  rather than as liabilities in the consolidated balance sheets when  a net operating loss carryforward, a similar tax loss, or a tax  credit carryforward exists. The new standard requires adoption on a  prospective basis in the first quarter of 2015; however, early  adoption is permitted. The Company does not anticipate that this  adoption will have a significant impact on its financial position,  results of operations, or cash flows.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; BACKGROUND: transparent"&gt;  &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; BACKGROUND: transparent"&gt;  &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;Other pronouncements  issued by the FASB or other authoritative accounting standards  group with future effective dates are either not applicable or not  significant to the consolidated financial statements of the  Company.&lt;/font&gt;&lt;/div&gt;  &lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>

  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P01_01_2013To12_31_2013" id="Factid_592">              &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;BASIS OF  PRESENTATION&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;  The Company has generated limited revenue from its operations and,  accordingly, the financial statements have been prepared in  accordance with the provisions of accounting and reporting for  Development Stage Enterprises.&lt;/font&gt;&lt;/div&gt;  &lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>

  <us-gaap:UseOfEstimates contextRef="P01_01_2013To12_31_2013" id="Factid_593">              &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;USE OF ESTIMATES&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;The preparation of financial  statements in conformity with U.S. generally accepted accounting  principles (&amp;#8220;GAAP&amp;#8221;) requires management to make  estimates and judgments that affect the reported amounts of assets  and liabilities and the disclosure of contingent assets and  liabilities at the date of the financial statements and the  reported amounts of revenues and expenses during the applicable  reporting period. Actual results could differ from those estimates.  Such differences could be material to the financial  statements.&lt;/font&gt;&lt;/div&gt;  &lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:UseOfEstimates>

  <us-gaap:MarketableSecuritiesPolicy contextRef="P01_01_2013To12_31_2013" id="Factid_594">              &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;b&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font   style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;INVESTMENT  SECURITIES&lt;/font&gt;&lt;/b&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;Investment securities at December 31,  2013 consist of long-term government securities. We classify our  long-term debt securities as held-to-maturity. Held-to-maturity  securities are those securities in which we have the ability and  intent to hold the security until maturity. Held-to-maturity  securities are recorded at amortized cost, adjusted for the  amortization or accretion of premiums or discounts. Premiums and  discounts are amortized or accreted over the life of the related  held-to-maturity security as an adjustment to yield using the  effective interest method.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;A decline in the market value of any  investment security below cost, that is deemed to be other than  temporary, results in a reduction in the carrying amount to fair  value. The impairment is charged to operations and a new cost basis  for the security is established. Other-than-temporary impairment  charges are included in interest and other income, net. Unrealized  gains, if determined to be temporary, are included in accumulated  other comprehensive income in stockholders&amp;#8217; equity. Dividend  and interest income are recognized when earned.&lt;/font&gt;&lt;/div&gt;  &lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:MarketableSecuritiesPolicy>

  <us-gaap:StockholdersEquityReverseStockSplit contextRef="P04_01_2012To04_30_2012" id="Factid_595">ratio of 56.25 for 1</us-gaap:StockholdersEquityReverseStockSplit>

  <tgtx:CashEquivalentsMaturityPeriod contextRef="P01_01_2013To12_31_2013" id="Factid_596">less than three months</tgtx:CashEquivalentsMaturityPeriod>

  <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet contextRef="P01_01_2012To12_31_2012" id="Factid_597" unitRef="USD" decimals="0">0</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>

  <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet contextRef="P01_01_2013To12_31_2013" id="Factid_598" unitRef="USD" decimals="0">27169</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>

  <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet contextRef="P12_01_2011To12_31_2013" id="Factid_599" unitRef="USD" decimals="0">27169</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>

  <us-gaap:PaymentsToAcquireHeldToMaturitySecurities contextRef="P01_01_2012To12_31_2012" id="Factid_600" unitRef="USD" decimals="0">0</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>

  <us-gaap:PaymentsToAcquireHeldToMaturitySecurities contextRef="P01_01_2013To12_31_2013" id="Factid_601" unitRef="USD" decimals="0">4919871</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>

  <us-gaap:PaymentsToAcquireHeldToMaturitySecurities contextRef="P12_01_2011To12_31_2013" id="Factid_602" unitRef="USD" decimals="0">4919871</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>

  <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="PAsOn12_31_2012" id="Factid_603" unitRef="USD" decimals="0">500007</us-gaap:MoneyMarketFundsAtCarryingValue>

  <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="PAsOn12_31_2013" id="Factid_604" unitRef="USD" decimals="0">554069</us-gaap:MoneyMarketFundsAtCarryingValue>

  <tgtx:CommonStockIssuedDuringPeriodValueToFoundersInExchangeForSeedCapital contextRef="P01_01_2011To12_31_2011" id="Factid_605" unitRef="USD" decimals="0">106578</tgtx:CommonStockIssuedDuringPeriodValueToFoundersInExchangeForSeedCapital>

  <tgtx:CommonStockIssuedDuringPeriodValueToFoundersInExchangeForSeedCapital contextRef="P01_01_2011To12_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_606" unitRef="USD" decimals="0">2500</tgtx:CommonStockIssuedDuringPeriodValueToFoundersInExchangeForSeedCapital>

  <tgtx:CommonStockIssuedDuringPeriodValueToFoundersInExchangeForSeedCapital contextRef="P01_01_2011To12_31_2011_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_607" unitRef="USD" decimals="0">104078</tgtx:CommonStockIssuedDuringPeriodValueToFoundersInExchangeForSeedCapital>

  <tgtx:CommonStockIssuedDuringPeriodSharesToFoundersInExchangeForSeedCapital contextRef="P01_01_2011To12_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_608" unitRef="shares" decimals="INF">2500000</tgtx:CommonStockIssuedDuringPeriodSharesToFoundersInExchangeForSeedCapital>

  <tgtx:CommonStockIssuedDuringPeriodValueInExchangeForLicenseOption contextRef="P01_01_2011To12_31_2011" id="Factid_609" unitRef="USD" decimals="0">297000</tgtx:CommonStockIssuedDuringPeriodValueInExchangeForLicenseOption>

  <tgtx:CommonStockIssuedDuringPeriodValueInExchangeForLicenseOption contextRef="P01_01_2011To12_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_610" unitRef="USD" decimals="0">132</tgtx:CommonStockIssuedDuringPeriodValueInExchangeForLicenseOption>

  <tgtx:CommonStockIssuedDuringPeriodValueInExchangeForLicenseOption contextRef="P01_01_2011To12_31_2011_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_611" unitRef="USD" decimals="0">296868</tgtx:CommonStockIssuedDuringPeriodValueInExchangeForLicenseOption>

  <tgtx:CommonStockIssuedDuringPeriodSharesInExchangeForLicenseOption contextRef="P01_01_2011To12_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_612" unitRef="shares" decimals="INF">132000</tgtx:CommonStockIssuedDuringPeriodSharesInExchangeForLicenseOption>

  <us-gaap:StockIssuedDuringPeriodValueOther contextRef="P01_01_2011To12_31_2011" id="Factid_613" unitRef="USD" decimals="0">322964</us-gaap:StockIssuedDuringPeriodValueOther>

  <us-gaap:StockIssuedDuringPeriodValueOther contextRef="P01_01_2011To12_31_2011_PreferredStockMemberusgaapStatementEquityComponentsAxis" id="Factid_614" unitRef="USD" decimals="0">281</us-gaap:StockIssuedDuringPeriodValueOther>

  <us-gaap:StockIssuedDuringPeriodValueOther contextRef="P01_01_2011To12_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_615" unitRef="USD" decimals="0">-2501</us-gaap:StockIssuedDuringPeriodValueOther>

  <us-gaap:StockIssuedDuringPeriodValueOther contextRef="P01_01_2011To12_31_2011_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_616" unitRef="USD" decimals="0">277500</us-gaap:StockIssuedDuringPeriodValueOther>

  <us-gaap:StockIssuedDuringPeriodValueOther contextRef="P01_01_2011To12_31_2011_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" id="Factid_617" unitRef="USD" decimals="0">47678</us-gaap:StockIssuedDuringPeriodValueOther>

  <us-gaap:StockIssuedDuringPeriodValueOther contextRef="P01_01_2011To12_31_2011_ContingentlyIssuableShareMemberusgaapStatementEquityComponentsAxis" id="Factid_618" unitRef="USD" decimals="0">6</us-gaap:StockIssuedDuringPeriodValueOther>

  <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="P01_01_2011To12_31_2011_PreferredStockMemberusgaapStatementEquityComponentsAxis" id="Factid_619" unitRef="shares" decimals="INF">281250</us-gaap:StockIssuedDuringPeriodSharesOther>

  <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="P01_01_2011To12_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_620" unitRef="shares" decimals="INF">-2500124</us-gaap:StockIssuedDuringPeriodSharesOther>

  <us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock contextRef="P01_01_2013To12_31_2013" id="Factid_621">              &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;The Company&amp;#8217;s assets measured  at fair value on a nonrecurring basis as of December 31, 2013 and  2012 were as follows:&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times','serif'; FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="35%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="47%" colspan="8"&gt;  &lt;div&gt;Fair&amp;#160;value&amp;#160;measurements&lt;br/&gt;   &amp;#160;as&amp;#160;of&amp;#160;December&amp;#160;31,&amp;#160;2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="14%"&gt;  &lt;div&gt;Total&amp;#160;impairment&amp;#160;charge&amp;#160;  for&amp;#160;the&amp;#160;year&amp;#160;ended&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="35%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="15%" colspan="2"&gt;  &lt;div&gt;Level&amp;#160;1&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="15%" colspan="2"&gt;  &lt;div&gt;Level&amp;#160;2&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="15%" colspan="2"&gt;  &lt;div&gt;Level&amp;#160;3&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="14%"&gt;  &lt;div&gt;December&amp;#160;31,&amp;#160;2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="35%"&gt;  &lt;div&gt;Assets:&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="35%"&gt;  &lt;div&gt;In-process research and development&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;(2,797,600)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="35%"&gt;  &lt;div&gt;Total&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;(2,797,600)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;strong&gt;&lt;font style="FONT-FAMILY: 'Times','serif'; FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="35%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="47%" colspan="8"&gt;  &lt;div&gt;Fair&amp;#160;value&amp;#160;measurements&lt;br/&gt;   as&amp;#160;of&amp;#160;December&amp;#160;31,&amp;#160;2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="14%"&gt;  &lt;div&gt;Total&amp;#160;impairment&amp;#160;charge  for&amp;#160;the&amp;#160;year&amp;#160;ended&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="35%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="15%" colspan="2"&gt;  &lt;div&gt;Level&amp;#160;1&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="15%" colspan="2"&gt;  &lt;div&gt;Level&amp;#160;2&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="15%" colspan="2"&gt;  &lt;div&gt;Level&amp;#160;3&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="14%"&gt;  &lt;div&gt;December&amp;#160;31,&amp;#160;2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="35%"&gt;  &lt;div&gt;Assets:&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="35%"&gt;  &lt;div&gt;In-process research and development&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;2,797,600&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;(1,104,700)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="35%"&gt;  &lt;div&gt;Total&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;2,797,600&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;(1,104,700)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt;  &lt;/div&gt;  &lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsMeasuredOnNonrecurringBasisTextBlock>

  <tgtx:StockIssuedDuringPeriodValueConversionOfNotePayableToPreferredStock contextRef="P01_01_2011To12_31_2011" id="Factid_622" unitRef="USD" decimals="0">55271</tgtx:StockIssuedDuringPeriodValueConversionOfNotePayableToPreferredStock>

  <tgtx:StockIssuedDuringPeriodValueConversionOfNotePayableToPreferredStock contextRef="P01_01_2011To12_31_2011_PreferredStockMemberusgaapStatementEquityComponentsAxis" id="Factid_623" unitRef="USD" decimals="0">3</tgtx:StockIssuedDuringPeriodValueConversionOfNotePayableToPreferredStock>

  <tgtx:StockIssuedDuringPeriodValueConversionOfNotePayableToPreferredStock contextRef="P01_01_2011To12_31_2011_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_624" unitRef="USD" decimals="0">55268</tgtx:StockIssuedDuringPeriodValueConversionOfNotePayableToPreferredStock>

  <tgtx:StockIssuedDuringPeriodSharesConversionOfNotePayableToPreferredStock contextRef="P01_01_2011To12_31_2011_PreferredStockMemberusgaapStatementEquityComponentsAxis" id="Factid_625" unitRef="shares" decimals="INF">2763</tgtx:StockIssuedDuringPeriodSharesConversionOfNotePayableToPreferredStock>

  <us-gaap:LossContingencyDamagesSoughtValue contextRef="P01_01_2011To12_31_2011_ThorntonRossLtdMembertgtxStatementScenariooAxis" id="Factid_626" unitRef="USD" decimals="0">20000000</us-gaap:LossContingencyDamagesSoughtValue>

  <us-gaap:LossContingencyDamagesSoughtValue contextRef="P04_01_2011To04_19_2011" id="Factid_627" unitRef="USD" decimals="0">7000000</us-gaap:LossContingencyDamagesSoughtValue>

  <tgtx:StockIssuedDuringPeriodValueOfReplacementRestrictedPreferredStockToEmployees contextRef="P01_01_2011To12_31_2011" id="Factid_628" unitRef="USD" decimals="0">0</tgtx:StockIssuedDuringPeriodValueOfReplacementRestrictedPreferredStockToEmployees>

  <tgtx:StockIssuedDuringPeriodValueOfReplacementRestrictedPreferredStockToEmployees contextRef="P01_01_2011To12_31_2011_PreferredStockMemberusgaapStatementEquityComponentsAxis" id="Factid_629" unitRef="USD" decimals="0">129</tgtx:StockIssuedDuringPeriodValueOfReplacementRestrictedPreferredStockToEmployees>

  <tgtx:StockIssuedDuringPeriodValueOfReplacementRestrictedPreferredStockToEmployees contextRef="P01_01_2011To12_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_630" unitRef="USD" decimals="0">-1150</tgtx:StockIssuedDuringPeriodValueOfReplacementRestrictedPreferredStockToEmployees>

  <tgtx:StockIssuedDuringPeriodValueOfReplacementRestrictedPreferredStockToEmployees contextRef="P01_01_2011To12_31_2011_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_631" unitRef="USD" decimals="0">1021</tgtx:StockIssuedDuringPeriodValueOfReplacementRestrictedPreferredStockToEmployees>

  <tgtx:StockIssuedDuringPeriodSharesOfReplacementRestrictedPreferredStockToEmployees contextRef="P01_01_2011To12_31_2011_PreferredStockMemberusgaapStatementEquityComponentsAxis" id="Factid_632" unitRef="shares" decimals="INF">129375</tgtx:StockIssuedDuringPeriodSharesOfReplacementRestrictedPreferredStockToEmployees>

  <tgtx:StockIssuedDuringPeriodSharesOfReplacementRestrictedPreferredStockToEmployees contextRef="P01_01_2011To12_31_2011_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_633" unitRef="shares" decimals="INF">-1150000</tgtx:StockIssuedDuringPeriodSharesOfReplacementRestrictedPreferredStockToEmployees>

  <tgtx:SharesIssuedToNonControllingInterestInConnectionWithLicensingAgreement contextRef="P01_01_2012To12_31_2012" id="Factid_634" unitRef="USD" decimals="0">16578000</tgtx:SharesIssuedToNonControllingInterestInConnectionWithLicensingAgreement>

  <tgtx:SharesIssuedToNonControllingInterestInConnectionWithLicensingAgreement contextRef="P01_01_2012To12_31_2012_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" id="Factid_635" unitRef="USD" decimals="0">16578000</tgtx:SharesIssuedToNonControllingInterestInConnectionWithLicensingAgreement>

  <tgtx:PossibleMilestonePayments contextRef="P01_01_2012To12_31_2012_CollaborationAgreementMemberdeiLegalEntityAxis" id="Factid_636" unitRef="USD" decimals="0">1000000</tgtx:PossibleMilestonePayments>

  <tgtx:PossibleMilestonePayments contextRef="P01_01_2013To12_31_2013_LfbBiotechnologiesMemberdeiLegalEntityAxis" id="Factid_637" unitRef="USD" decimals="-5">31000000</tgtx:PossibleMilestonePayments>

  <tgtx:BussinessAcquisitonPurchaseAgreementPeriodDescription contextRef="P01_01_2013To12_31_2013_LfbBiotechnologiesMemberdeiLegalEntityAxis" id="Factid_638">The license will terminate on a country by country basis upon the expiration of the last licensed patent right or 15 years after the first commercial sale of a product in such country, unless the agreement is earlier terminated.</tgtx:BussinessAcquisitonPurchaseAgreementPeriodDescription>

  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="P01_01_2013To12_31_2013_LfbBiotechnologiesMemberdeiLegalEntityAxis" id="Factid_639" unitRef="shares" decimals="INF">7368000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>

  <tgtx:ContributionPerLicenceAgreementInExchangeOfCommonStock contextRef="P01_01_2013To12_31_2013_LfbBiotechnologiesMemberdeiLegalEntityAxis" id="Factid_640" unitRef="USD" decimals="-6">15000000</tgtx:ContributionPerLicenceAgreementInExchangeOfCommonStock>

  <tgtx:CommonStockSharesSubscribedSubsidiarySaleOfStock contextRef="P01_01_2013To12_31_2013_LfbBiotechnologiesMemberdeiLegalEntityAxis" id="Factid_641" unitRef="shares" decimals="INF">7500000</tgtx:CommonStockSharesSubscribedSubsidiarySaleOfStock>

  <tgtx:SharesIssuedForLicenceAgreementExchange contextRef="P01_01_2013To12_31_2013_LfbBiotechnologiesMemberdeiLegalEntityAxis" id="Factid_642" unitRef="shares" decimals="INF">7500000</tgtx:SharesIssuedForLicenceAgreementExchange>

  <us-gaap:MinorityInterestDescription contextRef="P01_01_2013To12_31_2013_LfbBiotechnologiesMemberdeiLegalEntityAxis" id="Factid_643">the Board of Directors of the Company shall nominate a designee named by LFB Group for election at each annual meeting of the stockholders until such time as LFB Group owns less than 10% of the outstanding Company Common Stock.</us-gaap:MinorityInterestDescription>

  <tgtx:PotentialFutureMilestonePayments contextRef="P01_01_2013To12_31_2013_CollaborationAgreementMemberdeiLegalEntityAxis" id="Factid_644" unitRef="USD" decimals="0">2000000</tgtx:PotentialFutureMilestonePayments>

  <tgtx:PotentialFutureMilestonePayments contextRef="P01_01_2013To12_31_2013" id="Factid_645" unitRef="USD" decimals="-5">182500000</tgtx:PotentialFutureMilestonePayments>

  <tgtx:UpfrontFeeReceivedFromSubLicense contextRef="P01_01_2012To12_31_2012" id="Factid_646" unitRef="USD" decimals="0">2000000</tgtx:UpfrontFeeReceivedFromSubLicense>

  <tgtx:UpfrontFeeReceivedFromSubLicense contextRef="P01_01_2013To12_31_2013_CollaborationAgreementMemberdeiLegalEntityAxis" id="Factid_647" unitRef="USD" decimals="0">2000000</tgtx:UpfrontFeeReceivedFromSubLicense>

  <tgtx:PotentialAdditionalAmountPayableOnAchievementOfPreSpecifiedMilestones contextRef="P01_01_2013To12_31_2013_CollaborationAgreementMemberdeiLegalEntityAxis" id="Factid_648" unitRef="USD" decimals="-5">182500000</tgtx:PotentialAdditionalAmountPayableOnAchievementOfPreSpecifiedMilestones>

  <us-gaap:ConversionOfStockSharesConverted1 contextRef="P11_01_2012To11_09_2012_LfbBiotechnologiesMemberdeiLegalEntityAxis" id="Factid_649" unitRef="shares" decimals="INF">7500000</us-gaap:ConversionOfStockSharesConverted1>

  <us-gaap:ConversionOfStockAmountConverted1 contextRef="P01_01_2012To12_31_2012" id="Factid_650" unitRef="USD" decimals="0">0</us-gaap:ConversionOfStockAmountConverted1>

  <us-gaap:ConversionOfStockAmountConverted1 contextRef="P01_01_2012To12_31_2012_PreferredStockMemberusgaapStatementEquityComponentsAxis" id="Factid_651" unitRef="USD" decimals="0">-1109</us-gaap:ConversionOfStockAmountConverted1>

  <us-gaap:ConversionOfStockAmountConverted1 contextRef="P01_01_2012To12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_652" unitRef="USD" decimals="0">9858</us-gaap:ConversionOfStockAmountConverted1>

  <us-gaap:ConversionOfStockAmountConverted1 contextRef="P01_01_2012To12_31_2012_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_653" unitRef="USD" decimals="0">-8749</us-gaap:ConversionOfStockAmountConverted1>

  <us-gaap:ConversionOfStockSharesIssued1 contextRef="P11_01_2012To11_09_2012_LfbBiotechnologiesMemberdeiLegalEntityAxis" id="Factid_654" unitRef="shares" decimals="INF">5000000</us-gaap:ConversionOfStockSharesIssued1>

  <us-gaap:ConversionOfStockSharesConverted1 contextRef="P01_01_2012To12_31_2012_PreferredStockMemberusgaapStatementEquityComponentsAxis" id="Factid_655" unitRef="shares" decimals="INF">-1108816</us-gaap:ConversionOfStockSharesConverted1>

  <us-gaap:ConversionOfStockSharesConverted1 contextRef="P01_01_2012To12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_656" unitRef="shares" decimals="INF">9857596</us-gaap:ConversionOfStockSharesConverted1>

  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="PAsOn11_09_2012_LfbBiotechnologiesMemberdeiLegalEntityAxis" id="Factid_657" unitRef="shares" decimals="INF">2500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>

  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="PAsOn11_09_2012_LfbBiotechnologiesMemberdeiLegalEntityAxis" id="Factid_658" unitRef="USD_Warrant" decimals="3">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>

  <tgtx:IncrementalCommonShareAttributableToSecurityExchangeAgreement contextRef="PAsOn11_09_2012_LfbBiotechnologiesMemberdeiLegalEntityAxis" id="Factid_659" unitRef="USD" decimals="0">750000</tgtx:IncrementalCommonShareAttributableToSecurityExchangeAgreement>

  <tgtx:NonControllingInterestSubsidiarySharesValue contextRef="P01_01_2012To12_31_2012" id="Factid_660" unitRef="USD" decimals="0">0</tgtx:NonControllingInterestSubsidiarySharesValue>

  <tgtx:NonControllingInterestSubsidiarySharesValue contextRef="P01_01_2012To12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_661" unitRef="USD" decimals="0">5000</tgtx:NonControllingInterestSubsidiarySharesValue>

  <tgtx:NonControllingInterestSubsidiarySharesValue contextRef="P01_01_2012To12_31_2012_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" id="Factid_662" unitRef="USD" decimals="0">8474448</tgtx:NonControllingInterestSubsidiarySharesValue>

  <tgtx:NonControllingInterestSubsidiarySharesValue contextRef="P01_01_2012To12_31_2012_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" id="Factid_663" unitRef="USD" decimals="0">-8479448</tgtx:NonControllingInterestSubsidiarySharesValue>

  <tgtx:NonControllingInterestSubsidiaryShares contextRef="P01_01_2012To12_31_2012_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_664" unitRef="shares" decimals="INF">5000000</tgtx:NonControllingInterestSubsidiaryShares>

  <tgtx:TreasuryStockValueDuringPeirod contextRef="P01_01_2012To12_31_2012" id="Factid_665" unitRef="USD" decimals="0">-84538</tgtx:TreasuryStockValueDuringPeirod>

  <tgtx:TreasuryStockValueDuringPeirod contextRef="P01_01_2012To12_31_2012_TreasuryStockMemberusgaapStatementEquityComponentsAxis" id="Factid_666" unitRef="USD" decimals="0">-84538</tgtx:TreasuryStockValueDuringPeirod>

  <tgtx:TreasuryStockValueDuringPeirod contextRef="P01_01_2013To12_31_2013" id="Factid_667" unitRef="USD" decimals="0">-149799</tgtx:TreasuryStockValueDuringPeirod>

  <tgtx:TreasuryStockValueDuringPeirod contextRef="P01_01_2013To12_31_2013_TreasuryStockMemberusgaapStatementEquityComponentsAxis" id="Factid_668" unitRef="USD" decimals="0">-149799</tgtx:TreasuryStockValueDuringPeirod>

  <tgtx:TreasuryStockSharesDuringPeirod contextRef="P01_01_2012To12_31_2012_TreasuryStockMemberusgaapStatementEquityComponentsAxis" id="Factid_669" unitRef="shares" decimals="INF">13526</tgtx:TreasuryStockSharesDuringPeirod>

  <tgtx:TreasuryStockSharesDuringPeirod contextRef="P01_01_2013To12_31_2013_TreasuryStockMemberusgaapStatementEquityComponentsAxis" id="Factid_670" unitRef="shares" decimals="INF">27783</tgtx:TreasuryStockSharesDuringPeirod>

  <us-gaap:AssetsFairValueDisclosureNonrecurring contextRef="PAsOn12_31_2012_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_671" unitRef="USD" decimals="0">0</us-gaap:AssetsFairValueDisclosureNonrecurring>

  <us-gaap:AssetsFairValueDisclosureNonrecurring contextRef="PAsOn12_31_2012_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_672" unitRef="USD" decimals="0">0</us-gaap:AssetsFairValueDisclosureNonrecurring>

  <us-gaap:AssetsFairValueDisclosureNonrecurring contextRef="PAsOn12_31_2012_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_673" unitRef="USD" decimals="0">0</us-gaap:AssetsFairValueDisclosureNonrecurring>

  <us-gaap:AssetsFairValueDisclosureNonrecurring contextRef="PAsOn12_31_2012_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_674" unitRef="USD" decimals="0">0</us-gaap:AssetsFairValueDisclosureNonrecurring>

  <us-gaap:AssetsFairValueDisclosureNonrecurring contextRef="PAsOn12_31_2012_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_675" unitRef="USD" decimals="0">2797600</us-gaap:AssetsFairValueDisclosureNonrecurring>

  <us-gaap:AssetsFairValueDisclosureNonrecurring contextRef="PAsOn12_31_2012_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_676" unitRef="USD" decimals="0">2797600</us-gaap:AssetsFairValueDisclosureNonrecurring>

  <us-gaap:AssetsFairValueDisclosureNonrecurring contextRef="PAsOn12_31_2013_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_677" unitRef="USD" decimals="0">0</us-gaap:AssetsFairValueDisclosureNonrecurring>

  <us-gaap:AssetsFairValueDisclosureNonrecurring contextRef="PAsOn12_31_2013_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_678" unitRef="USD" decimals="0">0</us-gaap:AssetsFairValueDisclosureNonrecurring>

  <us-gaap:AssetsFairValueDisclosureNonrecurring contextRef="PAsOn12_31_2013_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_679" unitRef="USD" decimals="0">0</us-gaap:AssetsFairValueDisclosureNonrecurring>

  <us-gaap:AssetsFairValueDisclosureNonrecurring contextRef="PAsOn12_31_2013_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_680" unitRef="USD" decimals="0">0</us-gaap:AssetsFairValueDisclosureNonrecurring>

  <us-gaap:AssetsFairValueDisclosureNonrecurring contextRef="PAsOn12_31_2013_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_681" unitRef="USD" decimals="0">0</us-gaap:AssetsFairValueDisclosureNonrecurring>

  <us-gaap:AssetsFairValueDisclosureNonrecurring contextRef="PAsOn12_31_2013_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" id="Factid_682" unitRef="USD" decimals="0">0</us-gaap:AssetsFairValueDisclosureNonrecurring>

  <us-gaap:AssetImpairmentCharges contextRef="P01_01_2012To12_31_2012" id="Factid_683" unitRef="USD" decimals="0">1104700</us-gaap:AssetImpairmentCharges>

  <us-gaap:AssetImpairmentCharges contextRef="P01_01_2012To12_31_2012_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_684" unitRef="USD" decimals="0">1104700</us-gaap:AssetImpairmentCharges>

  <us-gaap:AssetImpairmentCharges contextRef="P01_01_2013To12_31_2013" id="Factid_685" unitRef="USD" decimals="0">2797600</us-gaap:AssetImpairmentCharges>

  <us-gaap:AssetImpairmentCharges contextRef="P01_01_2013To12_31_2013_InProcessResearchAndDevelopmentMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" id="Factid_686" unitRef="USD" decimals="0">2797600</us-gaap:AssetImpairmentCharges>

  <us-gaap:IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems contextRef="P01_01_2012To12_31_2012" id="Factid_687" unitRef="USD" decimals="0">-8790003</us-gaap:IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems>

  <us-gaap:IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems contextRef="P01_01_2013To12_31_2013" id="Factid_688" unitRef="USD" decimals="0">-6962592</us-gaap:IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems>

  <tgtx:OperatingLossCarryforwardsExpirationPeriod contextRef="P01_01_2013To12_31_2013_UsFederalIncomeTaxMemberusgaapIncomeTaxAuthorityAxis" id="Factid_689">2033</tgtx:OperatingLossCarryforwardsExpirationPeriod>

  <us-gaap:NotesPayable contextRef="PAsOn12_31_2013_ExchangeTransactionMemberusgaapStatementScenarioAxis" id="Factid_690" unitRef="USD" decimals="0">3287700</us-gaap:NotesPayable>

  <tgtx:DebtInstrumentRepaymentTerm contextRef="P04_01_2010To04_30_2010_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis" id="Factid_691">36 monthly</tgtx:DebtInstrumentRepaymentTerm>

  <us-gaap:DebtInstrumentMaturityDate contextRef="P03_01_2010To03_08_2010_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis" id="Factid_692">2015-03-08</us-gaap:DebtInstrumentMaturityDate>

  <tgtx:FairValuePerShareIssued contextRef="PAsOn12_31_2011_ExchangeForLicenseOptionMemberusgaapStatementClassOfStockAxis" id="Factid_693" unitRef="USD_per_Share" decimals="2">2.25</tgtx:FairValuePerShareIssued>

  <tgtx:FairValuePerShareIssued contextRef="PAsOn12_31_2011_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_694" unitRef="USD_per_Share" decimals="2">2.25</tgtx:FairValuePerShareIssued>

  <tgtx:PreferredStockIssued contextRef="P01_01_2012To12_31_2012_PreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_695" unitRef="USD_per_Share" decimals="2">20.00</tgtx:PreferredStockIssued>

  <tgtx:ConversionOfPreferredStockToRestrictedCommonStock contextRef="P01_01_2012To12_31_2012_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_696" unitRef="shares" decimals="INF">-129375</tgtx:ConversionOfPreferredStockToRestrictedCommonStock>

  <tgtx:ConversionOfPreferredStockToRestrictedCommonStock contextRef="P01_01_2012To12_31_2012_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_697" unitRef="shares" decimals="INF">1150000</tgtx:ConversionOfPreferredStockToRestrictedCommonStock>

  <tgtx:ConversionOfPreferredStockToRestrictedCommonStockWeightedAverageGrantDateFairValue contextRef="P01_01_2012To12_31_2012_SeriesAPreferredStockMemberusgaapStatementClassOfStockAxis" id="Factid_698" unitRef="USD_per_Share" decimals="2">20.00</tgtx:ConversionOfPreferredStockToRestrictedCommonStockWeightedAverageGrantDateFairValue>

  <tgtx:ConversionOfPreferredStockToRestrictedCommonStockWeightedAverageGrantDateFairValue contextRef="P01_01_2012To12_31_2012_CommonStockMemberusgaapStatementClassOfStockAxis" id="Factid_699" unitRef="USD_per_Share" decimals="2">2.25</tgtx:ConversionOfPreferredStockToRestrictedCommonStockWeightedAverageGrantDateFairValue>

  <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="P01_01_2013To12_31_2013" id="Factid_700">              &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;NOTE 3 &amp;#150; INVESTMENT  SECURITIES&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;We record our investments as either  held-to-maturity or available-for-sale. Held-to-maturity  investments are recorded at amortized cost.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;  &lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;We were not invested in investment  securities at December 31, 2012. The following tables summarize our  investment securities at December 31, 2013:&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;WIDTH: 100%; TEXT-INDENT: 0in"&gt;  &lt;table style="OVERFLOW: visible; WIDTH: 100%; BORDER-COLLAPSE: collapse; MARGIN: 0in"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center"   width="45%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center"   width="53%" colspan="11"&gt;  &lt;div&gt;December&amp;#160;31,&amp;#160;2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center"   width="45%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center"   width="15%" colspan="2"&gt;  &lt;div&gt;Amortized&amp;#160;cost,&lt;br/&gt;   as&amp;#160;adjusted&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center"   width="11%" colspan="2"&gt;  &lt;div&gt;Gross&lt;br/&gt;   unrealized&lt;br/&gt;   holding&amp;#160;gains&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center"   width="11%" colspan="2"&gt;  &lt;div&gt;Gross&lt;br/&gt;   unrealized&lt;br/&gt;   holding&amp;#160;losses&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center"   width="13%" colspan="2"&gt;  &lt;div&gt;Estimated&amp;#160;&lt;br/&gt;   fair value&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="45%"&gt;  &lt;div&gt;Long-term investments:&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right"   width="12%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="45%"&gt;  &lt;div&gt;Obligations of domestic governmental agencies&lt;br/&gt;   &amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(maturing between January 2015 and  April 2015) (held-to-maturity)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px"   width="14%"&gt;  &lt;div&gt;4,918,897&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px"   width="10%"&gt;  &lt;div&gt;650&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px"   width="12%"&gt;  &lt;div&gt;4,918,247&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left; PADDING-LEFT: 13px"   width="45%"&gt;  &lt;div&gt;Total long-term investment securities&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px"   width="14%"&gt;  &lt;div&gt;4,918,897&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px"   width="10%"&gt;  &lt;div&gt;650&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px"   width="12%"&gt;  &lt;div&gt;4,918,247&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;  &lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>

  <us-gaap:HeldToMaturitySecuritiesTextBlock contextRef="P01_01_2013To12_31_2013" id="Factid_701">              &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; TEXT-INDENT: 0.5in"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;The following tables summarize our  investment securities at December 31, 2013:&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;WIDTH: 100%; TEXT-INDENT: 0in"&gt;  &lt;table style="OVERFLOW: visible; WIDTH: 100%; BORDER-COLLAPSE: collapse; MARGIN: 0in"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center"   width="45%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center"   width="53%" colspan="11"&gt;  &lt;div&gt;December&amp;#160;31,&amp;#160;2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center"   width="45%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center"   width="15%" colspan="2"&gt;  &lt;div&gt;Amortized&amp;#160;cost,&lt;br/&gt;   as&amp;#160;adjusted&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center"   width="11%" colspan="2"&gt;  &lt;div&gt;Gross&lt;br/&gt;   unrealized&lt;br/&gt;   holding&amp;#160;gains&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center"   width="11%" colspan="2"&gt;  &lt;div&gt;Gross&lt;br/&gt;   unrealized&lt;br/&gt;   holding&amp;#160;losses&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 700; FONT-STYLE: normal; TEXT-ALIGN: center"   width="13%" colspan="2"&gt;  &lt;div&gt;Estimated&amp;#160;&lt;br/&gt;   fair value&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: center"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="45%"&gt;  &lt;div&gt;Long-term investments:&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right"   width="12%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="45%"&gt;  &lt;div&gt;Obligations of domestic governmental agencies&lt;br/&gt;   &amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;(maturing between January 2015 and  April 2015) (held-to-maturity)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px"   width="14%"&gt;  &lt;div&gt;4,918,897&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px"   width="10%"&gt;  &lt;div&gt;650&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ffffff; BORDER-BOTTOM: #000000 1px solid; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px"   width="12%"&gt;  &lt;div&gt;4,918,247&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ffffff; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left; PADDING-LEFT: 13px"   width="45%"&gt;  &lt;div&gt;Total long-term investment securities&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px"   width="14%"&gt;  &lt;div&gt;4,918,897&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px"   width="10%"&gt;  &lt;div&gt;650&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; BORDER-TOP: #000000 1px solid; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: bottom; BACKGROUND: #ccffcc; BORDER-BOTTOM: #000000 3px double; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: right; PADDING-RIGHT: 5px"   width="12%"&gt;  &lt;div&gt;4,918,247&lt;/div&gt;  &lt;/td&gt;  &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; VERTICAL-ALIGN: middle; BACKGROUND: #ccffcc; FONT-WEIGHT: 400; FONT-STYLE: normal; TEXT-ALIGN: left"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;  &lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:HeldToMaturitySecuritiesTextBlock>

  <us-gaap:HeldToMaturitySecurities contextRef="PAsOn12_31_2013" id="Factid_702" unitRef="USD" decimals="0">4918897</us-gaap:HeldToMaturitySecurities>

  <us-gaap:HeldToMaturitySecurities contextRef="PAsOn12_31_2013_USGovernmentAgenciesDebtSecuritiesMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_703" unitRef="USD" decimals="0">4918897</us-gaap:HeldToMaturitySecurities>

  <us-gaap:HeldToMaturitySecuritiesUnrecognizedHoldingGains contextRef="P01_01_2013To12_31_2013" id="Factid_704" unitRef="USD" decimals="0">0</us-gaap:HeldToMaturitySecuritiesUnrecognizedHoldingGains>

  <us-gaap:HeldToMaturitySecuritiesUnrecognizedHoldingGains contextRef="P01_01_2013To12_31_2013_USGovernmentAgenciesDebtSecuritiesMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_705" unitRef="USD" decimals="0">0</us-gaap:HeldToMaturitySecuritiesUnrecognizedHoldingGains>

  <us-gaap:HeldToMaturitySecuritiesUnrecognizedHoldingLosses contextRef="P01_01_2013To12_31_2013" id="Factid_706" unitRef="USD" decimals="0">650</us-gaap:HeldToMaturitySecuritiesUnrecognizedHoldingLosses>

  <us-gaap:HeldToMaturitySecuritiesUnrecognizedHoldingLosses contextRef="P01_01_2013To12_31_2013_USGovernmentAgenciesDebtSecuritiesMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_707" unitRef="USD" decimals="0">650</us-gaap:HeldToMaturitySecuritiesUnrecognizedHoldingLosses>

  <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="PAsOn12_31_2013" id="Factid_708" unitRef="USD" decimals="0">4918247</us-gaap:HeldToMaturitySecuritiesFairValue>

  <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="PAsOn12_31_2013_USGovernmentAgenciesDebtSecuritiesMemberusgaapMajorTypesOfDebtAndEquitySecuritiesAxis" id="Factid_709" unitRef="USD" decimals="0">4918247</us-gaap:HeldToMaturitySecuritiesFairValue>

  <tgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm contextRef="P01_01_2013To12_31_2013_EquityIncentivePlansMemberusgaapPlanNameAxis" id="Factid_710">P10Y</tgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTerm>

  <tgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssued contextRef="PAsOn12_31_2013_EquityIncentivePlansMemberusgaapPlanNameAxis" id="Factid_711" unitRef="shares" decimals="INF">10</tgtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssued>

  <us-gaap:ConversionOfStockSharesConverted1 contextRef="P11_01_2012To11_09_2012_LfbMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_712" unitRef="shares" decimals="INF">7500000</us-gaap:ConversionOfStockSharesConverted1>

  <us-gaap:ConversionOfStockSharesIssued1 contextRef="P11_01_2012To11_09_2012_LfbMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_713" unitRef="shares" decimals="INF">5000000</us-gaap:ConversionOfStockSharesIssued1>

  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="PAsOn12_31_2013_TgBioMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_714" unitRef="pure" decimals="3">0.429</us-gaap:EquityMethodInvestmentOwnershipPercentage>

  <us-gaap:EquityMethodInvestments contextRef="PAsOn12_31_2013_LfbMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" id="Factid_715" unitRef="USD" decimals="0">8479000</us-gaap:EquityMethodInvestments>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="P01_01_2013To12_31_2013_WarrantMemberusgaapStatementEquityComponentsAxis" id="Factid_716" unitRef="shares" decimals="INF">757096</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>

  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="P01_01_2013To12_31_2013_PlacementAgentMemberusgaapSubsidiarySaleOfStockAxis" id="Factid_717" unitRef="shares" decimals="INF">6533</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>

  <tgtx:DebtInstrumentMaturityPeriod contextRef="P03_01_2010To03_31_2010_ManhattanAndAristonPharmaceuticalsMergerMembertgtxTypeOfTransactionAxis" id="Factid_718">P5Y</tgtx:DebtInstrumentMaturityPeriod>

  <us-gaap:DebtInstrumentTerm contextRef="P03_01_2010To03_08_2010_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis" id="Factid_719">P3Y</us-gaap:DebtInstrumentTerm>

  <tgtx:StockIssuedDuringPeriodSharesOfReplacementRestrictedPreferredStockToEmployees contextRef="P04_01_2012To04_30_2012_CommonStockMemberusgaapStatementEquityComponentsAxis" id="Factid_720" unitRef="shares" decimals="INF">1150000</tgtx:StockIssuedDuringPeriodSharesOfReplacementRestrictedPreferredStockToEmployees>

  <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="P01_01_2013To12_31_2013_PreferredRestrictedStockMemberusgaapStatementEquityComponentsAxis" id="Factid_721">              &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  Certain employees had been awarded restricted preferred stock. The  restricted stock vesting consisted of milestone and time-based  vesting. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;The following table summarizes restricted share activity for  the years ended December 31, 2013 and 2012:&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="18%"&gt;  &lt;div&gt;Number&amp;#160;of&amp;#160;Shares&lt;br/&gt;   Restricted&amp;#160;Series&amp;#160;&lt;br/&gt;   A&amp;#160;Preferred&amp;#160;&lt;br/&gt;   Stock&lt;sup style="FONT-STYLE: normal"&gt;(1)&lt;/sup&gt;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="19%" colspan="2"&gt;  &lt;div&gt;Weighted&amp;#160;&lt;br/&gt;   Average&lt;br/&gt;   Grant&amp;#160;Date&amp;#160;&lt;br/&gt;   Fair&amp;#160;Value&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Outstanding at January 1, 2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;129,375&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;20.00&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 11px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Granted&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 11px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Vested&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 11px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Forfeited&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Conversion to restricted common stock&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;(129,375)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;20.00&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Outstanding at December 31, 2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 11px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Granted&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 11px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Vested&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 11px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Forfeited&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Outstanding at December 31, 2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt;  &lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -1pt; MARGIN: 0in 0in 0pt"&gt;  &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="TEXT-DECORATION: none"&gt;&amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;sup&gt;&lt;font style="FONT-FAMILY: ; FONT-SIZE: 10pt"&gt;(&lt;/font&gt;&lt;font  style="FONT-FAMILY: ; FONT-SIZE: 10pt"&gt;1)&amp;#160;&lt;/font&gt;&lt;/sup&gt; &lt;font  style="FONT-SIZE: 10pt"&gt;The restricted preferred stock listed in  the table above was granted in connection with the Exchange  Transaction to certain executives. Each share of preferred stock  was convertible into &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  8.89&lt;/font&gt; shares of the Company&amp;#8217;s Common Stock. In  conjunction with the reverse split effected on April 30, 2012 (as  discussed in Note 1), all outstanding restricted Preferred Stock  automatically converted to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  1,150,000&lt;/font&gt; shares of restricted Common Stock as of that  date.&lt;/font&gt;&lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>

  <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="P01_01_2013To12_31_2013_CommonRestrictedStockMemberusgaapStatementEquityComponentsAxis" id="Factid_722">              &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  Certain employees, directors and consultants have been awarded  restricted Company Common Stock. The restricted stock vesting  consists of milestone and time-based vesting.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;  The following table summarizes restricted share activity for the  years ended December 31, 2013 and 2012:&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="18%"&gt;  &lt;div&gt;Number&amp;#160;of&amp;#160;Shares&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="19%" colspan="2"&gt;  &lt;div&gt;Weighted&amp;#160;&lt;br/&gt;   Average&lt;br/&gt;   Grant&amp;#160;Date&amp;#160;&lt;br/&gt;   Fair&amp;#160;Value&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Outstanding at January 1, 2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Converted preferred stock&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;1,150,000&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;2.25&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Granted&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;5,901,743&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;4.77&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Vested&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;(437,500)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;2.25&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Forfeited&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Outstanding at December 31, 2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;6,614,243&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;4.49&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Granted&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;944,464&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;4.13&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Vested&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;(523,750)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;2.48&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Forfeited&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Outstanding at December 31, 2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;7,034,957&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;4.60&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>

  <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock contextRef="P01_01_2013To12_31_2013" id="Factid_723">              &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;strong&gt;NOTE 5 &amp;#150;  STOCKHOLDERS&amp;#8217; EQUITY&lt;/strong&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;i&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;strong&gt;Preferred  Stock&lt;/strong&gt;&lt;/font&gt;&lt;/i&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;Our amended and restated certificate  of incorporation authorizes the issuance of up to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  10,000,000&lt;/font&gt; shares of preferred stock, $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.001&lt;/font&gt;  par value, with rights senior to those of our common stock, &lt;font  style="COLOR: black"&gt;issuable in one or more series. Upon issuance,  the Company can determine the rights, preferences, privileges and  restrictions thereof. These rights, preferences and privileges  could include dividend rights, conversion rights, voting rights,  terms of redemption, liquidation preferences, sinking fund terms  and the number of shares constituting any series or the designation  of such series, any or all of which may be greater than the rights  of common stock.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Common  Stock&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-FAMILY: ; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;Our amended and restated certificate  of incorporation authorizes the issuance of up to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  500,000,000&lt;/font&gt; shares of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.001&lt;/font&gt;  par value common stock.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;On December 30, 2011, we &lt;font style="COLOR: black"&gt;completed the first closing of the private placement  of our securities, issuing &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  4,929,523&lt;/font&gt; shares of Common Stock at a price per share of  $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2.25&lt;/font&gt;  for total gross proceeds, before placement commissions and  expenses, of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;11,091,425&lt;/font&gt;  (the &amp;#8220;2011 Equity PIPE&amp;#8221;).&amp;#160;Investors also received  warrants to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  1,232,381&lt;/font&gt; shares of Common Stock. The warrants have an  exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2.25&lt;/font&gt;  per share and are exercisable for five years.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;In 2012, we completed  two additional closings of the 2011 Equity PIPE. These closings  were held on January 31, 2012, and February 24, 2012. In these  closings, the Company issued &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  695,428&lt;/font&gt; shares of our Company Preferred Stock at a price per  share of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;20.00&lt;/font&gt;  for total gross proceeds, before placement commissions and  expenses, of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;13,908,560&lt;/font&gt;.  Each share of Company Preferred Stock was convertible into &lt;font  style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  8.89&lt;/font&gt; shares of Common Stock; provided that such conversion  rights were subject to sufficient available authorized shares of  Common Stock. In connection with the reverse stock split effected  by the Company on April 30, 2012, all shares of Preferred Stock  issued in the 2011 Equity PIPE were converted to Common Stock.  Investors also received warrants to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  1,545,396&lt;/font&gt; shares of Common Stock. The warrants have an  exercise price of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2.25&lt;/font&gt;  per share and are exercisable for five years.&amp;#160;The shares of  Company Preferred Stock and warrants sold in these closings were  offered and sold to accredited investors, including members of  management, without registration under the Securities Act, or state  securities laws, in reliance on the exemptions provided by  Section&amp;#160;4(2) of the Securities Act, and Regulation&amp;#160;D  promulgated thereunder and in reliance on similar exemptions under  applicable state laws. Accordingly, the securities issued in the  offering have not been registered under the Securities Act, and  until so registered, these securities may not be offered or sold in  the United States absent registration or availability of an  applicable exemption from registration.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;On July 18, 2013, we  announced the pricing of an underwritten public offering of &lt;font  style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  5,700,000&lt;/font&gt; shares of our Common Stock at a price of $&lt;font  style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;6.15&lt;/font&gt;  per share for gross proceeds of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;35&lt;/font&gt;  million. We also granted to the underwriters a 30-day option to  acquire an additional &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  855,000&lt;/font&gt; shares to cover overallotments in connection with  the offering. Total net proceeds from this offering, including the  overallotment, were approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;37.6&lt;/font&gt;  million, net of underwriting discounts and offering expenses of  approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2.7&lt;/font&gt;  million. The shares were sold under a shelf registration statement  on Form S-3 (File No. 333-189015) that was previously filed and  declared effective by the SEC on June 17, 2013.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;We currently have one  shelf registration statement on Form S-3 filed and declared  effective by the SEC (File No. 333-189015). Subsequent to the July  2013 offering, this shelf registration statement provides for the  offering of up to approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;135&lt;/font&gt;  million of common stock. We may offer the securities under our  shelf registration statement from time to time in response to  market conditions or other circumstances if we believe such a plan  of financing is in the best interests of our stockholders. We  believe that this shelf registration statement provides us with the  flexibility to raise additional capital to finance our operations  as needed.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font   style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; BACKGROUND: transparent"&gt;  &lt;strong&gt;&lt;i&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;Treasury Stock&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; BACKGROUND: transparent"&gt;  &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; BACKGROUND: transparent"&gt;  &lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;&amp;#160;&lt;font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"&gt;As of December  31, 2013,&lt;/font&gt; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  41,309&lt;/font&gt; shares of common stock are being held by the Company  in Treasury, at a cost of approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;234,000&lt;/font&gt;,  representing the fair market value on the date the shares were  surrendered &lt;font style="FONT-FAMILY: 'Times New Roman'; FONT-SIZE: 10pt"&gt;to the Company to  satisfy employee tax obligations&lt;/font&gt;.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; BACKGROUND: transparent"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Equity Incentive  Plans&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;We have in effect the following stock  option and incentive plans.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &amp;#160;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;  a&lt;/font&gt;. The Company has shareholder-approved incentive stock  option plans for employees under which it has granted non-qualified  and incentive stock options, which provided for the granting of  options to purchase up to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  5,333&lt;/font&gt; shares of the Company&amp;#8217;s common stock. The  options have a maximum term of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;10&lt;/font&gt;  years and vest over a period determined by the Company&amp;#8217;s  Board of Directors. At December 31, 2013, options to purchase &lt;font  style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  591&lt;/font&gt; shares were outstanding, &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;10&lt;/font&gt;  shares of common stock were issued and there were no shares  reserved for future grants under the Plan.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;  b&lt;/font&gt;. In May 2012, the Company established the TG Therapeutics,  Inc. Amended and Restated 2012 Incentive Plan (&amp;#8220;2012  Incentive Plan&amp;#8221;). Under the 2012 Incentive Plan, the  compensation committee of the Company&amp;#8217;s board of directors is  authorized to grant stock-based awards to directors, consultants,  employees and officers. The 2012 Incentive Plan authorizes grants  to purchase up to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  6,000,000&lt;/font&gt; shares of authorized but unissued common stock. As  of December 31, 2013, options to purchase &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  46,000&lt;/font&gt; shares were outstanding and up to an additional &lt;font  style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  1,107,793&lt;/font&gt; shares may be issued under the 2012 Incentive  Plan.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;u&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;strong&gt;Stock  Options&lt;/strong&gt;&lt;/font&gt;&lt;/u&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;The following table summarizes stock option activity for the  years ended December 31, 2013 and 2012:&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="37%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="14%"&gt;  &lt;div&gt;Number&lt;br/&gt;   of&amp;#160;shares&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="15%" colspan="2"&gt;  &lt;div&gt;Weighted-&lt;br/&gt;   average&lt;br/&gt;   exercise&amp;#160;price&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="14%"&gt;  &lt;div&gt;Weighted-&lt;br/&gt;   average&lt;br/&gt;   Contractual&lt;br/&gt;   Term&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="15%" colspan="2"&gt;  &lt;div&gt;Aggregate Intrinsic&amp;#160;&lt;br/&gt;   Value&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="37%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700"   width="14%"&gt;  &lt;div&gt;(in&amp;#160;years)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="37%"&gt;  &lt;div&gt;Outstanding at January 1, 2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;3,379&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;1,315.62&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 12px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="37%"&gt;  &lt;div&gt;Granted&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;46,000&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;4.40&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 12px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="37%"&gt;  &lt;div&gt;Exercised&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 12px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="37%"&gt;  &lt;div&gt;Forfeited&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;(2,475)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;720.45&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 12px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="37%"&gt;  &lt;div&gt;Expired&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="37%"&gt;  &lt;div&gt;Outstanding at December 31, 2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;46,904&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;61.08&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;9.44&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 12px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="37%"&gt;  &lt;div&gt;Granted&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 12px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="37%"&gt;  &lt;div&gt;Exercised&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 12px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="37%"&gt;  &lt;div&gt;Forfeited&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;(313)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;2,249.85&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 12px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="37%"&gt;  &lt;div&gt;Expired&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="37%"&gt;  &lt;div&gt;Outstanding at December 31, 2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;46,591&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;46.37&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;8.50&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="37%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="37%"&gt;  &lt;div&gt;Vested and expected to vest at December 31, 2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;9,591&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;208.30&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;8.16&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="37%"&gt;  &lt;div&gt;Exercisable at December 31, 2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;9,591&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;208.30&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;8.16&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="14%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;    &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;     &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;&lt;/font&gt;     &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;As  of December 31, 2013, there is no unrecognized compensation cost  related to unvested time-based option awards. This amount does not  include, as of December 31, 2013, &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  37,000&lt;/font&gt; non-employee options outstanding which are  milestone-based and vest upon certain corporate milestones.  Stock-based compensation will be measured and recorded if and when  a milestone occurs.&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;u&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;strong&gt;Restricted Stock-  Preferred&lt;/strong&gt;&lt;/font&gt;&lt;/u&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font   style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Certain  employees had been awarded restricted preferred stock. The  restricted stock vesting consisted of milestone and time-based  vesting. &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;The following table summarizes restricted share activity for  the years ended December 31, 2013 and 2012:&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="18%"&gt;  &lt;div&gt;Number&amp;#160;of&amp;#160;Shares&lt;br/&gt;   Restricted&amp;#160;Series&amp;#160;&lt;br/&gt;   A&amp;#160;Preferred&amp;#160;&lt;br/&gt;   Stock&lt;sup style="FONT-STYLE: normal"&gt;(1)&lt;/sup&gt;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="19%" colspan="2"&gt;  &lt;div&gt;Weighted&amp;#160;&lt;br/&gt;   Average&lt;br/&gt;   Grant&amp;#160;Date&amp;#160;&lt;br/&gt;   Fair&amp;#160;Value&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Outstanding at January 1, 2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;129,375&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;20.00&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 11px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Granted&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 11px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Vested&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 11px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Forfeited&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Conversion to restricted common stock&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;(129,375)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;20.00&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Outstanding at December 31, 2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 11px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Granted&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 11px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Vested&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 11px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Forfeited&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Outstanding at December 31, 2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt;  &lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -1pt; MARGIN: 0in 0in 0pt"&gt;  &lt;strong&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="TEXT-DECORATION: none"&gt;&amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;sup&gt;&lt;font style="FONT-FAMILY: ; FONT-SIZE: 10pt"&gt;(&lt;/font&gt;&lt;font  style="FONT-FAMILY: ; FONT-SIZE: 10pt"&gt;1)&amp;#160;&lt;/font&gt;&lt;/sup&gt; &lt;font  style="FONT-SIZE: 10pt"&gt;The restricted preferred stock listed in  the table above was granted in connection with the Exchange  Transaction to certain executives. Each share of preferred stock  was convertible into &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  8.89&lt;/font&gt; shares of the Company&amp;#8217;s Common Stock. In  conjunction with the reverse split effected on April 30, 2012 (as  discussed in Note 1), all outstanding restricted Preferred Stock  automatically converted to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  1,150,000&lt;/font&gt; shares of restricted Common Stock as of that  date.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font   style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;    &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font   style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;     &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;u&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;strong&gt;Restricted Stock-  Common&lt;/strong&gt;&lt;/font&gt;&lt;/u&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;Certain  employees, directors and consultants have been awarded restricted  Company Common Stock. The restricted stock vesting consists of  milestone and time-based vesting.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;  The following table summarizes restricted share activity for the  years ended December 31, 2013 and 2012:&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="18%"&gt;  &lt;div&gt;Number&amp;#160;of&amp;#160;Shares&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="19%" colspan="2"&gt;  &lt;div&gt;Weighted&amp;#160;&lt;br/&gt;   Average&lt;br/&gt;   Grant&amp;#160;Date&amp;#160;&lt;br/&gt;   Fair&amp;#160;Value&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Outstanding at January 1, 2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Converted preferred stock&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;1,150,000&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;2.25&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Granted&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;5,901,743&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;4.77&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Vested&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;(437,500)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;2.25&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Forfeited&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Outstanding at December 31, 2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;6,614,243&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;4.49&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Granted&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;944,464&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;4.13&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Vested&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;(523,750)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;2.48&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 13px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Forfeited&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="40%"&gt;  &lt;div&gt;Outstanding at December 31, 2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;7,034,957&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="18%"&gt;  &lt;div&gt;4.60&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160; &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;    &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;     &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;Total expense associated with  restricted stock grants was $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;5,146,743&lt;/font&gt;  and $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;3,422,182&lt;/font&gt;  during the years ended December 31, 2013 and 2012, respectively. As  of December 31, 2013, there was approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;7,977,072&lt;/font&gt;  of total unrecognized compensation cost related to unvested time  based restricted stock, which is expected to be recognized over a  weighted-average period of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  1.9&lt;/font&gt; years. This amount does not include, as of December 31,  2013, &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  1,800,960&lt;/font&gt; shares of restricted stock outstanding which are  milestone-based and vest upon certain corporate milestones; and  &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  2,556,375&lt;/font&gt; shares of restricted stock outstanding issued to  non-employees (see Note 10 &amp;#150; Related Party Transactions for  additional information). Milestone based non-cash compensation  expense will be measured and recorded if and when a milestone  occurs.&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="TEXT-DECORATION: none"&gt;  &amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="TEXT-DECORATION: none"&gt;  &lt;/font&gt;&lt;/font&gt;     &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;u&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;strong&gt;  Warrants&lt;/strong&gt;&lt;/font&gt;&lt;/u&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;The following table summarizes warrant activity for the  years ended December 31, 2013 and 2012:&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in; WIDTH: 80%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="44%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="10%"&gt;  &lt;div&gt;Warrants&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Weighted-&lt;br/&gt;   average&lt;br/&gt;   exercise&amp;#160;price&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;Aggregate&lt;br/&gt;   Intrinsic&amp;#160;&lt;br/&gt;   Value&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="44%"&gt;  &lt;div&gt;Outstanding at January 1, 2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;1,625,911&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;5.27&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="44%"&gt;  &lt;div&gt;Issued&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;5,156,599&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;1.21&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="44%"&gt;  &lt;div&gt;Exercised&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="44%"&gt;  &lt;div&gt;Expired&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(1,503)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2,739.75&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="44%"&gt;  &lt;div&gt;Outstanding at December 31, 2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;6,781,007&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;1.58&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;14,563,539&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="44%"&gt;  &lt;div&gt;Issued&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="44%"&gt;  &lt;div&gt;Exercised&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(1,018,068)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;2.25&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="44%"&gt;  &lt;div&gt;Expired&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;(43,992)&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;16.26&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="44%"&gt;  &lt;div&gt;Outstanding at December 31, 2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;5,718,947&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;1.34&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;14,809,030&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;&lt;/div&gt;  &lt;/div&gt;    &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;     &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;As discussed above, as part of the  2011 Equity PIPE, we issued warrants to purchase up to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  2,777,962&lt;/font&gt; shares of our common stock at an exercise price of  $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2.25&lt;/font&gt;  per warrant share, &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  757,096&lt;/font&gt; of which have been exercised as of December 31,  2013. In addition, we issued to the placement agent in the  transaction warrants to purchase up to &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  1,111,111&lt;/font&gt; shares of our common stock at an exercise price of  $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;2.48&lt;/font&gt;  per warrant share, &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  6,533&lt;/font&gt; of which have been exercised as of December 31,  2013.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;In connection with the Securities  Exchange Agreement between the Company and LFB Group as discussed  in Note 8 &amp;#150; License Agreements, we issued LFB Group a warrant  to purchase an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  2,500,000&lt;/font&gt; shares of Company Common Stock at a purchase price  of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.001&lt;/font&gt;  per share.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt"&gt;Stock-Based  Compensation&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;The fair value of stock options  granted is estimated at the date of grant using the Black-Scholes  pricing model. The expected term of options granted is derived from  historical data and the expected vesting period. Expected  volatility is based on the historical volatility of our common  stock. The risk-free interest rate is based on the U.S. Treasury  yield for a period consistent with the expected term of the option  in effect at the time of the grant. We have assumed no expected  dividend yield, as dividends have never been paid to stock or  option holders and will not be paid for the foreseeable future. The  Company did not grant any stock options during the year-ended  December 31, 2013.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;The following table summarizes stock-based compensation  expense information about stock options and restricted stock for  the years ended December 31, 2013 and 2012:&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"&gt;  &lt;table style="MARGIN: 0in; WIDTH: 85%; BORDER-COLLAPSE: collapse; FONT-SIZE: 10pt; OVERFLOW: visible"   cellspacing="0" cellpadding="0" align="left"&gt;  &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="60%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;2013&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700"   width="11%" colspan="2"&gt;  &lt;div&gt;2012&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="60%"&gt;  &lt;div&gt;Stock-based compensation expense associated with restricted  stock&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;5,146,743&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;3,422,182&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="60%"&gt;  &lt;div&gt;Stock-based compensation expense associated with option  grants&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;56,405&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;&amp;#151;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;    &lt;tr style="HEIGHT: 12px"&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400"   width="60%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;5,203,148&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;$&lt;/div&gt;  &lt;/td&gt;  &lt;td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 5px; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400"   width="10%"&gt;  &lt;div&gt;3,422,182&lt;/div&gt;  &lt;/td&gt;  &lt;td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ccffcc; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400"   width="1%"&gt;  &lt;div&gt;&amp;#160;&lt;/div&gt;  &lt;/td&gt;  &lt;/tr&gt;  &lt;/table&gt;  &lt;/div&gt;    &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;font   style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;&lt;/font&gt;     &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"&gt;  &amp;#160;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;     &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"&gt;  &lt;strong&gt;&lt;i&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  &lt;/font&gt;Non-controlling Interest&lt;/font&gt;&lt;/i&gt;&lt;/strong&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"&gt;  &lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"   align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;On  November 9, 2012, LFB Group exercised their right to exchange their  TG Bio common stock for Company Common Stock. The Company and LFB  Group entered into a Securities Exchange Agreement pursuant to  which, LFB Group agreed to exchange its &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  7,500,000&lt;/font&gt; shares of the common stock of TG Bio, for &lt;font  style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  5,000,000&lt;/font&gt; shares of Company Common Stock, and a warrant to  purchase an aggregate of &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  2,500,000&lt;/font&gt; shares of Company Common Stock at a purchase price  of $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;0.001&lt;/font&gt;  per share. Refer to&lt;/font&gt; &lt;font style="FONT-SIZE: 10pt"&gt;Note 8  &amp;#150; License Agreements for further information.&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"   align="justify"&gt;&lt;font style="FONT-SIZE: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;    &lt;div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"   align="justify"&gt;&lt;font style="COLOR: black; FONT-SIZE: 10pt"&gt;  Accordingly, in connection with the aforementioned Securities  Exchange Agreement, TG Bio became a wholly owned subsidiary of the  Company. Prior to the execution of the Securities Exchange  Agreement LFB Group owned approximately &lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;  42.9&lt;/font&gt;% of TG Bio. The non-controlling interest in subsidiary  balance was approximately $&lt;font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"&gt;8,479,000&lt;/font&gt;  immediately prior to LFB Group exercising their option, which was  transferred to equity in connection with the  transaction.&lt;/font&gt;&lt;/div&gt;  &lt;/div&gt;  &lt;/div&gt;  &lt;/div&gt;  &lt;/div&gt;  &lt;/div&gt;        &lt;table border="0"  style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"&gt;&lt;tr&gt;&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>

  <tgtx:AdvancePaymentsForResearchAndDevelopment contextRef="P01_01_2012To12_31_2012_LfbGroupMembertgtxPlacementAgencyAgreementAxis" id="Factid_724" unitRef="USD" decimals="0">1719828</tgtx:AdvancePaymentsForResearchAndDevelopment>

  <tgtx:AdvancePaymentsForResearchAndDevelopment contextRef="P01_01_2013To12_31_2013_LfbGroupMembertgtxPlacementAgencyAgreementAxis" id="Factid_725" unitRef="USD" decimals="0">1629340</tgtx:AdvancePaymentsForResearchAndDevelopment>

  <tgtx:NonCashCompensationExpenses contextRef="P01_01_2012To12_31_2012_ResearchDevelopmentExpensesMembertgtxResearchDevelopmentExpensesAxis" id="Factid_726" unitRef="USD" decimals="0">134000</tgtx:NonCashCompensationExpenses>

  <tgtx:NonCashCompensationExpenses contextRef="P01_01_2013To12_31_2013_ResearchDevelopmentExpensesMembertgtxResearchDevelopmentExpensesAxis" id="Factid_727" unitRef="USD" decimals="0">437000</tgtx:NonCashCompensationExpenses>

  <tgtx:DebtInstrumentSettlementOfPrincipalAndInterest contextRef="P01_01_2014To01_23_2014_IconClinicalResearchMemberusgaapBusinessAcquisitionAxis" id="Factid_728" unitRef="USD" decimals="0">772369</tgtx:DebtInstrumentSettlementOfPrincipalAndInterest>

  <us-gaap:InvestmentIncomeAmortizationOfPremium contextRef="P01_01_2012To12_31_2012" id="Factid_729" unitRef="USD" decimals="0">0</us-gaap:InvestmentIncomeAmortizationOfPremium>

  <us-gaap:InvestmentIncomeAmortizationOfPremium contextRef="P01_01_2013To12_31_2013" id="Factid_730" unitRef="USD" decimals="0">975</us-gaap:InvestmentIncomeAmortizationOfPremium>

  <us-gaap:InvestmentIncomeAmortizationOfPremium contextRef="P12_01_2011To12_31_2013" id="Factid_731" unitRef="USD" decimals="0">975</us-gaap:InvestmentIncomeAmortizationOfPremium>

  <tgtx:IncomeTaxReconciliationChangeIncontingentNotePayable contextRef="P01_01_2012To12_31_2012" id="Factid_732" unitRef="USD" decimals="0">0</tgtx:IncomeTaxReconciliationChangeIncontingentNotePayable>

  <tgtx:IncomeTaxReconciliationChangeIncontingentNotePayable contextRef="P01_01_2013To12_31_2013" id="Factid_733" unitRef="USD" decimals="0">-1924558</tgtx:IncomeTaxReconciliationChangeIncontingentNotePayable>

<!--FootNote Section Ref-->

  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="#Factid_146" xlink:type="locator" xlink:label="loc_1" />

    <link:footnote xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:type="resource" xlink:label="FN_1">The restricted preferred stock listed in the table above was granted in connection with the Exchange Transaction to certain executives. Each share of preferred stock was convertible into 8.89 shares of the Company&#8217;s Common Stock. In conjunction with the reverse split effected on April 30, 2012 (as discussed in Note 1), all outstanding restricted Preferred Stock automatically converted to 1,150,000 shares of restricted Common Stock as of that date.</link:footnote>

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_148" xlink:type="locator" xlink:label="loc_3" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_150" xlink:type="locator" xlink:label="loc_4" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_152" xlink:type="locator" xlink:label="loc_5" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_154" xlink:type="locator" xlink:label="loc_6" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_156" xlink:type="locator" xlink:label="loc_7" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_158" xlink:type="locator" xlink:label="loc_8" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_160" xlink:type="locator" xlink:label="loc_9" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_162" xlink:type="locator" xlink:label="loc_10" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />

    <link:loc xlink:href="#Factid_696" xlink:type="locator" xlink:label="loc_11" />

    <link:footnoteArc xlink:type="arc" order="1" xlink:to="FN_1" xlink:from="loc_11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" />
  </link:footnoteLink>
</xbrli:xbrl>

